A Phase 1b/2 Study of the Safety and Efficacy of Rociletinib (CO-1686) Administered in Combination With MPDL3280A in Patients With Activating EGFR Mutation-positive (EGFRm) Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)
Phase: PHASE1
Conditions: Non-small Cell Lung Cancer
Sponsor: Clovis Oncology, Inc.

Clovis Oncology, Inc. 
Clinical Protocol 
Rociletinib (CO-1686) 
CO-1686-032 
 
26 May 2015 
 
 
Page 1 of 131 
 
 
A Phase 1b/2 study of the safety and efficacy of rociletinib (CO-1686) 
administered in combination with MPDL3280A in patients with activating 
EGFR mutation-positive (EGFRm) advanced or metastatic non-small cell 
lung cancer (NSCLC) 
Protocol Number: 
CO-1686-032 
Investigational Product: 
Rociletinib, MPDL3280A 
IND Number: 
113,560 
EUDRA CT Number 
2015-001872-23 
Development Phase: 
Phase 1b/2 
Indication Studied: 
Locally advanced or metastatic NSCLC with mutant 
epidermal growth factor receptor (EGFR) 
Sponsor Name and Address: 
Clovis Oncology, Inc. 
2525 28th Street 
Boulder, CO 80301 USA 
Phone Number: 
303-625-5000 
Facsimile Number: 
303-245-0360 
Responsible Medical Officer: 
Paula O’Connor, M.D. 
Compliance Statement: 
This study will be conducted in accordance with the 
ethical principles that have their origin in the 
Declaration of Helsinki, clinical research guidelines 
established by the Code of Federal Regulations (Title 
21, CFR Parts 50, 56, and 312), and ICH GCP 
Guidelines. Essential study documents will be archived 
in accordance with applicable regulations. 
Protocol Date: 
26 May 2015 
Version: 
1.0  
CONFIDENTIALITY STATEMENT 
The information in this document contains commercial information and trade secrets that are 
privileged or confidential and may not be disclosed unless such disclosure is required by 
applicable laws and regulations. In any event, persons to whom the information is disclosed must 
be informed that the information is privileged or confidential and may not be further disclosed by 
them. These restrictions on disclosure will apply equally to all future information supplied to you 
which is indicated as privileged or confidential. 

Clovis Oncology, Inc. 
Clinical Protocol 
Rociletinib (CO-1686) 
CO-1686-032 
 
26 May 2015 
 
 
Page 2 of 131 
 
 
Protocol Approval Signature Page 
Protocol: 
CO-1686-032 
Title: 
A Phase 1b/2 study of the safety and efficacy of rociletinib (CO-1686) 
administered in combination with MPDL3280A in patients with 
activating EGFR mutation-positive (EGFRm) advanced or metastatic 
non-small cell lung cancer (NSCLC) 
Date: 
26 May 2015 
Version: 
1.0  
 
Reviewed and Approved by: 
 
 
 
 
Andrew Allen, M.D., Ph.D.  
Date 
Chief Medical Officer; Executive Vice President, Clinical and Preclinical Development 
Clovis Oncology, Inc. 
 
 
 
Gillian Ivers-Read  
Date 
Chief Regulatory Officer; Executive Vice President, Technical Operations  
Clovis Oncology, Inc. 
 
 
 
Jeff Isaacson, Ph.D. 
Director, Biostatistics and Data Management 
Clovis Oncology, Inc. 
 
 
Date 
Todd Yancey, M.D. 
Senior Vice President, Global Medical Affairs 
Clovis Oncology, Inc. 
 
Date 
 
 

Clovis Oncology, Inc. 
Clinical Protocol 
Rociletinib (CO-1686) 
CO-1686-032 
 
26 May 2015 
 
 
Page 3 of 131 
 
 
Protocol Acceptance Form 
Protocol: 
CO-1686-032 
Title: 
A Phase 1b/2 study of the safety and efficacy of rociletinib (CO-1686) 
administered in combination with MPDL3280A in patients with 
activating EGFR mutation-positive (EGFRm) advanced or metastatic 
non-small cell lung cancer (NSCLC) 
Date: 
26 May 2015  
Version: 
1.0  
 
Reviewed and Approved by: 
 
I have carefully read this protocol and agree that it contains all of the necessary information 
required to conduct this study. I agree to conduct this study as described and according to 
the Declaration of Helsinki, ICH Guidelines for GCP, and all applicable regulatory 
requirements. 
 
 
 
  
Investigator’s Signature 
 Date 
 
 
 
  
Name (printed) 
  
 
 
 

Clovis Oncology, Inc. 
Clinical Protocol 
Rociletinib (CO-1686) 
CO-1686-032 
 
26 May 2015 
 
 
Page 4 of 131 
 
 
Table of Contents  
SYNOPSIS ........................................................................................................................ 11 
LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS .............................. 29 
1 
INTRODUCTION ............................................................................................ 32 
1.1 
ROCILETINIB NONCLINICAL OVERVIEW ...................................................... 34 
1.2 
MPDL3280A NONCLINICAL OVERVIEW .......................................................... 36 
1.3 
CLINICAL EXPERIENCE WITH ROCILETINIB ............................................... 36 
1.3.1 
Safety of Rociletinib from Clinical Studies .............................................................. 37 
1.3.2 
Activity of Rociletinib from Clinical Studies ........................................................... 42 
1.3.3 
Pharmacokinetics of Rociletinib ............................................................................... 42 
1.4 
CLINICAL EXPERIENCE WITH MPDL3280A ................................................... 42 
1.4.1 
Safety of MPDL3280A from Clinical Studies .......................................................... 43 
1.4.2 
Pharmacokinetics of MPDL3280A ........................................................................... 43 
1.5 
RATIONALE FOR STUDY ...................................................................................... 43 
2 
STUDY OBJECTIVES AND ENDPOINTS .................................................. 46 
2.1 
OBJECTIVES ............................................................................................................. 46 
2.1.1 
Primary Objectives ..................................................................................................... 46 
2.1.2 
Secondary Objectives ................................................................................................. 46 
2.2 
ENDPOINTS ............................................................................................................... 47 
2.2.1 
Primary Endpoints ..................................................................................................... 47 
2.2.2 
Secondary Endpoints ................................................................................................. 47 
2.2.3 
Exploratory Endpoints ............................................................................................... 47 
3 
STUDY DESIGN .............................................................................................. 48 
3.1 
CLINICAL SAFETY COMMITTEE ....................................................................... 48 
3.2 
DOSE FINDING PHASE (PHASE 1) ....................................................................... 49 
3.2.1 
Dose-Limiting Toxicity ............................................................................................... 49 
3.2.2 
Assignment of Dosing Cohorts .................................................................................. 50 
3.2.3 
Recommended Phase 2 Dose ..................................................................................... 51 
3.3 
DOSE EXPANSION PHASE (PHASE 2) ................................................................. 52 
3.4 
STUDY CONDUCT AND DURATION OF PATIENT FOLLOW-UP ................ 52 
4 
STUDY POPULATION ................................................................................... 53 

Clovis Oncology, Inc. 
Clinical Protocol 
Rociletinib (CO-1686) 
CO-1686-032 
 
26 May 2015 
 
 
Page 5 of 131 
 
 
4.1 
NUMBER OF PATIENTS AND SITES ................................................................... 53 
4.2 
INCLUSION CRITERIA ........................................................................................... 53 
4.3 
EXCLUSION CRITERIA .......................................................................................... 55 
4.4 
PATIENTS OR PARTNERS OF PATIENTS OF REPRODUCTIVE 
POTENTIAL .............................................................................................................. 58 
4.5 
WAIVERS OF INCLUSION/EXCLUSION CRITERIA ....................................... 58 
5 
DESCRIPTIONS OF STUDY TREATMENT AND DOSE 
MODIFICATIONS .......................................................................................... 59 
5.1 
DESCRIPTION OF ROCILETINIB ........................................................................ 59 
5.2 
DESCRIPTION OF MPDL3280A ............................................................................ 59 
5.3 
PREPARATION AND ADMINISTRATION OF STUDY TREATMENT .......... 59 
5.4 
BLINDING/MASKING OF TREATMENT ............................................................ 60 
5.5 
TREATMENT COMPLIANCE ................................................................................ 61 
5.6 
STUDY DRUG ACCOUNTABILITY ...................................................................... 61 
5.7 
DOSE MODIFICATION GUIDELINES ................................................................. 61 
5.7.1 
Study Treatment Dose Reductions ........................................................................... 61 
5.7.2 
Phase 1 – Run-in-Period ............................................................................................ 62 
5.7.3 
Phase 1 – Cycle 1 ........................................................................................................ 62 
5.7.4 
Beyond DLT Assessment (Phase 1 – Cycle 2+ and Phase 2 – All Cycles) ............. 62 
5.8 
TREATMENT OF STUDY DRUG OVERDOSE ................................................... 64 
6 
MONITORING AND MANAGEMENT OF EXPECTED OR 
POTENTIAL TREATMENT-RELATED TOXICITY ............................... 65 
6.1 
ROCILETINIB EXPECTED OR POTENTIAL TOXICITIES ............................ 65 
6.1.1 
Management of Prolonged QTc ................................................................................ 65 
6.1.2 
Management of Hyperglycemia ................................................................................ 66 
6.2 
MPDL3280A EXPECTED OR POTENTIAL TOXICITIES ................................. 67 
6.2.1 
Management of Infusion Reactions .......................................................................... 68 
6.2.2 
Management of Gastrointestinal Toxicity ................................................................ 69 
6.2.3 
Management of Hepatotoxicity ................................................................................. 70 
6.2.4 
Management of Dermatologic Toxicity .................................................................... 71 
6.2.5 
Management of Endocrine Toxicity (Hypothyroidism) .......................................... 72 
6.2.6 
Management of Pericardial and Pleural Effusions ................................................. 72 
6.2.7 
Management of Potential Pancreatic Toxicity ......................................................... 72 

Clovis Oncology, Inc. 
Clinical Protocol 
Rociletinib (CO-1686) 
CO-1686-032 
 
26 May 2015 
 
 
Page 6 of 131 
 
 
6.2.8 
Management of Potential Ocular Toxicity ............................................................... 74 
6.3 
OVERLAPPING EXPECTED OR POTENTIAL TOXICITIES .......................... 74 
7 
PRIOR AND CONCOMITANT THERAPIES ............................................. 79 
7.1 
ANTICANCER OR EXPERIMENTAL THERAPY .............................................. 79 
7.2 
HEMATOPOIETIC GROWTH FACTORS AND BLOOD PRODUCTS ........... 79 
7.3 
MEDICATIONS FOR TREATMENT OF INFUSION REACTIONS ................. 79 
7.4 
SYSTEMIC CORTICOSTEROIDS AND TNF- INHIBITORS ......................... 79 
7.5 
OTHER CONCOMITANT MEDICATIONS .......................................................... 80 
7.6 
EXCLUDED THERAPIES CONCURRENT WITH ROCILETINIB .................. 80 
7.6.1 
Drugs that prolong QTc interval .............................................................................. 80 
7.6.2 
CYP450 Isozyme Inhibitors and Inducers ............................................................... 81 
7.6.3 
P-gp Substrates, Inhibitors and Inducers ................................................................ 81 
7.6.4 
Proton Pump Inhibitors ............................................................................................. 81 
7.7 
EXCLUDED THERAPIES CONCURRENT WITH MPDL3280A ...................... 82 
7.7.1 
Denosumab .................................................................................................................. 82 
7.7.2 
Immunomodulatory Agents ....................................................................................... 82 
8 
STUDY PROCEDURES .................................................................................. 83 
8.1 
SCREENING PERIOD .............................................................................................. 83 
8.2 
TREATMENT PERIOD ............................................................................................ 83 
8.2.1 
Post-Progression Treatment ...................................................................................... 84 
8.2.2 
End-of-Treatment Visit .............................................................................................. 84 
8.3 
FOLLOW-UP PERIOD ............................................................................................. 85 
8.4 
METHODS OF DATA COLLECTION ................................................................... 85 
8.4.1 
Patient History ............................................................................................................ 85 
8.4.2 
Safety Evaluations ...................................................................................................... 85 
8.4.3 
Efficacy Evaluations ................................................................................................... 88 
8.4.4 
Pharmacokinetic Evaluations .................................................................................... 88 
8.4.5 
Pharmacodynamic Evaluations ................................................................................. 89 
8.4.6 
Patient Diary ............................................................................................................... 90 
9 
ADVERSE EVENT REPORTING ................................................................. 91 
9.1 
DEFINITION OF AN ADVERSE EVENT (AE) ..................................................... 91 
9.2 
DEFINITION OF A SERIOUS ADVERSE EVENT (SAE) ................................... 91 

Clovis Oncology, Inc. 
Clinical Protocol 
Rociletinib (CO-1686) 
CO-1686-032 
 
26 May 2015 
 
 
Page 7 of 131 
 
 
9.3 
EVENTS OR OUTCOMES NOT QUALIFYING AS SAES ................................. 92 
9.4 
CLINICAL LABORATORY ASSESSMENTS AS AES AND SAES.................... 92 
9.5 
PREGNANCY OR DRUG EXPOSURE DURING PREGNANCY ....................... 92 
9.6 
ADVERSE EVENTS OF SPECIAL INTEREST FOR MPDL3280A ................... 93 
9.7 
RECORDING OF AES AND SAES.......................................................................... 93 
9.7.1 
Intensity of Adverse Events ....................................................................................... 94 
9.7.2 
Causal Relationship of Adverse Events to Investigational Study Drugs ............... 94 
9.7.3 
Outcome and Action Taken ....................................................................................... 95 
9.8 
FOLLOW-UP OF AES AND SAES .......................................................................... 95 
9.9 
REGULATORY ASPECTS OF SAE REPORTING .............................................. 96 
10 
STATISTICAL METHODS ............................................................................ 97 
10.1 
ANALYSIS POPULATIONS .................................................................................... 97 
10.2 
STATISTICAL METHODS ...................................................................................... 97 
10.2.1 
General Considerations ............................................................................................. 97 
10.2.2 
Patient Disposition ...................................................................................................... 97 
10.2.3 
Baseline Characteristics ............................................................................................. 97 
10.2.4 
Efficacy Analyses ........................................................................................................ 97 
10.2.5 
Safety Analyses ........................................................................................................... 99 
10.3 
SAMPLE SIZE CONSIDERATIONS .................................................................... 102 
11 
PATIENT DISPOSITION ............................................................................. 104 
11.1 
PERMANENT DISCONTINUATION OF STUDY TREATMENT ................... 104 
12 
STUDY ADMINISTRATION ....................................................................... 105 
12.1 
REGULATORY AND ETHICAL CONSIDERATIONS ..................................... 105 
12.1.1 
Regulatory Authority Approvals ............................................................................ 105 
12.1.2 
Institutional Review Board (IRB) ........................................................................... 105 
12.2 
CONFIDENTIALITY OF INFORMATION ......................................................... 106 
12.3 
PATIENT INFORMED CONSENT ....................................................................... 106 
12.4 
STUDY MONITORING .......................................................................................... 107 
12.5 
ELECTRONIC CASE REPORT FORM (ECRF) ................................................ 107 
12.6 
STUDY TERMINATION AND SITE CLOSURE ................................................ 108 
12.7 
MODIFICATION OF THE STUDY PROTOCOL ............................................... 108 
12.8 
RETENTION OF STUDY DOCUMENTS ............................................................ 108 

Clovis Oncology, Inc. 
Clinical Protocol 
Rociletinib (CO-1686) 
CO-1686-032 
 
26 May 2015 
 
 
Page 8 of 131 
 
 
12.9 
CLINICAL STUDY REPORT ................................................................................ 109 
12.10 
STUDY PUBLICATION .......................................................................................... 109 
12.11 
QUALITY ASSURANCE AUDITS ........................................................................ 109 
13 
REFERENCES ............................................................................................... 110 
14 
APPENDICES ................................................................................................. 112 
 

Clovis Oncology, Inc. 
Clinical Protocol 
Rociletinib (CO-1686) 
CO-1686-032 
 
26 May 2015 
 
 
Page 9 of 131 
 
 
List of Tables 
Table 1: 
Study CO-1686-032 Schedule of Assessments........................................ 24 
Table 2: 
Clinical Sample Collection (PK, ATA, TBNK, 
Pharmacodynamic)a ................................................................................. 28 
Table 3: 
Treatment-Related Serious Adverse Events 
Reported by Patients in Study CO-1686-008........................................... 39 
Table 4: 
Treatment-Related Adverse Events Reported by at 
Least 5% of Patients in Study CO-1686-008 ........................................... 41 
Table 5: 
Phase 1 Dosing Cohorts ........................................................................... 51 
Table 6:  
Study Schematic (CO-1686-032) ............................................................. 52 
Table 7: 
Dose Reductions for Rociletinib .............................................................. 61 
Table 8: 
Phase 1 and Phase 2 Dose Modification .................................................. 63 
Table 9: 
Withholding and Stopping Criteria for QTc-
Prolongation ............................................................................................. 65 
Table 10: 
Management Guidelines for Hyperglycemia ........................................... 67 
Table 11:  
Management Guidelines for Infusion-Related 
Reactions during Cycle 1 ......................................................................... 68 
Table 12: 
Management Guidelines for Gastrointestinal 
Toxicity (Diarrhea) .................................................................................. 69 
Table 13: 
Management Guidelines for Hepatotoxicity (LFT 
Abnormalities) ......................................................................................... 70 
Table 14: 
Management Guidelines for Rash ............................................................ 71 
Table 15: 
Management Guidelines for Hypothyroidism ......................................... 72 
Table 16: 
Management Guidelines for Amylase/Lipase 
Abnormalities ........................................................................................... 73 
Table 17: 
Management Guidelines for Ocular Toxicities ........................................ 74 
Table 18: 
Management of Overlapping Toxicities .................................................. 75 
 
 
 
 

Clovis Oncology, Inc. 
Clinical Protocol 
Rociletinib (CO-1686) 
CO-1686-032 
 
26 May 2015 
 
 
Page 10 of 131 
 
 
 
List of Figures 
Figure 1: 
Study Schematic....................................................................................... 48 
 
 
 
List of Appendices 
Appendix A: 
Response Evaluation Criteria in Solid Tumor 
(RECIST) Version 1.1 ........................................................................... 113 
Appendix B: 
Modified RECIST Incorporating Immune-Related 
Response Criteria ................................................................................... 118 
Appendix C: 
Eastern Cooperative Oncology Group Performance 
Status Scale ............................................................................................ 124 
Appendix D: 
QT Interval on Electrocardiogram Corrected Using 
the Fridericia’s  Formula (QTcF) ........................................................... 125 
Appendix E: 
Pre-Existing Autoimmune Diseases ...................................................... 126 
Appendix F: 
Anaphylaxis Precautions ........................................................................ 127 
Appendix G: 
New York Heart Association Classification of 
Functional Cardiac Capacity .................................................................. 128 
Appendix H: 
The Modified Toxicity Probability Interval (mTPI) 
Method ................................................................................................... 129 
 
 
 
 

Clovis Oncology, Inc. 
Clinical Protocol 
Rociletinib (CO-1686) 
CO-1686-032 
 
26 May 2015 
 
 
Page 11 of 131 
 
 
SYNOPSIS 
Protocol 
Number 
CO-1686-032 
Title 
A Phase 1b/2 study of the safety and efficacy of rociletinib (CO-1686) administered in 
combination with MPDL3280A in patients with activating EGFR mutation-positive (EGFRm) 
advanced or metastatic non-small cell lung cancer (NSCLC) 
Phase 
1b/2 
Introduction  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Rociletinib is a novel, potent, covalent (irreversible) small molecule, tyrosine kinase inhibitor 
(TKI) that selectively targets mutant forms of the epidermal growth factor receptor (EGFR). 
Rociletinib inhibits the EGFR “gatekeeper” mutation, T790M, which is associated with 
clinical resistance to Tarceva™ (erlotinib) and Iressa™ (gefitinib), as well as the common 
EGFR-activating mutations (eg, L858R, del19), and rociletinib has minimal inhibitory activity 
towards the wild-type EGFR at clinically relevant doses. Clovis Oncology, Inc. (Clovis or 
Sponsor) is developing rociletinib as a therapeutic to be administered orally (PO) to patients 
with EGFRm NSCLC. 
The recommended Phase 2 doses (RP2Ds) of rociletinib, 500 mg and 625 mg, twice daily 
(BID), were determined in Study CO-1686-008, a study conducted in patients with EGFRm 
advanced or metastatic NSCLC who had prior treatment with an EGFR inhibitor. Overall 
responses based on Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) 
were observed across a range of doses with rociletinib. Among NSCLC patients with the 
T790M mutation (T790M+) treated at the 500 mg or 625 mg BID, the overall response rate 
(ORR) was 67%.1 Responses to rociletinib are rapid, frequently occurring within less than 
12 weeks. The median progression-free survival (PFS) for subjects receiving rociletinib 
monotherapy at 500 mg or 625 mg in the context of acquired resistance has been reported as 
10.4 months.1 Responses to rociletinib have also been observed in patients without the 
T790M mutation (T790M–).1 The most common rociletinib-related toxicity observed is 
hyperglycemia, which is generally managed with oral anti-hyperglycemic therapy. Adverse 
events (AEs) typical of wild-type (WT) EGFR inhibition (the combination of rash and chronic 
diarrhea) have not been observed with rociletinib. 
MPDL3280A is a human IgG1 monoclonal antibody consisting of two heavy chains 
(448 amino acids) and two light chains (214 amino acids) and is produced in Chinese hamster 
ovary cells. MPDL3280A was engineered to eliminate Fc-effector function via a single amino 
acid substitution (asparagine to alanine) at position 298 on the heavy chain, which results in a 
non-glycosylated antibody that has minimal binding to Fc receptors and consequently, 
eliminates detectable Fc-effector function and depletion of cells expressing PD-L1. 
MPDL3280A targets human PD-L1 and inhibits its interaction with its receptor, PD-1. 
MPDL3280A also blocks the binding of PD-L1 to B7.1, an interaction that is reported to 
provide additional inhibitory signals to T cells.2 
In Phase 1 studies of MPDL3280A, the maximum tolerated dose (MTD) was not reached, and 
no dose-limiting toxicity (DLT) was reported. The most commonly observed AEs have been 
rash and diarrhea. The RP2D of intravenous (IV) single-agent MPDL3280A has been 
identified as 1200 mg every 3 weeks. 
Data for 53 patients with NSCLC (including squamous and non-squamous histologies) treated 
with MPDL3280A have been presented. A 23% ORR was reported.3 The response rate in 
subjects with PD-L1 expression in infiltrating immune cells was 46%. Tumor responses 

Clovis Oncology, Inc. 
Clinical Protocol 
Rociletinib (CO-1686) 
CO-1686-032 
 
26 May 2015 
 
 
Page 12 of 131 
 
 
occurred as early as the first assessment. PFS in this group was remarkable, with a 45% PFS 
at a 24-week landmark assessment. The most common AEs in this group were fatigue and 
decreased appetite. 
PD-L1 was found to be down regulated in the presence of erlotinib in EGFRm NSCLC tumors 
but not in those with WT EGFR, suggesting that PD-L1 expression is dependent on EGFR 
signaling conferred by activating EGFR mutations. Furthermore, recent data indicate that PD-
L1 is overexpressed in EGFR-TKI-resistant cell lines, suggesting that PD-L1 upregulation 
could contribute to acquired resistance to EGFR TKIs. Based on these data, dual therapies of 
EGFR TKIs and anti-PD-L1 antibodies, targeted at overcoming acquired resistance in 
EGFRm NSCLC, may provide significant benefit to these patients with a high unmet medical 
need. In addition, the combination of therapies may prevent the commonly acquired 
mechanisms of resistance to occur. 
In this study, the safety and efficacy of rociletinib in combination with MPDL3280A will be 
investigated in patients with EGFRm NSCLC. 
Planned 
Number of 
Patients 
Phase 1: Approximately 18 patients. 
Phase 2: Up to 75 patients. 
Planned 
Number of 
Sites 
Up to 14 sites in the United States, France and Spain. 
Study 
Objectives 
 
 
Primary Objectives: 
Phase 1:  
• 
To determine the safety and tolerability, DLTs, MTD or maximum administered 
dose (MAD) and RP2D of the combination of rociletinib and MPDL3280A; 
• 
To assess the pharmacokinetic (PK) profile of rociletinib (and its metabolites) 
and MPDL3280A when given in combination. 
Phase 2:  
• 
To determine the efficacy of the combination of rociletinib and MPDL3280A 
based on ORR per RECIST v1.1 (Appendix A) in the following groups of 
patients: 
▪ 
Group A: Patients with EGFRm advanced or metastatic NSCLC who 
have not previously received an EGFR TKI or chemotherapy; 
▪ 
Group B: Patients with EGFRm advanced or metastatic NSCLC who 
have progressed on a prior EGFR TKI. 
 
Secondary Objectives: 
Phase 1:  
• 
To determine preliminary efficacy and pharmacodynamics of the combination of 
rociletinib and MPDL3280A in enrolled patients. 
Phase 2:  
• 
To determine the efficacy of the combination of rociletinib and MPDL3280A 
based on ORR per modified RECIST incorporating immune-related response 
criteria (irRC; Appendix B) in Groups A and B; 

Clovis Oncology, Inc. 
Clinical Protocol 
Rociletinib (CO-1686) 
CO-1686-032 
 
26 May 2015 
 
 
Page 13 of 131 
 
 
 
 
 
• 
To assess the activity of the combination of rociletinib and MPDL3280A based 
upon duration of response (DOR) and PFS; 
• 
To assess the pharmacodynamic relationship between biomarkers and clinical 
activity, and/or resistance to study drug. 
Study 
Endpoints 
Primary Endpoints: 
Phase 1: 
• 
Treatment-emergent AEs; 
• 
DLTs; 
• 
PK parameters for rociletinib (and its metabolites) and MPDL3280A. 
Phase 2: 
• 
ORR according to RECIST v1.1 (Appendix A) as determined by Investigator 
assessment. 
Secondary Endpoints: 
• 
ORR according to modified RECIST incorporating irRC (Appendix B); 
• 
DOR, DCR, and PFS according to RECIST v1.1 as determined by Investigator 
assessment; 
• 
DOR, DCR, and PFS according to modified RECIST incorporating irRC 
(Appendix B); 
• 
Overall survival (OS); 
• 
Change from baseline in mutant EGFR levels in circulating tumor DNA 
(ctDNA) obtained from plasma; 
Exploratory Endpoints: 
• 
Positive and negative percent agreement between blood and tissue results for 
T790M and EGFR activating mutations. 
• 
Incidence of anti-therapeutic antibody (ATA) response to MPDL3280A and 
potential correlation with PK, pharmacodynamics, safety and efficacy 
parameters; 
• 
Identification of biomarkers associated with response or resistance to rociletinib 
and/or MPDL3280A; 
• 
Changes in expression of immune-related markers (including, but not limited to, 
granzyme B or other exploratory markers) in archival and/or fresh tumor tissue 
prior to and after MPDL3280A and rociletinib treatment; 
• 
Markers of RAS-RAF-MEK signaling cascade (including, but not limited to, 
EGFR) in archival and/or fresh tissue; 
• 
PD-L1 status by immunohistochemistry (IHC) or quantitative polymerase chain 
reaction (PCR) in archival and/or fresh tissue. 
 

Clovis Oncology, Inc. 
Clinical Protocol 
Rociletinib (CO-1686) 
CO-1686-032 
 
26 May 2015 
 
 
Page 14 of 131 
 
 
 
Study Design 
 
This is a Phase 1b/2 multicenter, open-label, non-randomized study in patients with EGFRm 
advanced or metastatic NSCLC to be conducted in two phases: a Dose Finding Phase 
(Phase 1) and a Dose Expansion Phase (Phase 2). A schematic of the study is presented 
below. 
 
Phase 1: The Dose Finding Phase will be conducted with patients who have progressed after 
at least 12 weeks of treatment with a prior first- or second-generation EGFR TKI 
(ie, erlotinib, gefitinib, afatanib), regardless of T790M mutation status. The Dose Finding 
Phase will be used to determine the MTD or MAD and RP2D of the combination of 
rociletinib and MPDL3280A, and to evaluate the safety, tolerability, and PK profile of the 
combination treatment.  
Specific doses of rociletinib will be administered in combination with a fixed dose of 
MPDL3280A. Combination doses of rociletinib with MPDL3280A will be defined for each 
Dosing Cohort enrolled during the Dose Finding Phase, and currently two potential Dosing 
Cohorts are planned (see table below). The first Dosing Cohort will be 500 mg BID 
rociletinib and 1200 mg MPDL3280A on Day 1 of each 21-day cycle. At minimum, 
3 patients will be enrolled into this first cohort. If this combination dose is determined to be 
safe and tolerable, no further dose modifications for either drug will be made. Based on 
emerging safety and evaluable PK and/or pharmacodynamics data, additional doses or 
schedules of rociletinib may be evaluated. 
Cohort 
Rociletinib Dose 
MPDL3280A Dose 
1 
500 mg PO BID 
1200 mg IV every 3 weeks 
Day 1 of each 21-day cycle 
2 
375 mg PO BID 
BID, twice daily; IV, intravenous; PO, oral. 
The Dose Finding Phase will include a 7-day Run-in-Period of rociletinib monotherapy at the 
specified dose of the Dosing Cohort prior to the initiation of combination treatment. Patients 
who experience an adverse event that requires a reduction or delay of more than 48 hours in 

Clovis Oncology, Inc. 
Clinical Protocol 
Rociletinib (CO-1686) 
CO-1686-032 
 
26 May 2015 
 
 
Page 15 of 131 
 
 
 
 
the dosing of rociletinib during the Run-in-Period will not go on to receive the combination of 
rociletinib and MPDL3280A, but will remain on study to receive rociletinib monotherapy; an 
additional patient will be enrolled as a replacement for inclusion in the same Dosing Cohort.  
For the Dose Finding Phase, Cycle 1 will begin with the initiation of combination treatment 
following a successful Run-in-Period and will be the period of safety and DLT evaluation for 
each Dosing Cohort (see Section 3.2 for further details on DLT evaluation and Dosing Cohort 
decision-making). Thereafter, treatment and monitoring of patients will be conducted in 
21-day treatment cycles. 
The RP2D for the combination of rociletinib and MPDL3280A will be determined based on 
cumulative data from all cohorts. A safety expansion cohort of up to 6 patients may be 
enrolled to further examine the tolerability of a dose combination of interest or the tolerability 
of combination dosing without a rociletinib monotherapy Run-in-Period.  
Phase 2: The Dose Expansion Phase will be conducted in EGFR TKI treatment-naïve and 
chemotherapy-naïve patients (Phase 2 Group A) and in the same population of patients as in 
Phase 1 (Phase 2 Group B) (see schematic above). The Dose Expansion Phase will be used to 
assess the RP2D of the combination of rociletinib and MPDL3280A for preliminary efficacy 
and pharmacodynamics effects, in addition to safety and tolerability in these patient 
populations. For the Dose Expansion Phase, there will not be a Run-in-Period; treatment will 
begin with both rociletinib and MPDL3280A on C1D1, and treatment and monitoring of 
patients will be conducted in consecutive 21-day treatment cycles. 
Safety Monitoring: 
Throughout the study, oversight will be provided by the Clinical Safety Committee (CSC), 
comprised of all Principal Investigators and the Sponsor’s Medical Monitor and Drug Safety 
representative. The CSC will: 
• 
Review and confirm all DLTs;  
• 
Determine all cohort dose-escalation and de-escalation decisions during the 
Dose Finding Phase; 
• 
Determine the MTD or MAD and RP2D to take into the Dose Expansion Phase; 
• 
Review safety evaluation of all patients. 

Clovis Oncology, Inc. 
Clinical Protocol 
Rociletinib (CO-1686) 
CO-1686-032 
 
26 May 2015 
 
 
Page 16 of 131 
 
 
Inclusion 
Criteria 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
All patients must meet all of the following inclusion criteria: 
1. Signed and dated informed consent, approved by the Independent Ethics Committee 
(IEC) or Institutional Review Board (IRB), obtained prior to the performance of any 
study-specific procedures or assessments and ability to understand and comply with 
protocol requirements and instructions; 
Baseline Characteristics 
2. Males and females ≥18 years of age; 
3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1; 
4. Adequate hematological and biological function, based on the following laboratory 
values: 
• 
Bone Marrow Function: 
▪ 
Absolute neutrophil count (ANC)  1.5 x 109/L; 
▪ 
Lymphocyte count  0.5 x 109/L; 
▪ 
Platelets  100.0 × 109/L (without transfusion within 2 weeks prior to 
receipt of study drug); 
▪ 
Hemoglobin  9 g/dL (or 5.6 mmol/L) (patients may be transfused and/or 
receive erythropoietin stimulating agents to meet this criterion per 
institutional guidelines). 
• 
Hepatic Function: 
▪ 
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) 
 2.5 × upper limit of normal (ULN); if liver metastases,  5 × ULN; 
▪ 
Bilirubin  2.0 × ULN (Patients with documented Gilbert’s syndrome 
and conjugated bilirubin within the normal range may be allowed into 
the study. In this event, it will be documented that the patient was 
eligible based on conjugated bilirubin levels). 
• 
Renal Function: 
▪ 
Serum creatinine  1.5 × ULN or creatinine clearance  50 mL/min. 
• 
Electrolytes: 
▪ 
Potassium and magnesium within normal range, patients may receive 
supplements to meet this requirement. 
• 
Coagulation status: 
▪ 
International normalized ratio (INR) and activated partial thromboplastin 
time (aPTT)  1.5 × ULN; 
▪ 
This applies only to patients who are not receiving therapeutic 
anticoagulation; patients receiving therapeutic anticoagulation should be 
on a stable dose. 
5. Ability to swallow and retain orally administered study drug; 
EGFRm NSCLC Disease Characteristics 
6. Histologically or cytologically documented metastatic or unresectable, locally 
advanced or metastatic NSCLC, with prior histopathological reports showing 
evidence of one or more activating EGFR mutation (eg, G719X, exon 19 deletion, 
L858R, L861Q), except for exon 20 insertion; 
7. Measurable disease as defined by RECIST v1.1 (Appendix A): 
• 
Previously irradiated lesions should not be counted as target lesions; 

Clovis Oncology, Inc. 
Clinical Protocol 
Rociletinib (CO-1686) 
CO-1686-032 
 
26 May 2015 
 
 
Page 17 of 131 
 
 
 
 
 
Inclusion 
Criteria 
(continued) 
• 
Lesions that are intended to be used to collect tissue samples for biopsy should 
not be counted as target lesions. 
8. Biopsy of tumor tissue for central evaluation within 60 days prior to the first day of 
study treatment (Run-in-Period Day 1 for Phase 1; C1D1 for Phase 2); 
9. For Phase 1 and Phase 2 Group B, patients must have progressed after at least 
12 weeks of treatment with a 1st or 2nd generation EGFR TKI (eg, erlotinib, gefitinib, 
afatinib) for advanced or metastatic NSCLC. A minimum of a 3 day washout period 
is required for previous EGFR TKIs.  
• 
Previous chemotherapy for NSCLC is allowed for patients enrolled in Phase 1 
and Phase 2 Group B 
10. For Phase 2 Group A, patients must be EGFR TKI treatment-naïve and 
chemotherapy-naïve 
11. Anticipated life expectancy of at least 3 months; 
Medical/Surgical History 
12. A minimum of 14 days must have elapsed since any palliative radiotherapy;  
13. A minimum of 14 days must have elapsed from last invasive surgery, and wound 
healing has occurred; 
14. Any ongoing potentially reversible treatment-related toxicities must be resolved to 
Grade ≤ 1 EXCEPT alopecia or (with agreement from the Medical Monitor) the 
expected EGFR TKI toxicities of rash or diarrhea that are stable with intervention; 
15. No planned major surgery while on study; 
Concomitant Medications or Procedures 
16. Women of childbearing potential must have a negative serum pregnancy test within 
7 days prior to the first dose of study treatment and agree to use highly effective 
contraception as defined in the full protocol, during the study and for 90 days 
following the last dose of MPDL3280A or rociletinib; 
17. Men with a female partner of childbearing potential must have either had a prior 
vasectomy or agree to use effective contraception as described in the full protocol for 
at least 14 days prior to administration of the first dose of study treatment, during the 
study, and for 90 days following the last dose of MPDL3280A or rociletinib. 
 

Clovis Oncology, Inc. 
Clinical Protocol 
Rociletinib (CO-1686) 
CO-1686-032 
 
26 May 2015 
 
 
Page 18 of 131 
 
 
 
Exclusion 
Criteria 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Any of the following criteria will exclude patients from study participation: 
EGFRm NSCLC Disease Characteristics 
1. Documented evidence of an exon 20 insertion mutation in the EGFR gene; 
2. Symptomatic, untreated or unstable central nervous system or leptomeningeal 
metastases. (Patients with treated and stable brain metastases [confirmed by 2 scans 
at least 4 weeks apart], with no evidence of cavitation or hemorrhage in the brain 
lesion are eligible provided that they are asymptomatic and do not require 
corticosteroids); 
Medical/Surgical History 
3. Previous treatment with rociletinib or MPDL3280A, or other 3rd generation EGFR 
TKI (eg, AZD-9291, HM61713), or PD-1 axis-targeted therapy (eg, anti-PD-1 or 
anti-PD-L1); 
4. Prior treatment with CD137 agonists or other immune checkpoint blockade therapies, 
including anti-CTLA-4 therapeutic antibodies; 
5. Uncontrolled pleural effusion, pericardial effusion or ascites requiring recurrent 
drainage procedures (once monthly or more frequently); 
6. Uncontrolled hypercalcemia (> 1.5 mmol/L ionized calcium or Ca > 12 mg/dL or 
corrected calcium > ULN) or symptomatic hypercalcemia requiring continued use of 
bisphosphonate therapy or denosumab: 
• 
Patients who are receiving bisphosphonate therapy or denosumab specifically to 
prevent skeletal events and who do not have a history of clinically significant 
hypercalcemina are eligible; 
• 
Patients who are receiving denosumab prior to enrollment must be willing and 
eligible to receive a bisphosphonate instead while on study. 
7. History of severe allergic, anaphylactic, or other hypersensitivity reactions to 
chimeric humanized antibodies or fusion proteins; 
8. Known hypersensitivity to Chinese hamster ovary cell products or any component of 
the MPDL3280A or rociletinib formulations; 
9. History of prior allogeneic hematopoietic stem cell transplantation or prior solid 
organ transplantation; 
10. History of autoimmune disease (please review Appendix E): 
• 
Patients with a history of Type 1 diabetes on a stable anti-hyperglycemic 
regimen; autoimmune-related hypothyroidism on a stable dose of thyroid 
replacement hormone; vitiligo; or alopecia are eligible for this study. 
11. Positive test for human immunodeficiency virus (HIV); 
12. Patients with active hepatitis B virus (HBV) (defined by a positive hepatitis B 
surface antigen [HBsAg] test at screening): 
• 
Patients with past or resolved HBV infection (defined by a negative HBsAg test 
and a positive anti-hepatitis B core antigen [anti-HBc] antibody test) are eligible. 
HBV DNA must be obtained in these patients prior to first day of study 
treatment. 
 
 

Clovis Oncology, Inc. 
Clinical Protocol 
Rociletinib (CO-1686) 
CO-1686-032 
 
26 May 2015 
 
 
Page 19 of 131 
 
 
Exclusion 
Criteria 
(continued) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
13. Patients with active hepatitis C virus (HCV): 
• 
Patients positive for HCV antibody are eligible only if polymerase chain reaction 
(PCR) is negative for HCV ribonucleic acid (RNA). 
14. Active tuberculosis; 
15. Signs or symptoms of infection within 2 weeks prior to first day of study treatment; 
16. Received therapeutic oral or IV antibiotics within 2 weeks prior to first day of study 
treatment: 
• 
Patients receiving prophylactic antibiotics (eg, to prevent a urinary tract 
infection or chronic obstructive pulmonary disease exacerbation) are eligible. 
17. Administration of a live, attenuated vaccine within 4 weeks before first day of study 
treatment or anticipation that such a live attenuated vaccine will be required during 
the study: 
• 
Influenza vaccination should be given during influenza season only 
(approximately October to March). Patients must not receive live, attenuated 
influenza vaccine (eg, FluMist) within 4 weeks prior to first day of study 
treatment or at any time during the study. 
18. Class II to IV heart failure as defined by the New York Heart Association functional 
classification system (Appendix G) 
• 
Patients with a known left ventricular ejection fraction (LVEF) < 40% will be 
excluded; 
• 
Patients with known coronary artery disease, congestive heart failure not 
meeting the above criteria, or LVEF < 50% must be on a stable medical regimen 
that is optimized in the opinion of the treating physician, in consultation with a 
cardiologist if appropriate, to be eligible. 
19. Patients who have experienced untreated and/or uncontrolled cardiovascular 
conditions and/or have symptomatic cardiac dysfunction (unstable angina, congestive 
heart failure, myocardial infarction within the previous 3 months; coronary 
angioplasty, or stenting or bypass grafting within the past 6 months; cardiac 
ventricular arrhythmias requiring medication; any history of 2nd or 3rd degree 
atrioventricular conduction defects); 
20. Any of the following cardiac abnormalities or history:  
• 
Clinically significant abnormal 12-lead electrocardiogram (ECG) or QT interval 
corrected using Fridericia’s method (QTCF) > 450 ms; 
• 
Inability to measure QT interval on ECG; 
• 
Personal or family history of long QT syndrome; 
• 
Implantable pacemaker or implantable cardioverter defibrillator; 
• 
Resting bradycardia < 55 beats/min. 
21. History of idiopathic pulmonary fibrosis, organizing pneumonia (eg, bronchiolitis 
obliterans), drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active 
pneumonitis on screening chest computerized tomography (CT) scan: 
• 
History of radiation pneumonitis in the radiation field (fibrosis) is permitted. 
22. Females who are pregnant or breast feeding; 
23. Presence of active gastrointestinal (GI) disease (including GI bleeding or ulceration) 
or other condition that could affect GI absorption (eg, malabsorption syndrome, 
history of biliary tract disease); 

Clovis Oncology, Inc. 
Clinical Protocol 
Rociletinib (CO-1686) 
CO-1686-032 
 
26 May 2015 
 
 
Page 20 of 131 
 
 
 
 
Exclusion 
Criteria 
(continued) 
 
24. Uncontrolled medical, psychological, familial, sociological, or geographical 
conditions that interfere with the patient’s safety, ability to provide informed consent, 
or ability to comply with the protocol; 
25. Malignancies other than NSCLC within 5 years prior to enrollment, with the 
exception of those with a negligible risk of metastasis or death (such as adequately 
treated carcinoma in situ of the cervix, basal or squamous cell skin cancer, localized 
prostate cancer, or ductal carcinoma in situ); 
Previous and Concomitant Medications 
26. Patients who are currently receiving treatment with any medications that have the 
potential to prolong the QT interval if that treatment cannot be either discontinued or 
switched to a different medication prior to first day of study treatment. The wash out 
period for the medication should be at least 5 times the medication’s half-life (see 
http://crediblemeds.org/ for a list of QT-prolonging medications); 
27. Treatment with systemic immunostimulatory agents (including but not limited to 
interferon [IFN], interleukin [IL]-2) within 6 weeks or five half-lives of the drug, 
whichever is shorter, prior to first day of study treatment; 
28. Treatment with systemic immunosuppressive medications (including but not limited 
to prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and 
antitumor necrosis factor [anti-TNF] agents) within 2 weeks prior to first day of 
study treatment: 
• 
The use of inhaled corticosteroids and mineralocorticoids (eg, fludrocortisone) is 
allowed. 
Study 
Treatment 
Rociletinib is provided as 250 mg or 125 mg tablets. During the Dose Finding Phase 
(Phase 1), dosing with rociletinib at the cohort-assigned dose will begin on the first day of the 
7-day Run-in-Period of rociletinib monotherapy. During the Dose Expansion Phase (Phase 2), 
dosing with rociletinib at the RP2D for the combination will begin on C1D1. Patients will 
self-administer rociletinib orally BID at the cohort-assigned dose, unless dose reduction is 
required for adverse event management. Patients should take rociletinib as directed by the 
treating physician. Patients will be instructed to take each dose of rociletinib with 8 oz. 
(240 mL) of water and with a meal or within 30 minutes after a meal. Tablets should be 
swallowed whole. 
MPDL3280A is provided in single-use, 20-cc USP/Ph. Eur. Type 1 glass vials as a 
colorless-to-slightly yellow, sterile, preservative-free clear liquid solution intended for IV 
administration. The vial is designed to deliver 20 mL (1200 mg) of MPDL3280A solution but 
may contain more than the stated volume to enable delivery of the entire 20 mL volume. 
Dosing with MPDL3280A at a fixed dose of 1200 mg will begin on C1D1 (for Phase 1, C1D1 
follows the Run-in-Period of rociletinib monotherapy) and Day 1 of each 21-day cycle 
thereafter. 
Administration of MPDL3280A will be performed in a setting with emergency medical 
facilities and staff who are trained to monitor for and respond to medical emergencies. 
Dose modification guidelines for rociletinib and MPDL3280A are described in Section 5.7. 

Clovis Oncology, Inc. 
Clinical Protocol 
Rociletinib (CO-1686) 
CO-1686-032 
 
26 May 2015 
 
 
Page 21 of 131 
 
 
 
 
Concomitant 
Medications 
Concomitant therapy includes any prescription or over-the-counter medications or 
preparations used by a patient from 28 days prior to the first dose of study treatment through 
28 days after the last dose of study treatment, or the date of administration of subsequent 
anticancer therapy, whichever is earlier. All concomitant medications should be reported to 
the Investigator and recorded.  
Guidelines for use of concomitant medications are detailed in Section 7. 
Withdrawal 
Criteria 
A patient must be discontinued from all study treatment if any of the following apply: 
• Consent withdrawal at the patient’s own request or at the request of their legally 
authorized representative; 
• Clinical disease progression where the Investigator believes that the patient will not 
continue to benefit from study treatment (Note: patients will be permitted to continue 
study treatment after a radiographic progression [Appendix A and Appendix B] if the 
benefit-risk ratio is judged to be favorable and continued treatment is approved by the 
Medical Monitor); 
• Any event, adverse or otherwise, that, in the opinion of the Investigator, would pose an 
unacceptable safety risk to the patient; 
• An intercurrent illness that, in the opinion of the Investigator, would affect assessments 
of the clinical status to a significant degree and requires discontinuation of therapy; 
• A positive pregnancy test at any time during the study; 
• Non-compliance as described in Section 5.5; 
• Investigator decision. 
In addition, the Sponsor may discontinue the study early for any of the reasons noted in 
Section 12.6. 
Study 
Procedures 
The Screening Period will be 28 days prior to the first dose of study treatment. Some 
assessments are required to be performed within shorter windows (eg, 7 or 14 days) prior to 
the first dose of study treatment (see Table 1). A mandatory baseline biopsy will be collected 
within 60 days prior to first dose of study treatment. 
The Treatment Period will consist of 21-day treatment cycles. In Phase 1 only, there will be an 
additional 7-day Run-in-Period of rociletinib monotherapy. Clinic visits are scheduled on 
Day 1 of each cycle and more frequently during Cycle 1 (see Table 1). 
Tumor assessments will be conducted for the duration that the patient is on study treatment 
(Section 8.4.3.1). In addition, patients will provide blood samples for PK and 
pharmacodynamics/biomarker assessments at protocol-defined time points (see Table 2).  
During a Follow-up Period, patients will be followed for adverse events through 28 days after 
last dose of study treatment, or until initiation of subsequent anticancer therapy, whichever is 
earlier. Patients will also be contacted approximately every 3 months for collection of data on 
subsequent anticancer treatment and survival. In addition, the patient will be asked to return 
120 days after the last dose of MPDL3280A to collect samples for pharmacokinetic (PK) and 
anti-therapeutic antibody (ATA) samples (see Table 2). 
See the Table 1 for detailed study procedures. 

Clovis Oncology, Inc. 
Clinical Protocol 
Rociletinib (CO-1686) 
CO-1686-032 
 
26 May 2015 
 
 
Page 22 of 131 
 
 
 
 
PK 
Please refer to Table 2 for a detailed PK sampling schedule.  
On scheduled PK sampling days, patients should be instructed to not self-administer study 
drug at home, but to bring rociletinib to the clinic along with breakfast. After a predose PK 
blood draw, patients will eat breakfast and take the morning dose of rociletinib within 
30 minutes after starting their meal. On days of MPDL3280A infusions, patients will be 
administered IV MPDL3280A approximately 2 hours after the morning rociletinib dose. 
Times of the meals and administrations of study drugs in the clinic should be recorded. 
Additional unscheduled PK blood samples will be collected at the time of fresh tumor biopsy 
and may also be collected when a patient experiences an adverse event for which the 
Investigator would like to have PK data to help understand the safety observation. 
Pharmacody-
namics 
Please refer to Table 2 for a detailed pharmacodynamic blood sampling schedule.  
A mandatory fresh tumor tissue biopsy specimen will be collected within 60 days prior to the 
first day of study treatment for all patients. In addition, an optional fresh tumor biopsy may be 
collected at time of permanent treatment discontinuation due to disease progression (at the 
time the Investigator believes the patient is no longer deriving clinical benefit from study 
treatment, if treatment beyond radiographic disease progression is approved). 
The baseline tissue biopsy specimen from screening will be used for a retrospective 
confirmation of EGFR mutation status by a central laboratory. The baseline biopsy as well as 
the optional tissue biopsy collected at progression will also be used to investigate mechanisms 
of response, primary resistance, and acquired resistance to rociletinib and MPDL3280A.  
Blood samples will be collected for pharmacogenomic and pharmacodynamics analyses. The 
pharmacogenomic blood sample will be collected predose on C1D1 for genomic 
deoxyribonucleic acid (DNA) purification. The DNA sample may be evaluated by next 
generation sequencing (NGS), and molecular alterations in germline and tumor DNA may be 
compared so that molecular alterations unique to the tumor that may modulate response or 
resistance to EGFR targeted therapy can be unambiguously identified.  
Pharmacodynamic blood samples will be collected and processed as described in Table 2 and 
Section 8.4.5.  
Statistical 
Procedures 
Statistical methods are described in Section 10. 

Clovis Oncology, Inc. 
Clinical Protocol 
Rociletinib (CO-1686) 
CO-1686-032 
 
26 May 2015 
 
 
Page 23 of 131 
 
 
THIS PAGE IS INTENTIONALLY LEFT BLANK 
 
 

Clovis Oncology, Inc. 
Clinical Protocol 
Rociletinib (CO-1686) 
CO-1686-032 
FINAL Version 1.0 
26 May 2015 
 
 
Page 24 of 131 
Confidential 
 
Table 1: 
Study CO-1686-032 Schedule of Assessments 
ProcedureA 
Screening 
Period 
 
Treatment Period 
 
 
Rociletinib 
7-day Run-
In- Period 
(Phase 1 
only) 
Cycle 1 combination therapy 
(21-day cycle) 
 
Cycle 2+ 
combination 
therapy 
(21-day cycle) 
End of 
TreatmentC 
Follow Up 
Day -28 to  
Day 0 
 
 
Day 1B 
 
Day 1B 
Day 4 
 
Days 8 and 15 
±2 days 
 
Day 1  
±3 days 
Informed consent 
X 
 
 
 
 
 
 
 
Documentation of EGFR 
mutational statusD 
X 
 
 
 
 
 
 
 
Medical/oncology historyE 
X 
 
 
 
 
 
 
 
Physical examination 
CompleteF,G 
LimitedH 
CompleteG 
LimitedH 
LimitedH 
LimitedH 
CompleteG 
 
ECOG performance statusI 
XF 
X 
X 
 
 
X 
X 
 
Vital signsJ  
XF 
X 
X 
X 
X 
X 
X 
 
Hematology (including 
reticulocytes)K  
XF 
X 
X 
 
X 
X 
X 
 
Coagulation tests L 
XF 
 
 
 
 
 
 
 
UrinalysisM 
X 
 
 
 
 
 
 
 
Fasting serum chemistryN 
XF 
X 
X 
 
 
X 
X 
 
Fasting blood glucoseO 
 
 
 
X 
X 
 
 
 
Serum pregnancy testP 
X 
 
 
 
 
 
X 
 
Hemoglobin A1c 
X 
 
 
 
 
Odd cycles 
 
 
TSH, free T3 and free T4Q 
X 
 
 
 
 
X 
X 
 
HIV/HBV/HCV serologyR 
X 
 
 
 
 
 
 
 
ECHO/MUGAS 
X 
 
 
 
 
 
 
 
12-lead ECGT 
XF 
X 
X 
X 
X 
X 
X 
 
Pulmonary function testU 
X 
 
 
 
 
 
 
 

Clovis Oncology, Inc. 
Clinical Protocol 
Rociletinib (CO-1686) 
CO-1686-032 
FINAL Version 1.0 
26 May 2015 
 
 
Page 25 of 131 
Confidential 
 
ProcedureA 
Screening 
Period 
 
Treatment Period 
 
 
Rociletinib 
7-day Run-
In- Period 
(Phase 1 
only) 
Cycle 1 combination therapy 
(21-day cycle) 
 
Cycle 2+ 
combination 
therapy 
(21-day cycle) 
End of 
TreatmentC 
Follow Up 
Day -28 to  
Day 0 
 
 
Day 1B 
 
Day 1B 
Day 4 
 
Days 8 and 15 
±2 days 
 
Day 1  
±3 days 
Tumor biopsyV 
X 
 
 
 
 
 
XC,V 
 
Tumor assessmentsW 
X 
 
 
 
 
X 
XC,W 
 
Pharmacogenomic blood 
sample (predose) 
 
X 
X (Phase 2 
only) 
 
 
 
 
 
Rociletinib PK samplingX 
 
X 
X 
 
Days 8-9 
X (see Table 2) 
XC,X 
 
MPDL3280A PK 
samplingX 
 
 
X 
 
 
X (see Table 2) 
XC,X 
X 
ATA testingX 
 
 
X 
 
 
X (see Table 2) 
XC,X 
X 
TBNK blood sampleX 
XF 
 
X  
 
X 
 
XC,X 
 
Pharmacodynamic blood 
sampleX 
X 
 
X  
 
Day 8 
X (see Table 2) 
XC,X 
 
Dispense rociletinib/ drug 
accountability/diaryY 
 
X 
X 
 
 
X 
 
 
Rociletinib in-clinic 
administrationY 
 
X 
X 
 
Day 8 
X 
 
 
MPDL3280A 
administrationZ 
 
 
X 
 
 
X 
 
 
Adverse eventsAA 
X 
X 
X 
X 
X 
X 
X 
 
Concomitant 
medicationsBB 
X 
X 
X 
X 
X 
X 
X 
 
Survival assessment/ 
subsequent therapiesCC 
 
 
 
 
 
 
X 
X 
ATA, anti-therapeutic antibody; ECG, electrocardiogram; ECOG, Eastern Cooperative Oncology Group; EGFR, epidermal growth factor receptor; HBV, hepatitis B virus; HCV, hepatitis C virus; HIV, 
human immunodeficiency virus; MUGA, multigated acquisition (scan); PK, pharmacokinetic; TBNK, T, B, and natural killer; TSH, thyroid-stimulating hormone. 

Clovis Oncology, Inc. 
Clinical Protocol 
Rociletinib (CO-1686) 
CO-1686-032 
FINAL Version 1.0 
26 May 2015 
 
 
Page 26 of 131 
Confidential 
 
 
A 
Unless otherwise specified: Clinic visits for the specified assessments in Cycle 2+ should be completed ± 3 days of the scheduled time point relative to C1D1. 
Assessments are to be performed prior to administration of study treatment, when applicable. All results must be reviewed by the Investigator prior to administration 
of study treatment. Perform assessments as scheduled on C1D4 (ie, no window) and assessments for C1D8 and C1D15 within ± 2 days of the scheduled time points. 
B 
Procedures required on Day 1 of Run-in-Period (Phase 1) or C1D1 (Phase 2) may be omitted if completed ≤ 3 days earlier during the Screening Period. 
C 
Patients will be asked to return to the clinic 28 days (+7 days) after the last dose of study treatment, or before the patient initiates another anticancer agent, if sooner, 
for assessment of patient safety. Collect optional tumor biopsy and blood samples for PK, pharmacodynamic, TBNK, and ATA analyses scheduled for the EOT Visit 
as close as possible to the date of the decision to discontinue treatment (ie, not necessary to wait until EOT Visit for sample collection). Tumor assessment scans do 
not need to be repeated if radiographic disease progression has been documented previously or the last scans were performed < 2 weeks before the last dose of study 
treatment or the patient had disease progression at the last scan. All AEs (including SAEs and protocol-defined events of special interest), regardless of attribution, 
will be recorded until 28 days after the last dose of study treatment or until initiation of another anticancer therapy, whichever occurs first. Ongoing AEs considered 
related to study treatment and all SAEs will be followed until the event has resolved to baseline grade, the event is assessed by the Investigator as stable, new 
anticancer treatment is initiated, the patient is lost to follow up, the patient withdraws consent, or it is determined that the study treatment or participation is not the 
cause of the AE. 
D 
For patients being considered for enrollment in the study, screening assessments will not begin until patient tumor EGFR mutation status is determined through local 
assessments. 
E 
Record patient’s medical history, including smoking status, medical conditions, and oncology history, including date of cancer diagnosis, prior cancer treatment, and 
any surgical procedures. 
F 
Perform procedure within 14 days prior to first day of study treatment. 
G 
Includes height (at screening only), weight (the patient should be in light indoor clothes; no shoes), and the evaluation of head, eyes, ears, nose and throat (HEENT) 
and cardiovascular, dematologic, musculoskeletal, respiratory, gastrointestinal, and neurologic systems.  
H 
Includes weight (the patient should be in light indoor clothes; no shoes), an assessment of all baseline abnormalities and recording of associated changes, questioning 
of the patient about any skin or vision changes, and any other symptom-directed examination. 
I 
ECOG performance status should be assessed by the same study personnel at each visit, if possible. Care will be taken to accurately score performance status, 
especially during screening for study eligibility purposes. Additional consideration should be given to borderline ECOG performance status to avoid enrolling patients 
with significant impairment. 
J 
After the patient has been resting for at least 5 minutes, measure body temperature, heart rate, respiratory rate, and blood pressure. For the first infusion of 
MPDL3280A, measure vital signs within 60 minutes before, every 15 (± 5) minutes during the infusion, and 30 (± 10) minutes after the infusion. For subsequent 
infusions, vital signs will be collected within 60 minutes before the infusion, during the infusion if clinically indicated or if symptoms occurred in the prior infusion, 
and 1 hour (± 10 minutes) after the infusion. 
K 
Includes hemoglobin, hematocrit, WBC and differential (with ANC), reticulocyte count, and platelet count. Hematology results must be reviewed by the Investigator 
before administration of rociletinib and/or MPDL3280A. 
L 
Includes prothrombin time, international normalized ratio (INR), and activated partial thromboplastin time (aPTT). Patients known to require concomitant therapy 
with anticoagulants such as warfarin should also have INR monitored throughout the study. 
M  
Collect a freshly voided, clean sample and analyze by dipstick for protein, glucose, blood, pH, and ketones. If dipstick findings are abnormal, then a microscopic 
evaluation will be performed to assess the abnormal findings.  
N 
Includes total protein, albumin, creatinine, blood urea nitrogen (BUN) or urea, total bilirubin, alkaline phosphatase, alanine aminotransferase (ALT), aspartate 
aminotransferase (AST), total cholesterol, fasting glucose, sodium, potassium, magnesium, chloride, calcium, phosphorus and uric acid. Fasting glucose must be 
measured after an 8-hour fast (no food or liquid other than water). 
O 
Fasting glucose must be measured after an 8-hour fast (no food or liquid other than water). 
P 
Perform for females of childbearing potential ≤ 7days before first day of study treatment and at the EOT Visit. If the serum pregnancy test results are not available on 
the first day of study treatment, a urine pregnancy test can be performed on the first day of study treatment. A negative result must be confirmed by a physician before 
the first dose of study treatment. 

Clovis Oncology, Inc. 
Clinical Protocol 
Rociletinib (CO-1686) 
CO-1686-032 
FINAL Version 1.0 
26 May 2015 
 
 
Page 27 of 131 
Confidential 
 
Q 
TSH, free T3, and free T4 will be tested at screening, and thereafter, TSH will be tested every 3 months or as clinically indicated. 
R 
For patients who have positive serology for anti-HBc: HBV DNA must be collected prior to administration of MPDL3280A in patients who have positive serology 
for anti-HBc.  
S 
For patients with known history of (or suspected current potential for) pericardial effusions: baseline and as clinically indicated.  
T 
12-lead ECG performed in triplicate 10-sec tracings > 2 min apart in patient at rest for at least 5 minutes. The average of triplicates should be recorded. Data will also 
be transmitted for central review. 
U 
Conduct at baseline and as clinically indicated. Pulmonary function tests must include an assessment of diffusing capacity of lung for carbon monoxide (DLCO). 
V 
Collect a mandatory biopsy of either primary or metastatic tumor tissue within 60 days prior to the first day of study treatment. Corresponding blood samples (see 
Table 2) should be obtained before the tumor specimen collection. If a biopsy was performed outside of the protocol within 60 days prior to administration of study 
drug, and no intervening treatment was given, a repeat biopsy is not required if an adequate tumor tissue specimen from the recent biopsy can be provided to the 
Sponsor during the Screening Period. The optional tumor biopsy (requires separate consent) will be collected from patients who permanently discontinue study 
treatment because of disease progression (or patient is considered by the Investigator to no longer benefit from study treatment, if treatment is continued beyond a 
radiographic progression); the biopsy should be collected as close as possible to the date of the decision to discontinue treatment (ie, not necessary to wait until EOT 
Visit for sample collection).  
W 
Obtain baseline tumor assessments (clinical examination and scans) within 28 days before first day of study treatment. Scans will include the pelvis, chest, and 
abdomen (preferably CT scans with ≤ 5 mm slice thickness). Brain imaging is required at baseline and must be repeated at follow-up tumor assessments for patients 
with brain lesions. Other studies (magnetic resonance imaging [MRI] and X-ray) may be performed if required. The same methods used to detect lesions at baseline 
are to be used to follow the same lesions throughout the study. Tumor assessments during the Treatment Period will occur every 2 cycles (6 weeks ±1 week) through 
Cycle 6 (ie, at the end of Cycles 2, 4, and 6); every 3 cycles (9 weeks ± 1 week) after Cycle 6 (ie, at the end of Cycles 9, 12, etc); and at the EOT Visit. The frequency 
of tumor assessments may be further reduced after 2 years with approval of the Medical Monitor. Tumor assessments at the EOT Visit are not required if radiographic 
disease progression has been documented previously or the last tumor assessments were performed < 2 weeks before the last dose of study treatment. If an initial CR 
or PR is noted, confirmatory scans must be performed 4 to 6 weeks later.  
X 
Collect blood samples for PK, pharmacodynamic, TBNK, and ATA analyses according to the schedule and instructions in Table 2. On scheduled PK sampling days, 
instruct patients to not administer study drug at home, but to bring rociletinib to the clinic along with breakfast. After a predose PK blood draw, patients will eat 
breakfast and take the morning dose of rociletinib within 30 minutes after starting their meal. On days of MPDL3280A infusions, patients will be administered IV 
MPDL3280A approximately 2 hours after the morning rociletinib dose. Times of the PK blood draws, meals, and administrations of study drugs in the clinic should 
be recorded. Note: At the EOT Visit, collect samples as close as possible to the date of the decision to discontinue treatment (ie, not necessary to wait until EOT Visit 
for sample collection). During the Follow-up Period, patients will be asked to return 120 days after the last dose of MPDL3280A for collection of MPDL3280A PK 
and ATA samples. Samples for MPDL3280A PK and ATA and TBNK will only be collected in patients who have at least one dose of MPDL3280A (ie, not 
applicable to patients who remain on rociletinib monotherapy because they are ineligible for combination therapy [see Section 5.7.2]).  
Y 
Dispense a sufficient number of rociletinib tablets to last until the next visit and provide a medication diary. Extra study drug may be dispensed if there is a reasonable 
possibility that the patient’s next visit may be delayed (eg, because of inclement weather or distance of patient’s home from study center). Instruct patient on how to 
take study drug and to record the time and date they take each study drug dose in the diary and return all unused study drug at each study visit. Collect and review 
medication diary, collect unused tablets, and assess compliance at each subsequent visit. In-clinic administration of rociletinib is required on days that predose or 
postdose blood samples are collected (see Table 2). 
Z 
Administer MPDL3280A as an IV infusion at a fixed dose of 1200 mg IV starting at C1D1 and every 3 weeks thereafter (one infusion per 21-days). The initial dose 
of MPDL3280A will be delivered over 60 (± 15) minutes. If the first infusion is tolerated without infusion-associated adverse events, the second infusion may 
be delivered over 30 (± 10) minutes. If the 30-minute infusion is well tolerated, all subsequent infusions may be delivered over 30 (± 10) minutes. 
AA 
Monitor patients for AEs from the time of signed informed consent (study procedure-related events included) through 28 days after the last dose of study treatment, or 
subsequent anticancer therapy if sooner (see Section 9 for details).  
BB 
Record concomitant medications from 28 days prior to the first dose of study treatment through 28 days after the last dose of study treatment, or subsequent 
anticancer therapy, whichever is earlier. See Section 7 for details. 
CC 
Collect survival follow-up information, including all subsequent anticancer therapy, via telephone calls, patient medical records, and/or clinic visits 12 weeks 
(± 1 week) until death, loss to follow up, or study termination by the Sponsor. 

Clovis Oncology, Inc. 
Clinical Protocol 
Rociletinib (CO-1686) 
CO-1686-032 
FINAL Version 1.0 
26 May 2015 
 
 
Page 28 of 131 
Confidential 
 
Table 2: 
Clinical Sample Collection (PK, ATA, TBNK, Pharmacodynamic)a  
Study Visit 
Rociletinib PK 
MPDL3280A 
PK 
MPDL3280A 
ATA 
TBNK and/or 
pharmacodynamic  
Screening 
 
– 
– 
– 
Both b 
Run In 
Day 1 
Predose c 
(Phase 1 only) 
– 
– 
– 
Cycle 1d 
Day 1e 
Predose c 
 
Predose c 
 
30 ( 10) min 
(after end of 
infusion) e 
Predose c 
 
Both b  
(Predose) 
Day 8 
Predose c 
 
 
 
0.5, 1, 1.5, 2.5, 4, 
and 6 hours post-
morning dose 
(Phase 1 only) e 
– 
– 
 
Both b 
(Predose) 
 
Day 9 
(Phase 1 
only) 
Predose c 
(24-hrs after D8 
morning dose) 
– 
– 
– 
Day 15 
– 
– 
– 
TBNK 
Cycle 2-4 d 
Day 1 
Predose c  
Predose c 
Predose c 
Pharmacodynamic 
Cycle 5 
Day 1 
 – 
– 
– 
Pharmacodynamic 
Cycle 6 d 
Day 1 
Predose c 
Predose c 
Predose c 
Pharmacodynamic 
Cycle 8 d 
Day 1 
Predose c 
Predose c 
Predose c 
Pharmacodynamic 
Cycle 9 
Day 1 
– 
– 
– 
Pharmacodynamic 
Every 8 cycles after C8 
(Cycles 16, 24, etc) d  
Day 1 
Predose c 
Predose c 
Predose c 
Pharmacodynamic 
EOT Visit 
 
X 
X 
X 
Both b 
120 days 
(± 30 days) after last dose 
of MDPL3280A 
At visit 
– 
X  
X 
– 
At time of fresh biopsy 
– 
X 
X 
X 
Both b  
ATA, anti-therapeutic antibody; EOT, End of Treatment; PK, pharmacokinetics; TBNK, T, B, and natural killer cells. 
 
a 
Please refer to the Laboratory Manual for details on sample handling and processing. 
b 
The pharmacodynamics collection should occur after the TBNK collection and is always predose/pre-infusion. 
c 
Predose refers to the morning dose of rociletinib. 
d 
Collection of the actual time(s) of dose administration is essential for both rociletinib and MPDL3280A. 
e 
MPDL3280A dose administration should start approximately 2 hours after the morning rociletinib dose, which is to occur 
within 30 minutes after the start of the morning meal. 

Clovis Oncology, Inc. 
Clinical Protocol 
Rociletinib (CO-1686) 
CO-1686-032 
FINAL Version 1.0 
26 May 2015 
 
 
Page 29 of 131 
Confidential 
LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS 
AE 
adverse event 
ALT 
alanine aminotransferase 
ANC 
absolute neutrophil count 
anti-HBc 
anti-hepatitis B core antigen 
aPTT 
activated partial thromboplastin time 
AST 
aspartate aminotransferase  
ATA 
anti-therapeutic antibody 
AUC 
area under the curve 
AUC0-24 
area under the curve from time zero to 24 hours 
BID 
twice daily 
BSA 
body surface area 
BUN 
blood urea nitrogen 
CFR 
Code of Federal Regulations 
CK 
creatine kinase 
Cmax 
maximum concentration 
CR 
complete response  
CRO 
contract research organization  
CSC 
Clinical Safety Committee 
CT 
computed tomography 
ctDNA 
circulating tumor DNA 
CTCAE 
Common Terminology Criteria for Adverse Events (Version 4.03) 
CXDX 
Cycle X Day X 
CYP 
cytochrome P450 
DCR 
disease control rate 
DLCO 
diffusing capacity of lung for carbon monoxide 
DLT 
dose-limiting toxicity  
DNA 
deoxyribonucleic acid 
DOR 
duration of response 
DVT 
deep venous thrombosis 
ECG 
electrocardiogram 
ECHO 
echocardiogram 
ECOG 
Eastern Cooperative Oncology Group 
eCRF 
electronic case report form 
EDC 
electronic data capture 
EGFR 
epidermal growth factor receptor 
EGFRm 
epidermal growth factor receptor mutation-positive 
EOT 
End of Treatment 
EURTAC 
European Tarceva™ versus Chemotherapy Study 
FBG 
fasting blood glucose 
FDA 
Food and Drug Administration 
GCP 
Good Clinical Practice 
GGO 
ground glass opacities 
GI 
gastrointestinal 
GLP 
Good Laboratory Practice 
HBr 
hydrobromide 

Clovis Oncology, Inc. 
Clinical Protocol 
Rociletinib (CO-1686) 
CO-1686-032 
FINAL Version 1.0 
26 May 2015 
 
 
Page 30 of 131 
Confidential 
HBsAg 
hepatitis B surface antigen 
HBV 
hepatitis B virus 
HCV 
hepatitis C virus 
HEENT 
head, eyes, ears, nose and throat 
HIPAA 
Health Information Portability and Accountability Act  
HIV 
human immunodeficiency virus 
IB 
Investigator’s Brochure 
ICH 
International Conference on Harmonisation 
ICF 
Informed Consent Form 
IEC 
Independent Ethics Committee 
IFN 
interferon 
IHC 
immunohistochemistry 
IL 
interleukin 
IMP 
investigational medicinal product 
INR 
international normalized ratio 
irAE 
immune-related adverse event 
IRB 
Institutional Review Board  
irRC 
immune-related response criteria 
IV 
intravenous 
LFT 
liver function test 
LVEF 
left ventricular ejection fraction 
MAD 
maximum administered dose 
MAPK 
mitogen-activated protein kinase 
MedDRA 
Medical Dictionary for Regulatory Activities 
MRI 
magnetic resonance imaging 
MTD 
maximum tolerated dose 
mTPI 
modified toxicity probability interval 
MUGA 
multigated acquisition (scan) 
NCI 
National Cancer Institute 
NGS 
next generation sequencing 
NSAID 
nonsteroidal anti-inflammatory drug 
NSCLC 
OS 
non-small cell lung cancer 
overall survival 
ORR 
overall response rate 
PBMC 
peripheral blood mononuclear cells 
PCR 
polymerase chain reaction 
PD 
progressive disease 
PE 
pulmonary embolism 
PET 
positron emission tomography 
PFS 
progression free survival 
P-gp 
P-glycoprotein 
PK 
pharmacokinetic(s) 
PO 
oral(ly) 
PR 
partial response 
PRN 
as needed 
PT 
prothrombin time 
PVC 
polyvinylchloride 

Clovis Oncology, Inc. 
Clinical Protocol 
Rociletinib (CO-1686) 
CO-1686-032 
FINAL Version 1.0 
26 May 2015 
 
 
Page 31 of 131 
Confidential 
Q 
every 
QOD 
every other day 
QD 
once daily 
QTCF 
QT interval corrected using Fridericia’s method 
RECIST 
Response Evaluation Criteria in Solid Tumors, Version 1.1 
RNA 
ribonucleic acid 
RP2D 
recommended Phase 2 dose 
SAE 
serious adverse event 
SAS 
statistical analysis software 
SD 
stable disease 
SUSAR 
suspected unexpected serious adverse reaction 
t1/2 
elimination half-life 
T790M 
EGFR mutation in exon 20, gatekeeper mutation 
T790M– 
T790M mutation-negative 
T790M+ 
T790M mutation-positive 
TBNK 
T-cell, B-cell, and natural killer 
TKI 
tyrosine kinase inhibitor 
tmax 
time to maximum concentration 
TNF 
tumor necrosis factor 
TPI 
toxicity probability interval 
TSH 
thyroid-stimulating hormone 
ULN 
upper limit of normal 
US 
United States (of America) 
WBC 
white blood cell 
WT 
wild type 
 
 
 

Clovis Oncology, Inc. 
Clinical Protocol 
Rociletinib (CO-1686) 
CO-1686-032 
FINAL Version 1.0 
26 May 2015 
 
 
Page 32 of 131 
Confidential 
1 
INTRODUCTION 
Despite years of research and prevention strategies, lung cancer continues to be the most 
common cancer worldwide and the most common cause of cancer-related deaths worldwide,4 
accounting for 1.8 million new cases and 1.6 million deaths in 2012. Lung cancer has a 5-year 
survival rate of less than 10% in patients with advanced disease.5 
Activating epidermal growth factor receptor (EGFR) mutations are key drivers of non-small cell 
lung cancer (NSCLC) malignancy in 10% to 15% of patients of European descent and 
approximately 30% of patients of East Asian descent.6 The two most frequently detected EGFR 
mutations in NSCLC patients are in the kinase domain: L858R substitution in exon 21 and 
deletions in a specific amino acid motif in exon 19 (Del19). Following demonstration of 
improved response rates and progression-free survival (PFS) over cytotoxic chemotherapy in 
Phase 3 studies of erlotinib, gefitinib, and afatinib,7,8,9,10,11 treatment of such patients with 
EGFR inhibitors is now standard of care. 
While the toxicity profile is also improved with first-generation tyrosine kinase inhibitors (TKIs) 
compared to chemotherapy, significant toxicities do occur. Toxicity associated with both 
erlotinib and gefitinib includes skin rash and diarrhea related to inhibition of the wild-type (WT, 
normal) EGFR in skin and intestine, respectively.12,13,14 
Despite the initial response, patients generally experience progression within 9 months to 
14 months of starting erlotinib, gefitinib, or afatinib. After disease progression on an EGFR-TKI, 
patients are often treated with chemotherapy. A number of small studies report response rates of 
14% to 18% and PFS of around 4 months on chemotherapy after failure of an EGFR-TKI.15,16 
Mechanisms of resistance commonly include acquisition of secondary activating mutations while 
the initial activating mutation is maintained.17 The most common cause of resistance is thought 
to be due to development of a second site EGFR mutation in exon 20 called T790M (the 
“gatekeeper” mutation), which prevents drug from binding to the receptor.17,18,19,20 In addition, 
resistance may be associated with amplification of the EGFR gene or other genes that drive 
tumor growth such as MET gene amplification and PI3K mutations. Second-generation TKIs 
such as dacomitinib, neratinib, and afatinib have demonstrated limited clinical activity when the 
T790M mutation is present possibly because the toxicity from potent WT EGFR inhibition limits 
dosing such that drug concentrations required to inhibit T790M are not achieved.21 Assessment 
of post-progression survival in patients treated with EGFR-TKI indicated that those with EGFR 
T790M mutation-positive (T790M+) tumors had a median post-progression survival of 1.9 years 
(95% CI, 1.6-2.6 years).22 Thus, NSCLC patients who have failed treatment with TKIs and 
whose tumors express T790M mutation represent a group with fatal disease and unmet need. 
Furthermore, methods to prevent the acquisition of the T790M mutation are desirable. 
In addition to the development of acquired mutations, evasion of immune destruction has been 
found to be an important mechanism of tumorigenesis and disease progression. Programmed 
death 1 (PD-1) protein is a T-cell coinhibitory receptor and has two known ligands, PD-L1 
(B7-H1) and PD-L2 (B7-DC). PD-L1 is selectively expressed on many tumors and on cells 
within the tumor microenvironment. Binding of PD-L1 to its receptors suppresses T-cell 
migration, proliferation and secretion of cytotoxic mediators, and restricts tumor cell killing. 

Clovis Oncology, Inc. 
Clinical Protocol 
Rociletinib (CO-1686) 
CO-1686-032 
FINAL Version 1.0 
26 May 2015 
 
 
Page 33 of 131 
Confidential 
Potentiation of immune responses has been observed via blockade of the interaction between 
PD-1 and PD-L1 and has resulted in antitumor activity in both nonclinical models and early 
clinical studies.  
Recent studies suggest that activation of PD-1 pathway may contribute to immune escape in 
EGFR-driven tumors. PD-L1 is overexpressed in EGFR-mutated NSCLC cell lines and resected 
tumors. In addition, inhibition of EGFR signaling with erlotinib resulted in down-regulation of 
PD-L1 expression in EGFR-mutated NSCLC cells but not in those with WT EGFR. These and 
other data suggest that PD-L1 expression may be dependent on EGFR signaling via activating 
EGFR mutations. In a recent study, overexpression of PD-L1 was demonstrated in the presence 
of erlotinib in EGFR-TKI-resistant H195 cells, which harbor both an activating mutation and the 
T790 mutation. Thus, blockade of PD1- PD-L1 signaling may help to overcome acquired 
resistance to EGFR-TKIs. 
Rociletinib is a novel, potent, small molecule TKI that irreversibly binds and inhibits EGFR with 
the common activating (L858R, Del19) and T790M-resistance mutations and has minimal 
activity towards WT EGFR. Clovis Oncology, Inc. (Clovis or Sponsor) is developing rociletinib 
as a therapeutic agent to be administered orally (PO) to patients with EGFRm NSCLC who have 
been previously treated with an EGFR-targeted therapy and have a T790M mutation in EGFR. 
The recommended Phase 2 doses (RP2Ds) of single-agent rociletinib are 500 and 625 mg twice 
daily (BID), as determined in the Phase 1/2 study, CO-1686-008 in patients with advanced or 
metastatic EGFRm NSCLC previously treated with an EGFR inhibitor. In CO-1686-008, 
Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1) responses have been 
observed across a range of doses of rociletinib (500 mg BID to 1000 mg BID), and the overall 
response rate (ORR) among NSCLC patients with the T790M+ treated with rociletinib at 500 mg 
or 625 mg BID, the Phase 2 clinical doses, was approximately 67%.1 Responses to rociletinib 
are rapid, frequently occurring within less than 12 weeks. The median PFS in patients receiving 
rociletinib monotherapy at 500 mg or 625 mg in the context of acquired resistance has been 
reported as 10.4 months.1 Responses have also been observed in T790M negative (T790M–) 
patients.1 The most common rociletinib-related adverse event (AE) observed in single-agent 
studies has been hyperglycemia, which is generally managed with oral anti-hyperglycemic 
therapy. AEs typically associated with the inhibition of WT EGFR (eg, the combination of rash 
and chronic diarrhea) have not been observed with rociletinib. 
MPDL3280A is a human IgG1 monoclonal antibody consisting of two heavy chains (448 amino 
acids) and two light chains (214 amino acids) and is produced in Chinese hamster ovary cells. 
MPDL3280A was engineered to eliminate Fc-effector function via a single amino acid 
substitution (asparagine to alanine) at position 298 on the heavy chain, which results in a non-
glycosylated antibody that has minimal binding to Fc receptors and consequently, eliminates 
detectable Fc-effector function and depletion of cells expressing PD-L1. MPDL3280A targets 
human PD-L1 and inhibits its interaction with its receptor, PD-1. MPDL3280A also blocks the 
binding of PD-L1 to B7.1, an interaction that is reported to provide additional inhibitory signals 
to T cells.2 

Clovis Oncology, Inc. 
Clinical Protocol 
Rociletinib (CO-1686) 
CO-1686-032 
FINAL Version 1.0 
26 May 2015 
 
 
Page 34 of 131 
Confidential 
The interaction of PD-L1 with PD-1 and B7.1 inactivates T cells and prevents further T cell 
priming, and increased PD-L1 expression on tumor cells and/or tumor-infiltrating cells is a 
mechanism of cancer evasion of immune surveillance.  
In Phase 1 studies of MPDL3280A, the maximum tolerated dose (MTD) was not reached, and no 
dose-limiting toxicity (DLT) was reported. The most common observed AEs have been fatigue 
and decreased appetite. The RP2D of intravenous (IV) single-agent MPDL3280A has been 
identified as 1200 mg every 3 weeks. 
Antitumor activity has been observed in single-agent studies of MPDL3280A at doses from 
1 mg/kg to 20 mg/kg in multiple tumor types. Data for 53 patients with NSCLC (including 
squamous and non-squamous histologies) treated with MPDL3280A has been presented. A 23% 
ORR based on RECIST v1.1was reported.3 The response rate in patients with PD-L1 expression 
in infiltrating immune cells was 46%. Tumor responses occurred as early as the first assessment. 
PFS in this group was remarkable for a 45% PFS at a 24-week landmark assessment.3 
Treatment of tumors with rociletinib often results in a pronounced reduction in tumor volume, 
likely resulting in the increase of tumor antigen expression, CD8+ T cell infiltration, and a 
decrease in immunosuppressive cytokines. However, the immune response may be limited due to 
increased expression of immunomodulatory proteins such as PD-1, PD-L1, and B7.1 on the 
surface of tumor and T cells. As such, it is anticipated that the combination of MPDL3280A to 
rociletinib will enhance the immune antitumor immune response via blockade of the inhibitory 
signaling resulting from the interactions of PD-L1 with PD-1 and B7.1. 
Two independent mechanisms of action, each with promising activity in patients with NSCLC, 
the potential for complementarity of these mechanisms of action, and largely non-overlapping 
safety profiles provide strong rationale for the current study, which will examine the combination 
of rociletinib and MPDL3280A in patients with EGFRm NSCLC. The tolerability of the 
combination is expected to be acceptable given the minimal overlapping toxicity profile and the 
overall tolerability of the two agents in patients with previously treated advanced cancers. 
1.1 
Rociletinib Nonclinical Overview 
Refer to the rociletinib Investigator’s Brochure (IB) for detailed nonclinical data. 
Rociletinib has been evaluated as a free base formulation (rociletinib free base) and as a 
hydrobromide salt formulation (rociletinib HBr). The pharmacologically active moiety, 
irrespective of formulation, is rociletinib. 
Pharmacology  
Rociletinib exhibited nonclinical antitumor activity as a single agent in cell lines expressing the 
most common activating and T790M EGFR mutations. The in vitro activity of rociletinib was 
evaluated against common and rare lung cancer-associated EGFR mutants. Rociletinib was 
active against del19, L858R, G719S, an exon 19 insertion mutant, and L861Q, but not against an 
exon 20 insertion. Therefore, patients with exon 20 insertions have been excluded from 
participation in this study. 

Clovis Oncology, Inc. 
Clinical Protocol 
Rociletinib (CO-1686) 
CO-1686-032 
FINAL Version 1.0 
26 May 2015 
 
 
Page 35 of 131 
Confidential 
At clinically achievable doses, rociletinib shows potent activity in the NCI-H1975 
(EGFRL858R/T790M) and primary LUM1868 (EGFRL858R/T790M) subcutaneous xenograft models.23 
In addition, the efficacy of rociletinib was examined in an EGFRL858R/T790M transgenic model and 
compared with that of afatinib. Whereas complete responses were observed in all mice treated 
with rociletinib, there was very limited activity in the mice treated with afatinib (please refer to 
IB for additional details). 
Metabolism  
In human liver microsomes, rociletinib was stable, with ≤ 27% turnover in 60 minutes. 
Rociletinib was not metabolized significantly by human recombinant cytochrome P450 (CYP) 
enzymes, with ≤ 10% metabolized in a 60-minute incubation. CYP2C8 mediates the oxidative 
metabolism of rociletinib, and CYP2D6 potentially plays a minor role at most in rociletinib 
metabolism. There is no evidence to suggest the involvement of the polymorphically expressed 
CYP2C9 and CYP2C19 in rociletinib metabolism, implying a low potential for ethnic sensitivity 
variability in humans. Rociletinib is a substrate and an inhibitor of P-glycoprotein (P-gp) (see 
Section 7.6 for guidance on use of concomitant medication that may affect the metabolism of 
rociletinib). 
Safety Pharmacology and Toxicology  
Safety pharmacology and toxicology studies were performed in rats and dogs with rociletinib 
HBr. 
In repeat-dose toxicity studies in rats, primary indices of toxicity included dose-dependent 
clinical signs (thinning haircoat [females], squinting, pale ears or body, and hunched posture), 
decreased food consumption, and loss in body weight and decreased body weight gain. Squinting 
was observed in rats administered high-dose rociletinib and was associated with atrophy of the 
meibomian gland in the eyelid. The correlate of this finding in humans is dry eye. Other 
microscopic findings after 28 days of repeated dosing in rats included minimal to moderate 
atrophy of other glands (Harderian gland, mammary gland, and prostate). Pathological findings 
were minor glandular atrophy in all four tissues which was reversible and principally occurred in 
the high-dose group. Only minor effects were observed with rociletinib on hematopoietic tissue. 
All clinical observations were reversible with exception of body weight effects in male animals 
that received the highest dose (300 mg/kg/dose BID). All clinical pathology changes were fully 
reversed. 
In repeat-dose toxicity studies in dogs, primary indices of toxicity included dose-related clinical 
signs: abnormal feces (liquid and/or non-formed feces), vomiting, and redness of gingiva and 
lips. These observations were not considered adverse due to the overall good health of the 
animals and lack of impact on body weights or food consumption. All clinical observations were 
reversible, except for non-formed feces in one animal. Focal duodenal erosion in one male 
animal dosed at 50 mg/kg/dose BID was the only potential treatment-related effect identified 
histologically. 
No evidence of elevated serum glucose levels were observed in the rat and dog studies. There 
were no rociletinib-related cardiac safety or neurobehavioral findings from the Good Laboratory 

Clovis Oncology, Inc. 
Clinical Protocol 
Rociletinib (CO-1686) 
CO-1686-032 
FINAL Version 1.0 
26 May 2015 
 
 
Page 36 of 131 
Confidential 
Practice (GLP) repeat-dose toxicity studies. Rociletinib did not have any genotoxic activity in 
two in vitro assays and was not phototoxic when evaluated in a phototoxicity study with Long-
Evans pigmented rats. 
1.2 
MPDL3280A Nonclinical Overview 
Refer to the MPDL3280A IB for detailed nonclinical data. 
The nonclinical strategy of the MPDL3820A program was to demonstrate in vitro and in vivo 
activity, to determine in vivo pharmacokinetic (PK) behavior, to demonstrate an acceptable 
safety profile, and to identify a Phase 1 starting dose. Comprehensive pharmacology, PK, and 
toxicology evaluations were performed with MPDL3280A. 
The safety, PK, and toxicokinetics of MPDL3280A were investigated in mice and cynomolgus 
monkeys to support IV administration and to aid in projecting the appropriate starting dose in 
humans. Given the similar binding of MPDL3280A for cynomolgus monkey and human PD-L1, 
the cynomolgus monkey was selected as the primary and relevant nonclinical model for 
understanding the safety, PK, and toxicokinetics of MPDL3280A. 
Overall, the nonclinical PK and toxicokinetics observed for MPDL3280A supported entry into 
clinical studies, including providing adequate safety factors for the proposed Phase 1 starting 
doses. The results of the toxicology program were consistent with the anticipated pharmacologic 
activity of downmodulating the PD-L1/PD-1 pathway; heightened immune responses and the 
potential to increase immune-associated inflammatory lesions were identified as possible safety 
risks in patients. 
1.3 
Clinical Experience with Rociletinib 
Refer to the rociletinib IB for detailed clinical data. 
Five studies are currently ongoing (CO-1686-008, CO-1686-018, CO-1686-019, CO-1686-022, 
CO-1686-020), and one clinical study has been completed (CO-1686-016).  
Ongoing studies: 
• CO-1686-008 (TIGER-X) is a Phase 1/2, open-label, safety, PK, and preliminary 
efficacy study of rociletinib in patients with advanced NSCLC. Phase 1 is a dose 
escalation phase to determine the MTD, and it is fully enrolled. Phase 2 is the 
expansion portion in previously treated NSCLC patients who have documented 
evidence of an activating mutation in the EGFR gene and evidence of the T790M 
mutation based on prospective testing for T790M, and it is currently enrolling; 
• CO-1686-018 (TIGER-J) is a Phase 1, open-label, safety, PK, and preliminary 
efficacy study of rociletinib in Japanese patients with advanced NSCLC; 
• CO-1686-019 (TIGER-2) is a Phase 2, single arm, open-label, safety and efficacy 
study of rociletinib as second-line EGFR-directed TKI therapy in patients with 
EGFRm NSCLC with and without the T790M mutation. 

Clovis Oncology, Inc. 
Clinical Protocol 
Rociletinib (CO-1686) 
CO-1686-032 
FINAL Version 1.0 
26 May 2015 
 
 
Page 37 of 131 
Confidential 
• CO-1686-022 (TIGER-1) is a Phase 2/3, randomized, open-label study of 
rociletinib versus erlotinib as first-line treatment for patients with EGFR-mutant, 
advanced NSCLC. 
• CO-1686-020 (TIGER-3) is a Phase 3, randomized, open-label study of rociletinib 
versus single-agent chemotherapy in patients with EGFRm NSCLC after failure 
of at least one prior EGFR-targeted TKI and platinum-doublet chemotherapy. 
Completed study: 
• CO-1686-016 was a Phase 1, PK, safety and tolerability study in healthy adult 
male patients that was completed in order to evaluate 3 formulations of rociletinib 
HBr, and to support introduction of the rociletinib HBr formulation into Study 
CO-1686-008. 
1.3.1 
Safety of Rociletinib from Clinical Studies 
Preliminary safety data are presented for the ongoing CO-1686-008 and completed CO-1686-016 
studies. As of 04 June 2014, 190 patients have received at least one dose of rociletinib: 
42 healthy male volunteers (Study CO-1686-016) and 148 patients with advanced NSCLC 
(Study CO-1686-008). The overall safety data presented here are for NSCLC patients who 
received rociletinib in Study CO-1686-008.  
Study CO-1686-008 
Preliminary safety data are reported for 148 patients with advanced NSCLC in this study, 
including 57 patients who were treated with rociletinib free base at total daily doses ranging from 
150 mg up to 1800 mg (once daily [QD], BID, and three times daily [TID] dosing schedules) and 
91 patients who were treated with rociletinib HBr at total daily doses ranging from 1000 mg to 
2000 mg (500 mg BID, 625 mg BID, 750 mg BID and 1000 mg BID). Rociletinib HBr is being 
studied in ongoing clinical studies and will be used in this study (Section 5.1).  
Dose-Limiting Toxicities: Enrollment of patients to the dose escalation phase was completed in 
February 2014 with a DLT rate of < 33% at all evaluated doses. The DLT evaluable population 
included all patients who had completed Cycle 1, and who were enrolled while the dose 
escalation part of the study was ongoing. The most frequently reported DLT was 
hyperglycemia/glucose tolerance impaired which occurred at a similar frequency (11% to 25%) 
across all rociletinib dose levels with the rociletinib HBr formulation (500 mg BID, 625 mg BID, 
750 mg BID, and 1000 mg BID). Hyperglycemia can be effectively managed with the addition 
of anti-hyperglycemic therapy and/or dose reductions. Guidance for the management of 
hyperglycemia associated with rociletinib treatment is provided in Section 6.1.2.  
Serious Adverse Events (SAEs) and Deaths: A total of 43 patients experienced at least one 
SAE, and among these, 17 patients (11.5%) had an SAE assessed as related to study drug. The 
most commonly reported treatment-related SAE was hyperglycemia (reported by 6% of 
patients). Four patients (3%) experienced an SAE of vomiting, and 3 patients (2%) experienced 

Clovis Oncology, Inc. 
Clinical Protocol 
Rociletinib (CO-1686) 
CO-1686-032 
FINAL Version 1.0 
26 May 2015 
 
 
Page 38 of 131 
Confidential 
an SAE of nausea. All other treatment-related SAEs occurred in 2 or fewer patients. 
Treatment-related SAEs are summarized in Table 3. 
There were 11 deaths on study, including the 28-day post-treatment period after the last dose of 
rociletinib. Eight deaths were reported as due to progression of NSCLC, one death due to 
pulmonary embolism, one death due to pneumonia, and one death of unknown cause. A causal 
relationship with rociletinib could not be ruled out for the death of unknown cause; all other 
deaths were reported as unrelated to study drug. 

Clovis Oncology, Inc. 
Clinical Protocol 
Rociletinib (CO-1686) 
CO-1686-032 
FINAL Version 1.0 
26 May 2015 
 
 
Page 39 of 131 
Confidential 
Table 3: 
Treatment-Related Serious Adverse Events Reported by Patients in Study CO-1686-008 
System Organ Class 
Preferred Term 
< 900 BID FB 
(N = 38) 
900 BID FB 
(N = 19) 
500 BID HBr 
(N = 18) 
625 BID HBr 
(N = 17) 
750 BID HBr 
(N = 50) 
1000 BID HBr 
(N = 6) 
Overall 
(N = 148) 
Number of patients with at least 1 treatment-related treatment-emergent SAE 
Overall 
4 (10.5%) 
1 (5.3%) 
4 (22.2%) 
3 (17.6%) 
4 (8.0%) 
1 (16.7%) 
17 (11.5%) 
Cardiac Disorders 
Pericarditis 
1 (2.6%) 
0 
0 
0 
0 
0 
1 (0.7%) 
Gastrointestinal Disorders 
Diarrhea 
1 (2.6%) 
1 (5.3%) 
0 
0 
0 
0 
2 (1.4%) 
Nausea 
1 (2.6%) 
0 
1 (5.6%) 
0 
1 (2.0%) 
0 
3 (2.0%) 
Pancreatitis 
0 
0 
1 (5.6%) 
0 
0 
0 
1 (0.7%) 
Vomiting 
2 (5.3%) 
0 
1 (5.6%) 
0 
1 (2.0%) 
0 
4 (2.7%) 
Infections and Infestations 
Gastroenteritis 
0 
0 
0 
0 
1 (2.0%) 
0 
1 (0.7%) 
Investigations 
ECG QT prolonged 
0 
0 
0 
1 (5.9%) 
1 (2.0%) 
0 
2 (1.4%) 
ECG T wave 
inversion 
0 
0 
0 
0 
1 (2.0%) 
0 
1 (0.7%) 
Transaminases 
increased 
0 
1 (5.3%) 
0 
0 
0 
0 
1 (0.7%) 
Metabolism and Nutrition Disorders 
Combined terms of 
hyperglycemia 
1 (2.6%) 
0 
4 (22.2%) 
1 (5.9%) 
2 (4.0%) 
1 (16.7%) 
9 (6.1%) 
Decreased appetite 
0 
1 (5.3%) 
0 
0 
0 
0 
1 (0.7%) 
Hypoglycemia 
1 (2.6%) 
0 
0 
0 
0 
0 
1 (0.7%) 
Hypokalemia 
0 
0 
0 
1 (5.9%) 
0 
0 
1 (0.7%) 
Respiratory, Thoracic, and Mediastinal disorders 
Pneumonitis 
0 
0 
0 
1 (5.9%) 
0 
0 
1 (0.7%) 
BID, twice daily; ECG, electrocardiogram; FB, rociletinib free base; HBr, rociletinib hydrobromide; N, number of patients; SAE, serious adverse event. 

Clovis Oncology, Inc. 
Clinical Protocol 
Rociletinib (CO-1686) 
CO-1686-032 
FINAL Version 1.0 
26 May 2015 
 
 
Page 40 of 131 
Confidential 
Treatment-Related Adverse Events (AEs): The most frequently reported treatment-related 
AEs (all grades, ≥ 20% of patients) were hyperglycemia (33%; including Medical Dictionary for 
Regulatory Activities [MedDRA] Preferred Terms blood glucose elevated, glucose tolerance 
impaired, and hyperglycemia), nausea (28%), and fatigue (20%). Treatment-related AEs reported 
by at least 5% of patients are summarized in Table 4. The majority of AEs were mild or 
moderate in severity.  
Other Treatment-Related Adverse Events of Interest 
Rash and Diarrhea: Rociletinib selectively inhibits mutant EGFR, and as expected, the syndrome 
of dose-related WT-driven rash and diarrhea has not been observed in clinical studies of 
rociletinib. All reported events of diarrhea were either Grade 1 or Grade 2.  
The most common skin reaction reported by patients treated with EGFR TKIs is a follicular 
acneiform eruption. In Study CO-1686-008, rash (irrespective of causality) was reported 
infrequently (6 patients overall [4%]), and events were mild. One event of dermatitis acneiform, 
and one event of follicular rash have been reported to date. 
Pneumonitis: There have been two AEs of pneumonitis, and one SAE of pneumonitis, all 
assessed by the Investigator as related to rociletinib. Patients recovered after steroid therapy.  
QT Prolongation: Rociletinib exposure is associated with QT prolongation. The effect takes 
several days to develop and is not seen on Day 1 of therapy. Patients with low baseline resting 
heart rates appear to be at a higher risk for QT prolongation during treatment with rociletinib. 
Typically, the abnormality is evident by Day 15 of therapy, and the increase remains stable with 
continued dosing. QT interval corrected using Fridericia’s method (QTCF) intervals longer than 
500 msec have been observed in 10 patients (7.6%).  
 

Clovis Oncology, Inc. 
Clinical Protocol 
Rociletinib (CO-1686) 
CO-1686-032 
FINAL Version 1.0 
26 May 2015 
 
 
Page 41 of 131 
Confidential 
 
Table 4: 
Treatment-Related Adverse Events Reported by at Least 5% of Patients in Study CO-1686-008 
System Organ Class 
Preferred Term 
< 900 BID FB 
(N = 38) 
900 BID FB 
(N = 19) 
500 BID HBr 
(N = 18) 
625 BID HBr 
(N = 17) 
750 BID HBr 
(N = 50) 
1000 BID HBr 
(N = 6) 
Overall 
(N = 148) 
Number of Patients with at Least 1 Treatment-related treatment-emergentAE 
Overall 
28 (73.7%) 
18 (94.7%) 
16 (88.9%) 
15 (88.2%) 
28 (56.0%) 
6 (100.0%) 
111 (75.0%) 
Gastrointestinal Disorders 
Diarrhea 
6 (15.8%) 
6 (31.6%) 
4 (22.2%) 
4 (23.5%) 
6 (12.0%) 
2 (33.3%) 
28 (18.9%) 
Nausea 
8 (21.1%) 
6 (31.6%) 
6 (33.3%) 
7 (41.2%) 
12 (24.0%) 
3 (50.0%) 
42 (28.4%) 
Vomiting 
5 (13.2%) 
2 (10.5%) 
3 (16.7%) 
4 (23.5%) 
4 (8.0%) 
0 
18 (12.2%) 
General Disorders and Administration Site Conditions 
Fatigue 
9 (23.7%) 
6 (31.6%) 
5 (27.8%) 
3 (17.6%) 
5 (10.0%) 
1 (16.7%) 
29 (19.6%) 
Investigations 
Electrocardiogram QT prolonged 
0 
2 (10.5%) 
0 
2 (11.8%) 
5 (10.0%) 
3 (50.0%) 
12 (8.1%) 
Metabolism and Nutrition Disorders 
Combined terms of hyperglycemia 
4 (10.5%) 
6 (31.6%) 
11 (61.1%) 
10 (58.8%) 
14 (28.0%) 
4 (66.7%) 
49 (33.1%) 
Decreased appetite 
1 (2.6%) 
6 (31.6%) 
4 (22.2%) 
3 (17.6%) 
2 (4.0%) 
2 (33.3%) 
18 (12.2%) 
Musculoskeletal and Connective Tissue Disorders 
Muscle spasms 
3 (7.9%) 
4 (21.1%) 
3 (16.7%) 
0 
3 (6.0%) 
0 
13 (8.8%) 
Myalgia 
3 (7.9%) 
4 (21.1%) 
2 (11.1%) 
0 
1 (2.0%) 
1 (16.7%) 
11 (7.4%) 
BID, twice daily; FB, rociletinib free base; HBr, rociletinib hydrobromide; N, number of patients. 

Clovis Oncology, Inc. 
Clinical Protocol 
Rociletinib (CO-1686) 
CO-1686-032 
FINAL Version 1.0 
26 May 2015 
 
 
Page 42 of 131 
Confidential 
 
1.3.2 
Activity of Rociletinib from Clinical Studies 
Preliminary activity data for rociletinib are available from the Phase 1/2 CO-1686-008 study. 
Although the primary objectives of the first phase of Study CO-1686-008 were to evaluate the 
safety, toxicity, and PK profile of rociletinib, there is robust preliminary evidence of activity for 
rociletinib across therapeutic doses of rociletinib (rociletinib free base 900 mg BID, and 
rociletinib HBr 500 mg BID to 1000 mg BID) for T790M+ patients previously treated with one 
or more lines of an EGFR TKI. As of 04 June 2014, 22 of 40 patients (55%) had a Response 
Evaluation Criteria in Solid Tumors (RECIST) partial response (PR), and the disease control rate 
(DCR) was approximately 92%. 
1.3.3 
Pharmacokinetics of Rociletinib 
Study CO-1686-016: Completed Phase 1 Study 
In healthy volunteers (Study CO-1686-016), maximum concentration (Cmax) and area under the 
curve from time zero to 24 hours (AUC0-24) of rociletinib HBr increased with ascending single 
doses (50 mg to 1000 mg), with rociletinib plasma levels increasing in a less than dose 
proportional manner above 125 mg. 
The single-dose PK of rociletinib was compared in the fasted and fed state, and it was concluded 
that a high-fat meal increased the plasma drug concentrations from 3-12 hours postdose with a 
mean increase of 172% at 12 hours postdose (-22% to +400%) and a mean increase of 77% in 
AUC0-24 (+10% to 146%), with no change in elimination half-life (t1/2); a slight mean increase of 
12% in Cmax was observed, and a delayed time to maximum concentration (tmax) was seen in a 
majority of subjects.  
Data for repeat doses are available from six healthy subjects who were dosed in the fed state with 
500 mg BID rociletinib for 4 days. PK profiles of rociletinib following morning and evening 
dosings were similar, with low intra-subject variability (Day 1 and Day 4 comparison). There 
was no accumulation of rociletinib. 
Study CO-1686-008: Ongoing Phase 1/2 Study 
In the Phase 1/2 patient study (CO-1686-008), PK after rociletinib HBr administration were 
available from a total of 51 patients. (Rociletinib HBr showed increased absorption and thus 
higher exposure than rociletinib free base.) For rociletinib HBr, the median tmax was 1.5 to 
3.25 hours, and t1/2 ranged from 1.7 to 4.7 hours. After rociletinib HBr administration, exposure 
(measured as Cmax and AUC0-24) increased approximately dose-proportionally from 500 mg to 
1000 mg BID. 
1.4 
Clinical Experience with MPDL3280A 
Refer to the MPDL3280A IB for detailed clinical data. 

Clovis Oncology, Inc. 
Clinical Protocol 
Rociletinib (CO-1686) 
CO-1686-032 
FINAL Version 1.0 
26 May 2015 
 
 
Page 43 of 131 
Confidential 
 
1.4.1 
Safety of MPDL3280A from Clinical Studies 
The presented safety data for MPDL3280A have been derived from the treatment of patients in 
Study PCD4989g. In this study, patients are receiving MPDL3280A monotherapy. No DLTs 
have been observed at any dose level and no MTD was established. 
As of 10 May 2014, in the PCD4989g study, 412 patients have been treated with MPDL3280A. 
The PCD4989g study consisted of patients with NSCLC, renal cell carcinoma, melanoma, and 
urothelial bladder cancer (88, 69, 45, and 79 patients, respectively), as well as other tumor types. 
The majority of AEs reported were Grade 1 or 2 in maximum severity (based on National Cancer 
Institute Common Terminology Criteria for Adverse Events Version 4.03 [NCI CTCAE v4.03].24 
The most frequently observed AEs (occurring in  10% of treated patients) included fatigue, 
nausea, decreased appetite, pyrexia, dyspnea, diarrhea, constipation, cough, headache, back pain, 
vomiting, anemia, arthralgia, rash, insomnia, asthenia, abdominal pain, chills, and pruritus. 
Given the mechanism of action of MPDL3280A, events associated with inflammation and/or 
immune-mediated AEs are being closely monitored during the MPDL3280A clinical program. 
Potential immune-related events that have been reported include dermatologic, hepatic, 
endocrine, and respiratory events (eg, pneumonitis); hepatitis/elevated liver function tests 
(LFTs); and influenza-like illness.  
Dyspnea, cough, fatigue, hypoxia, pneumonitis and pulmonary infiltrates have been associated 
with the administration of MPDL3280A and have primarily been observed in patients with 
underlying NSCLC. Mild to moderate events of pneumonitis have been reported with 
MPDL3280A. 
1.4.2 
Pharmacokinetics of MPDL3280A 
On the basis of available preliminary PK data (0.03−20 mg/kg), MPDL3280A appeared to show 
linear PK at doses ≥ 1 mg/kg. For the 1-mg/kg and 20-mg/kg dose groups, the mean apparent CL 
and the mean Vss had a range of 3.20 to 4.44 mL/day/kg and 48.1 to 65.7 mL/kg, respectively, 
which is consistent with the expected profile of an IgG1 antibody in humans. 
1.5 
Rationale for Study  
Targeted approaches in cancer therapy aim to inhibit molecular pathways or mutant proteins that 
are critical for driving growth or survival of the tumor. Pharmacologic inhibition of the EGFR 
pathway with EGFR TKIs has proven successful in inducing regression of tumors whose 
transformation is driven by receptors or mutations that activate this dominant pathway. However, 
even when highly effective at reducing tumor burden, targeted therapies invariably drive 
emergence of resistance, limiting the duration of response (DOR). Rociletinib is a novel, 
irreversible, small molecule TKI that selectively targets mutant forms of EGFR including the 
T790M “gatekeeper” mutation as well as common activating mutations (eg, L858R and del 19), 
while sparing the WT EGFR.  

Clovis Oncology, Inc. 
Clinical Protocol 
Rociletinib (CO-1686) 
CO-1686-032 
FINAL Version 1.0 
26 May 2015 
 
 
Page 44 of 131 
Confidential 
 
Immunotherapy attempts to harness the host immune system to recognize and kill the 
transformed cells. Because the immune response is dynamic, it has the potential to match the 
cancer’s ability to mutate and evolve, increasing the odds of generating durable responses. Thus, 
combining tumor-targeted therapies with agents that enhance antitumor immunity represents an 
increasingly attractive treatment paradigm for cancer. Antibodies targeting T-cell immune 
checkpoint inhibitors such as PD-L1 and PD-1 have demonstrated the capacity to generate 
durable responses in patients with multiple cancer types.25,26 Nonclinical studies have shown that 
the combination of targeted therapies and blockade of PD-1 can lead to durable complete tumor 
responses that are not achieved by either approach alone.27 The increase in tumor cell death 
induced by combination treatment can be reasonably expected to result in more effective release 
and presentation of a greater diversity of tumor antigens, thus potentiating the antitumor immune 
response. 
PD-L1 was found to be down regulated in the presence of erlotinib in EGFRm NSCLC tumors 
but not in those with WT EGFR, suggesting that PD-L1 expression is dependent on EGFR 
signaling conferred by activating EGFR mutations. Furthermore, recent data indicate that PD-L1 
is overexpressed in EGFR-TKI resistant cell lines, suggesting that PD-L1 upregulation could 
contribute to acquired resistance to EGFR TKIs. Based on these data, dual therapies of EGFR 
TKIs and anti-PD-L1 antibodies, targeted at overcoming acquired resistance in EGFRm NSCLC 
may provide significant benefit to these patients with a high unmet medical need. In addition, the 
combination of therapies may prevent the commonly acquired mechanisms of resistance to 
occur. 
In this study, the safety and efficacy of rociletinib in combination with MPDL3280A will be 
investigated in patients with EGFRm NSCLC. The study will be conducted in 2 phases, a Dose 
Finding Phase (Phase 1) to determine the optimal dose for the combination of rociletinib against 
a fixed dose of MPDL3280A, and a Dose Expansion Phase (Phase 2) in two separate cohorts to 
evaluate preliminary efficacy of the combination of rociletinib and MPDL3280A in EGFRm 
NSCLC patients who are EGFR TKI treatment-naïve and chemotherapy-naïve or who have 
progressed on a prior EGFR TKI.  
MPDL3280A will be administered at a fixed dose of 1200 mg IV every 21 days. The fixed 
dosage (equivalent to an average body weight-based dose of 15 mg/kg) is informed by available 
clinical activity, safety, and PK data. Antitumor activity has been observed across doses from 
1 mg/kg to 20 mg/kg. The MTD of MPDL3280A was not reached, and no DLTs have been 
observed at any dose in Study PCD4989g. Available preliminary PK data (0.03-20 mg/kg) from 
Study PCD4989g suggest that for doses  1 mg/kg, overall MPDL3280A exhibits a PK profile 
that is both linear and consistent with typical IgG1 antibodies. Detectable anti-therapeutic 
antibodies (ATAs) were observed in patients at all dose levels but were associated with changes 
in PK for some patients in only the lower dose cohorts (0.3, 1, and 3 mg/kg). Patients dosed at 
the 10, 15, and 20 mg/kg dose levels have maintained target trough levels of drug despite the 
detection of ATAs. 

Clovis Oncology, Inc. 
Clinical Protocol 
Rociletinib (CO-1686) 
CO-1686-032 
FINAL Version 1.0 
26 May 2015 
 
 
Page 45 of 131 
Confidential 
 
Simulations do not suggest any clinically meaningful differences in exposure following a fixed 
dose or a dose adjusted for weight. On the basis of this analysis, a fixed dose of 1200 mg has 
been selected (equivalent to an average body weight-based dose of 15 mg/kg). 
The starting dose for rociletinib in this study is 500 mg PO BID. This is the lower of two 
clinically active doses that were expanded in Phase 1 and Phase 2 studies of rociletinib 
monotherapy in EGFRm NSCLC patients. It has been found to have comparable activity to the 
625 mg BID dose, with a more favorable overall safety profile. Section 3.2 provides detailed 
information regarding the planned doses for each dose escalation cohort and dose escalation 
guidelines for the study. 

Clovis Oncology, Inc. 
Clinical Protocol 
Rociletinib (CO-1686) 
CO-1686-032 
FINAL Version 1.0 
26 May 2015 
 
 
Page 46 of 131 
Confidential 
 
2 
STUDY OBJECTIVES AND ENDPOINTS 
2.1 
Objectives 
2.1.1 Primary Objectives 
The following are the primary objectives for Phase 1 and Phase 2: 
Phase 1 
• To determine the safety and tolerability, MTD or maximum administered dose (MAD), 
and RP2D of the combination of rociletinib and MPDL3280A; 
• To assess the PK profile of rociletinib (and its metabolites) and MPDL3280A when given 
in combination. 
Phase 2 
• To determine the efficacy of the combination of rociletinib and MPDL3280A based on 
overall response rate per RECIST v1.1 (Appendix A) in the following groups of patients: 
– Group A: Patients with EGFRm advanced or metastatic NSCLC who have not 
previously received an EGFR TKI or chemotherapy. 
– Group B: Patients with EGFRm advanced or metastatic NSCLC who have progressed 
on a prior EGFR TKI. 
2.1.2 Secondary Objectives 
The following are the secondary objectives for Phase 1 and Phase 2: 
Phase 1 
• To determine preliminary efficacy and pharmacodynamics of the combination of 
rociletinib and MPDL3280A in enrolled patients. 
Phase 2 
• To determine the efficacy of the combination of rociletinib and MPDL3280A based on 
ORR per modified RECIST incorporating immune related response criteria (irRC; 
Appendix B) in Groups A and B; 
• To assess the activity of the combination of rociletinib and MPDL3280A based upon 
DOR and PFS; 
• To assess the pharmacodynamic relationship between biomarkers and clinical activity, 
and/or resistance to study drug. 
 
 

Clovis Oncology, Inc. 
Clinical Protocol 
Rociletinib (CO-1686) 
CO-1686-032 
FINAL Version 1.0 
26 May 2015 
 
 
Page 47 of 131 
Confidential 
 
2.2 
Endpoints 
2.2.1 Primary Endpoints 
The following are the primary endpoints for Phase 1 and Phase 2: 
Phase 1 
• Treatment-emergent AEs; 
• DLTs; 
• PK parameters for rociletinib (and its metabolites) and MPDL3280A. 
Phase 2 
• ORR according to RECIST v1.1 (Appendix A) as determined by Investigator assessment. 
2.2.2 Secondary Endpoints 
The following are the secondary endpoints for this study: 
• ORR according to modified RECIST incorporating irRC (Appendix B); 
• Duration of response, DCR, and PFS according to RECIST v1.1 (Appendix A) as 
determined by Investigator assessment; 
• Duration of response, DCR, and PFS according to modified RECIST incorporating irRC 
(Appendix B); 
• Overall survival (OS); 
• Change from baseline in mutant EGFR levels in circulating tumor DNA (ctDNA) 
obtained from plasma. 
2.2.3 Exploratory Endpoints 
The following are the exploratory endpoints for this study: 
• Positive and negative percent agreement between blood and tissue results for T790M and 
EGFR activating mutations; 
• Incidence of ATA response to MPDL3280A and potential correlation with PK, 
pharmacodynamics, safety and efficacy parameters; 
• Identification of biomarkers associated with response or resistance to rociletinib and/or 
MPDL3280A; 
• Changes in expression of immune-related markers (including but not limited to 
granzyme B or other exploratory markers) in archival and/or fresh tumor tissue prior to 
and after MPDL3280A and rociletinib treatment; 
• Markers of RAS-RAF-MEK signaling cascade (including but not limited to EGFR) in 
archival and/or fresh tissue; 
• PD-L1 status by immunohistochemistry (IHC) or quantitative polymerase chain reaction 
(PCR) in archival and/or fresh tissue. 

Clovis Oncology, Inc. 
Clinical Protocol 
Rociletinib (CO-1686) 
CO-1686-032 
FINAL Version 1.0 
26 May 2015 
 
 
Page 48 of 131 
Confidential 
 
3 
STUDY DESIGN 
This is a multicenter, open-label, non-randomized study in patients with EGFRm advanced or 
metastatic NSCLC to be conducted in two phases: a Dose Finding Phase (Phase 1) and a Dose 
Expansion Phase (Phase 2). A schematic of the study design is presented in Figure 1. 
Figure 1: 
Study Schematic 
 
BID, twice daily; DOR, duration of response; EGFRm, epidermal growth factor receptor mutatant; MAD, maximum 
administered dose; MTD, maximum tolerated dose; NSCLC, non-small cell lung cancer; ORR, overall response rate; PFS, 
progression-free survival; T790M–, T790M mutation-negative; T790M+, T790M mutation-positive; TKI, tyrosine kinase 
inhibitor; TPI, toxicity probability interval. 
3.1 
Clinical Safety Committee 
Throughout the study, oversight will be provided by the Clinical Safety Committee (CSC), 
comprised of all Principal Investigators, the Sponsor’s Medical Monitor and the Sponsor’s drug 
safety representative. The CSC will: 
• Review and confirm all DLTs;  
• Determine all cohort dose-escalation and de-escalation decisions (assignment of Dosing 
Cohorts) during the Dose Finding Phase (Phase 1); 
• Determine the MAD or MTD and RP2D to extend into the Expansion Phase (Phase 2), based 
on available safety, tolerability, and PK data; 
• Review safety data for all patients during Phase 1 and Phase 2. 

Clovis Oncology, Inc. 
Clinical Protocol 
Rociletinib (CO-1686) 
CO-1686-032 
FINAL Version 1.0 
26 May 2015 
 
 
Page 49 of 131 
Confidential 
 
3.2 
Dose Finding Phase (Phase 1) 
The Dose Finding Phase will be conducted with patients who have progressed after at least 
12 weeks of treatment with a prior first- or second-generation EGFR TKI (ie, erlotinib, gefitinib, 
afatanib), regardless of T790M mutation status. The Dose Finding Phase will be used to 
determine the MTD or MAD and RP2D of the combination of rociletinib and MPDL3280A, and 
to evaluate the safety, tolerability, and PK profile of the combination treatment. The Dose 
Finding Phase will include a 7-day Run-in-Period of rociletinib monotherapy prior to the 
initiation of combination treatment. Patients will receive daily oral BID doses of rociletinib at the 
Dosing Cohort-defined dose level (Section 3.2.2). Patients who experience an AE that requires a 
reduction or more than 48-hour delay in dose of rociletinib during the Run-in-Period will not go 
on to receive the combination of rociletinib and MPDL3280A, but will remain on study to 
receive rociletinib monotherapy; an additional patient will be enrolled as a replacement for 
inclusion in the same Dosing Cohort.  
For the Dose Finding Phase, Cycle 1 will begin with the initiation of combination treatment 
following a successful completion of the Run-in-Period and will be used for the determination of 
DLTs. Patients will continue to receive daily oral BID doses of rociletinib (at the Dosing Cohort-
defined dose level) and IV doses of MPDL3280A on Day 1 of each cycle, in consecutive 21-day 
cycles. Thereafter, treatment and monitoring of patients will be conducted in 21-day treatment 
cycles. Patients will be evaluated regularly for safety, PK, efficacy and pharmacodynamics 
according to the Schedule of Assessments (see Table 1). For further details on the planned 
assessments and analyses of safety, PK, efficacy and pharmacodynamics, please refer to 
Sections 8.4.2-8.4.5. 
3.2.1 Dose-Limiting Toxicity 
Determination of DLTs will be made during the first 21 days of combination treatment with 
rociletinib and MPDL3280A (ie, during Cycle 1 after the rociletinib Run-in-Period) in the Dose 
Finding Phase. A DLT is defined as a clinically significant AE or laboratory abnormality 
assessed as at least related to the study drug (rociletinib and/or MPDL3280A), unrelated to 
disease progression, and that meets any of the following criteria: 
Cytopenia: 
• Grade 4 neutropenia persisting for more than 7 days; 
• Febrile neutropenia, defined as an absolute neutrophil count (ANC) < 1000/mm3 and a 
single temperature of > 38.3ºC (101ºF); 
• Grade 4 thrombocytopenia persisting for more than 7 days or thrombocytopenia with 
clinically significant bleeding (ie, bleeding that requires blood or platelet transfusion or 
other medical intervention, or that may cause disability or death, such as cerebral 
hemorrhage). 
Organ Toxicity: 
• Grade  3 symptomatic hepatic toxicities lasting for  48 hours, or Grade  3 
asymptomatic hepatic toxicities lasting for  7 days with the following exception: 

Clovis Oncology, Inc. 
Clinical Protocol 
Rociletinib (CO-1686) 
CO-1686-032 
FINAL Version 1.0 
26 May 2015 
 
 
Page 50 of 131 
Confidential 
 
▪ For patients with Grade 2 Alkaline phosphatase (ALP) abnormality at baseline, an 
increase to  8  the upper limit of normal (ULN) lasting  48 hours (if 
symptomatic) or  7 days (if asymptomatic) will be considered a DLT. 
• Grade  3 nonhematologic, nonhepatic organ toxicity, with the following exceptions: 
DLT Toxicity Exceptions  
▪ Grade 3 nausea, vomiting, or diarrhea that resolves to Grade  1 within 7 days 
after starting appropriate supportive therapy (see Section 6.2.2); 
▪ Grade  3 asymptomatic or mildly symptomatic rash that can be adequately 
managed with supportive care (see Section 6.2.4) or symptomatic rash that 
resolves to become asymptomatic and/or Grade  2 within 7 days of appropriate 
supportive therapy; 
▪ Grade  3 fatigue that resolves to Grade  2 within 7 days; 
▪ Grade 3 arthralgia that can be adequately managed with supportive care or that 
resolves to Grade  2 within 7 days; 
▪ Grade 3 autoimmune thyroiditis or other endocrine abnormality that can be 
managed by endocrine therapy and that would not necessitate initiation of 
systemic corticosteroids; 
▪ Grade 3 fever (in the absence of any clinically significant source of fever) that 
resolves to Grade  2 within 7 days with supportive care; 
▪ Grade 3 laboratory abnormality that is asymptomatic and deemed by the 
Investigator to be not clinically significant; 
▪ Grade  3 hyperglycemia lasting  7 days. Grade > 3 hyperglycemia will be 
considered a DLT only if it lasts for more than 7 days despite optimized anti-
hyperglycemic treatment (eg, oral anti-hyperglycemic therapy); 
▪ Grade  3 elevation of serum creatine kinase (CK) level that is asymptomatic (ie, 
not accompanied by signs, symptoms, or other laboratory abnormalities 
associated with rhabdomyolysis or myocardial injury) that is deemed by the 
Investigator to be clinically insignificant and that returns to Grade  2 within 
7 days. 
3.2.2 Assignment of Dosing Cohorts 
Specific doses of rociletinib will be administered in combination with a fixed dose of 
MPDL3280A. Combination doses of rociletinib with MPDL3280A will be defined for each 
Dosing Cohort enrolled during the Dose Finding Phase, and currently two potential Dosing 
Cohorts are planned (see Table 5). The first Dosing Cohort will be 500 mg BID rociletinib and 
1200 mg MPDL3280A on Day 1 of each 21-day cycle. At minimum, 3 patients will be enrolled 
into this cohort. If this combination dose is determined to be safe and tolerable, no further dose 
modifications for either drug will be made. Based on emerging safety and evaluable PK and/or 
pharmacodynamics data, the CSC may evaluate additional doses or schedules of rociletinib. 

Clovis Oncology, Inc. 
Clinical Protocol 
Rociletinib (CO-1686) 
CO-1686-032 
FINAL Version 1.0 
26 May 2015 
 
 
Page 51 of 131 
Confidential 
 
Table 5: 
Phase 1 Dosing Cohorts 
Cohort 
Rociletinib Dose 
MPDL3280A Dose 
1 
500 mg PO BID 
1200 mg IV every 3 weeks 
Day 1 of each 21-day cycle 
-1 
375 mg PO BID 
BID, twice daily; IV, intravenous; PO, oral. 
 
A modified toxicity probability interval (mTPI) method (Appendix H) will be used to guide 
decisions on assignment of patients to different Dosing Cohorts. Compared with the 3+3 design, 
the mTPI method reduces the risk of exposing patients to doses above the MTD, which is 
defined as the acceptable daily oral dose with estimated probability of toxicity closest to 33%. 
The mTPI design is a model-based approach that has a pre-specified decision matrix that 
recommends escalating, reducing or maintaining the same dose or stopping dose escalation, 
based on the number of DLTs observed in the dose level under evaluation. Consequently, 
patients enrolled into the trial can be allocated to appropriate doses without conducting 
additional computations. 
At each dose level, after the first evaluable 3 patients have completed Cycle 1, the CSC will meet 
to evaluate the Dosing Cohort data and to make a decision on the next step for Dosing Cohort 
assignment (increase dose, decrease dose, maintain same dose, or stop), which will be guided by 
the mTPI decision table (Appendix H). A patient will be deemed evaluable for safety and DLT 
determination if they have received at least 75% of the planned total dose of each drug within 
Cycle 1. Patients who receive <75% of the planned total dose of either rociletinib or 
MPDL3280A for reasons other than study drug-related AEs will not be included in the 
evaluation of the Dosing Cohort and will be replaced. If the dose is maintained, up to an 
additional 6 patients may be enrolled at the same dose, and the next safety evaluation will take 
place after all patients have completed Cycle 1. The CSC may decide to meet at any time to 
evaluate a Dosing Cohort if a safety signal arises or other data become available to justify re-
evaluation of the Dosing Cohort before it is fully enrolled. 
The enrollment/evaluation process will continue until at least 6 patients have been treated at any 
single dose level or enrollment of the maximum sample size of 18 patients for the Phase 1 
portion of this study has been achieved.  
3.2.3 Recommended Phase 2 Dose  
The RP2D will be determined by the CSC based on cumulative data from all Dosing Cohorts in 
the Dose Finding Phase. A Safety Expansion Cohort of up to 6 patients may be enrolled to 
further examine the tolerability of a dose combination of interest or the tolerability of the 
combination dosing without a rociletinib Run-in-Period. 

Clovis Oncology, Inc. 
Clinical Protocol 
Rociletinib (CO-1686) 
CO-1686-032 
FINAL Version 1.0 
26 May 2015 
 
 
Page 52 of 131 
Confidential 
 
3.3 
Dose Expansion Phase (Phase 2) 
The Dose Expansion Phase will be conducted in two patient cohorts (see also Figure 1): 
Group A: EGFR TKI treatment-naïve and chemotherapy-naïve patients. 
Group B: Patients who have progressed after at least 12 weeks of treatment with a prior  first- 
 
or second-generation EGFR TKI (ie, erlotinib, gefitinib, afatanib), regardless of 
 
T790M mutation status. 
The Dose Expansion Phase will be used to assess the RP2D of the combination of rociletinib and 
MPDL3280A for preliminary efficacy and pharmacodynamics effects, in addition to safety and 
tolerability, in these patient populations. For the Dose Expansion Phase, there will not be a 
Run-in-Period; rather, treatment will begin with both rociletinib and MPDL3280A on Cycle 1 
Day 1 (C1D1). Patients will receive daily oral BID doses of rociletinib (RP2D) and IV doses of 
MPDL3280A on Day 1 of each cycle, in consecutive 21-day cycles. Patients will be evaluated 
regularly for safety and efficacy according to the Schedule of Assessments (see Table 1). For 
further details on the planned assessments and analyses of safety, PK, efficacy and 
pharmacodynamics, please refer to Sections 8.4.2-8.4.5. 
3.4 
Study Conduct and Duration of Patient Follow-Up 
The study will comprise a Screening Period, and Treatment Period, and a Follow-up Period as 
outlined in Table 6. Please refer to Section 8 for additional details. 
Table 6:  
Study Schematic (CO-1686-032) 
 
ATA, anti-therapeutic antibody; BID, twice-daily; ICF, informed consent form; IV, intravenous; PK, pharmacokinetics 
Day 1
Day 4
Day 8
Day15
↓
Disease Progression
(Optional post-progression tumor biopsy)
↓
END OF STUDY PERIOD
Treatment discontinuation
Follow-up Safety Assessment
28 days after last dose of study drug (rociletinib or MPDL3280A)
PK/ATA blood samples 120 days after last dose of MPDL3280A (see Table 2)
Every 12 weeks
Follow-up for subsequent anticancer therapies and survival
TREATMENT PERIOD 
Oral rociletinib BID + IV 
MPDL3280A every 21days 
Sign ICF
SCREENING PERIOD
Screening Assessments
Up to 28 days before 1st dose of study drug (biopsy within 60 days prior)
Enrollment
Study assessments every 21 days. Additional ECG and glucose 
monitoring during Cycle 1 (Day 4, Day 8, and Day 15). Tumor 
assessments every 2 cycles through Cycle 6 (end of Cycles 2, 4, 
and 6); every 3 cycles after Cycle 6 (end of Cycles 9, 12, etc.); and 
at the EOT Visit. The frequency of tumor assessments may be 
reduced after 2 years with approval of Medical Monitor.
Cycle 1
Rociletinib and/or MPDL3280A 
treatment post-progression (Sponsor 
approval) with continued assessments 
per protocol
Day 1
Cycle 2 +

Clovis Oncology, Inc. 
Clinical Protocol 
Rociletinib (CO-1686) 
CO-1686-032 
FINAL Version 1.0 
26 May 2015 
 
 
Page 53 of 131 
Confidential 
 
4 
STUDY POPULATION 
4.1 
Number of Patients and Sites 
The total enrollment planned for this study is approximately 93 patients (18 patients in Phase 1, 
and up to 75 patients in Phase 2). There will be approximately 14 investigative sites in the United 
States (US), France, and Spain. 
4.2 
Inclusion Criteria 
All patients must meet all of the following inclusion criteria: 
1. Signed and dated informed consent, approved by the Independent Ethics Committee 
(IEC) or Institutional Review Board (IRB), obtained prior to the performance of any 
study-specific procedures or assessments and ability to understand and comply with 
protocol requirements and instructions; 
Baseline Characteristics 
2. Males and females ≥ 18 years of age; 
3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1; 
4. Adequate hematological and biological function, based on the following laboratory 
values: 
• 
Bone Marrow Function 
▪ ANC  1.5 × 109/L; 
▪ Lymphocyte count  0.5 × 109/L; 
▪ Platelets  100.0 × 109/L (without transfusion within 2 weeks prior to receipt of 
study drug); 
▪ Hemoglobin  9 g/dL (or 5.6 mmol/L) (patients may be transfused and/or receive 
erythropoietin stimulating agents to meet this criterion per institutional 
guidelines). 
• Hepatic Function 
▪ Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) 
 2.5 × upper limit of normal (ULN); if liver metastases,  5 × ULN; 
▪ Bilirubin  2.0 × ULN (Patients with documented Gilbert’s syndrome and 
conjugated bilirubin within the normal range may be allowed into the study. In 
this event, it will be documented that the patient was eligible based on conjugated 
bilirubin levels). 
• Renal Function  
▪ Serum creatinine  1.5 × ULN or creatinine clearance  50 mL/min. 

Clovis Oncology, Inc. 
Clinical Protocol 
Rociletinib (CO-1686) 
CO-1686-032 
FINAL Version 1.0 
26 May 2015 
 
 
Page 54 of 131 
Confidential 
 
• Electrolytes 
▪ Potassium and magnesium within normal range, patients may receive supplements 
to meet this requirement. 
• Coagulation status 
▪ International normalized ratio (INR) and activated partial thromboplastin time 
(aPTT)  1.5 × ULN; 
▪ This applies only to patients who are not receiving therapeutic anticoagulation; 
patients receiving therapeutic anticoagulation should be on a stable dose. 
5. Ability to swallow and retain orally administered study drug; 
EGFRm NSCLC Disease Characteristics 
6. Histologically or cytologically documented metastatic or unresectable, locally advanced 
or metastatic NSCLC, with prior histopathological reports showing evidence of one or 
more activating EGFR mutation (eg, G719X, exon 19 deletion, L858R, L861Q), except 
for exon 20 insertion; 
7. Measurable disease as defined by RECIST v1.1 (Appendix A): 
• Previously irradiated lesions should not be counted as target lesions; 
• Lesions that are intended to be used to collect tissue samples for biopsy should not be 
counted as target lesions. 
8. Biopsy of tumor tissue for central evaluation within 60 days prior to the first day of study 
treatment (Run-in-Period Day 1 for Phase 1; C1D1 for Phase 2); 
9. For Phase 1 and Phase 2 Group B, patients must have progressed after at least 12 weeks 
of treatment with a 1st or 2nd generation EGFR TKI (eg, erlotinib, gefitinib, afatinib) for 
advanced or metastatic NSCLC. A minimum of a 3-day washout period is required for 
previous EGFR TKIs. 
• Previous chemotherapy for NSCLC is allowed for patients enrolled in Phase 1 and 
Phase 2 Group B. 
10. For Phase 2 Group A, patients must be EGFR TKI treatment-naïve and 
chemotherapy-naïve; 
11. Anticipated life expectancy of at least 3 months; 
Medical/Surgical History 
12. A minimum of 14 days must have elapsed since any palliative radiotherapy; 
13. A minimum of 14 days must have elapsed from last invasive surgery, and wound healing 
has occurred; 
14. Any ongoing potentially reversible treatment-related toxicities must be resolved to 
Grade ≤ 1 EXCEPT alopecia or (with agreement from the Medical Monitor) the expected 
EGFR TKI toxicities of rash or diarrhea that are stable with intervention; 
15. No planned major surgery while on study; 

Clovis Oncology, Inc. 
Clinical Protocol 
Rociletinib (CO-1686) 
CO-1686-032 
FINAL Version 1.0 
26 May 2015 
 
 
Page 55 of 131 
Confidential 
 
Concomitant Medications or Procedures 
16. Women of childbearing potential must have a negative serum pregnancy test within 
7 days prior to the first dose of study treatment and agree to use highly effective 
contraception as defined in the full protocol, during the study and for 90 days following 
the last dose of MPDL3280A or rociletinib; 
17. Men with a female partner of childbearing potential must have either had a prior 
vasectomy or agree to use effective contraception as described in the full protocol for at 
least 14 days prior to administration of the first dose of study treatment, during the study, 
and for 90 days following the last dose of MPDL3280A or rociletinib. 
4.3 
Exclusion Criteria 
Any of the following criteria will exclude patients from study participation: 
EGFRm NSCLC Disease Characteristics 
1. Documented evidence of an exon 20 insertion mutation in the EGFR gene; 
2. Symptomatic, untreated or unstable central nervous system or leptomeningeal metastases. 
(Patients with treated and stable brain metastases [confirmed by 2 scans at least 4 weeks 
apart], with no evidence of cavitation or hemorrhage in the brain lesion are eligible 
provided that they are asymptomatic and do not require corticosteroids); 
Medical/Surgical History 
3. Previous treatment with rociletinib or MPDL3280A, or other 3rd generation EGFR TKI 
(eg, AZD-9291, HM61713), or PD-1 axis-targeted therapy (eg, anti-PD-1 or anti-PD-L1); 
4. Prior treatment with CD137 agonists or other immune checkpoint blockade therapies, 
including anti-CTLA-4 therapeutic antibodies; 
5. Uncontrolled pleural effusion, pericardial effusion or ascites requiring recurrent drainage 
procedures (once monthly or more frequently); 
6. Uncontrolled hypercalcemia (> 1.5 mmol/L ionized calcium or Ca > 12 mg/dL or 
corrected calcium > ULN) or symptomatic hypercalcemia requiring continued use of 
bisphosphonate therapy or denosumab: 
• Patients who are receiving bisphosphonate therapy or denosumab specifically to 
prevent skeletal events and who do not have a history of clinically significant 
hypercalcemina are eligible; 
• Patients who are receiving denosumab prior to enrollment must be willing and 
eligible to receive a bisphosphonate instead while on study. 
7. History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric 
humanized antibodies or fusion proteins; 
8. Known hypersensitivity to Chinese hamster ovary cell products or any component of the 
MPDL3280A or rociletinib formulations; 

Clovis Oncology, Inc. 
Clinical Protocol 
Rociletinib (CO-1686) 
CO-1686-032 
FINAL Version 1.0 
26 May 2015 
 
 
Page 56 of 131 
Confidential 
 
9. History of prior allogeneic hematopoietic stem cell transplantation or prior solid organ 
transplantation; 
10. History of autoimmune disease (please review Appendix E): 
• Patients with a history of Type 1 diabetes on a stable anti-hyperglycemic regimen; 
autoimmune-related hypothyroidism on a stable dose of thyroid replacement 
hormone; vitiligo; or alopecia are eligible for this study. 
11. Positive test for human immunodeficiency virus (HIV); 
12. Patients with active hepatitis B virus (HBV) (defined by a positive hepatitis B surface 
antigen [HBsAg] test at screening): 
• Patients with past or resolved HBV infection (defined by a negative HBsAg test and a 
positive anti-hepatitis B core antigen [anti-HBc] antibody test) are eligible. HBV 
DNA must be obtained in these patients prior to first day of study treatment. 
13. Patients with active hepatitis C virus (HCV): 
• Patients positive for HCV antibody are eligible only if PCR is negative for HCV 
RNA. 
14. Active tuberculosis; 
15. Signs or symptoms of infection within 2 weeks prior to first day of study treatment; 
16. Received therapeutic oral or IV antibiotics within 2 weeks prior to first day of study 
treatment: 
• Patients receiving prophylactic antibiotics (eg, to prevent a urinary tract infection or 
chronic obstructive pulmonary disease exacerbation) are eligible. 
17. Administration of a live, attenuated vaccine within 4 weeks before first day of study 
treatment or anticipation that such a live attenuated vaccine will be required during the 
study: 
• Influenza vaccination should be given during influenza season only (approximately 
October to March). Patients must not receive live, attenuated influenza vaccine (eg, 
FluMist) within 4 weeks prior to first day of study treatment or at any time during 
the study. 
18. Class II to IV heart failure as defined by the New York Heart Association functional 
classification system (Appendix G): 
• Patients with a known left ventricular ejection fraction (LVEF) < 40% will be 
excluded; 
• Patients with known coronary artery disease, congestive heart failure not meeting the 
above criteria, or LVEF < 50% must be on a stable medical regimen that is optimized 
in the opinion of the treating physician, in consultation with a cardiologist if 
appropriate, to be eligible. 
19. Patients who have experienced untreated and/or uncontrolled cardiovascular conditions 
and/or have symptomatic cardiac dysfunction (unstable angina, congestive heart failure, 

Clovis Oncology, Inc. 
Clinical Protocol 
Rociletinib (CO-1686) 
CO-1686-032 
FINAL Version 1.0 
26 May 2015 
 
 
Page 57 of 131 
Confidential 
 
myocardial infarction within the previous 3 months; coronary angioplasty, or stenting or 
bypass grafting within the past 6 months; cardiac ventricular arrhythmias requiring 
medication; any history of 2nd or 3rd degree atrioventricular conduction defects); 
20. Any of the following cardiac abnormalities or history:  
• Clinically significant abnormal 12-lead ECG or QT interval corrected using 
Fridericia’s method (QTCF) > 450 ms; 
• Inability to measure QT interval on ECG; 
• Personal or family history of long QT syndrome; 
• Implantable pacemaker or implantable cardioverter defibrillator; 
• Resting bradycardia < 55 beats/min. 
21. History of idiopathic pulmonary fibrosis, organizing pneumonia (eg, bronchiolitis 
obliterans), drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active 
pneumonitis on screening chest computerized tomography (CT) scan: 
• History of radiation pneumonitis in the radiation field (fibrosis) is permitted. 
22. Females who are pregnant or breastfeeding; 
23. Presence of active gastrointestinal (GI) disease (including GI bleeding or ulceration) or 
other condition that could affect GI absorption (eg, malabsorption syndrome, history of 
biliary tract disease); 
24. Uncontrolled medical, psychological, familial, sociological, or geographical conditions 
that interfere with the patient’s safety, ability to provide informed consent, or ability to 
comply with the protocol; 
25. Malignancies other than NSCLC within 5 years prior to enrollment, with the exception of 
those with a negligible risk of metastasis or death (such as adequately treated carcinoma 
in situ of the cervix, basal or squamous cell skin cancer, localized prostate cancer, or 
ductal carcinoma in situ); 
Previous and Concomitant Medications 
26. Patients who are currently receiving treatment with any medications that have the 
potential to prolong the QT interval if that treatment cannot be either discontinued or 
switched to a different medication prior to first day of study treatment. The wash out 
period for the medication should be at least 5 times the medication’s half-life (see 
http://crediblemeds.org/ for a list of QT-prolonging medications); 
27. Treatment with systemic immunostimulatory agents (including but not limited to 
interferon [IFN], interleukin [IL]-2) within 6 weeks or five half-lives of the drug, 
whichever is shorter, prior to first day of study treatment; 

Clovis Oncology, Inc. 
Clinical Protocol 
Rociletinib (CO-1686) 
CO-1686-032 
FINAL Version 1.0 
26 May 2015 
 
 
Page 58 of 131 
Confidential 
 
28. Treatment with systemic immunosuppressive medications (including but not limited to 
prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and antitumor 
necrosis factor [anti-TNF] agents) within 2 weeks prior to first day of study treatment: 
• The use of inhaled corticosteroids and mineralocorticoids (eg, fludrocortisone) is 
allowed. 
4.4 
Patients or Partners of Patients of Reproductive Potential 
Pregnancy is an exclusion criterion and females of childbearing potential must not be 
considering getting pregnant during the study. Female patients who are more than 2 years 
postmenopausal or have had a hysterectomy will not be considered of childbearing potential. 
Female patients of childbearing potential must have a negative serum pregnancy within 7 days 
prior to administration of the first dose of either study drug. If the serum pregnancy results are 
not available on first day of study treatment (Day of Run-in-Period for Phase 1; C1D1 for 
Phase 2), a urine pregnancy test can be performed on the first day of study treatment to confirm 
that the patient is not pregnant before dosing. Both values should be entered in the electronic 
case report form (eCRF). Another serum pregnancy test will be performed at the End of 
Treatment (EOT) Visit. 
Women of childbearing potential must practice double-barrier methods of contraception during 
treatment and for 90 days after the last dose of either study drug. Adequate contraception is 
defined as double-barrier protection (ie, condom plus spermicide in combination with a 
diaphragm, cervical/vault cap, or intrauterine device). Birth control pills, birth control patches 
and/or injections of hormones to prevent pregnancy are not considered an adequate method of 
preventing pregnancy. 
Men with a female partner of childbearing potential must have either had a prior vasectomy or 
agree to double-barrier methods of contraception during treatment and for 21 days after the last 
dose of either study drug to allow for clearance of any altered sperm.  
Patients will be instructed to notify the Investigator if pregnancy of a female patient or a partner 
of a male patient is discovered to have occurred either during the patient’s treatment or within 
90 days (female patients) or 21 days (partners of male patients) after completion of treatment 
with rociletinib and MPDL3280A.  
4.5 
Waivers of Inclusion/Exclusion Criteria 
No waivers of protocol-specified inclusion or exclusion criteria will be granted by the 
Investigator, the Sponsor, or its designee for any patient enrolling into the study. 

Clovis Oncology, Inc. 
Clinical Protocol 
Rociletinib (CO-1686) 
CO-1686-032 
FINAL Version 1.0 
26 May 2015 
 
 
Page 59 of 131 
Confidential 
 
5 
DESCRIPTIONS OF STUDY TREATMENT AND DOSE MODIFICATIONS 
5.1 
Description of Rociletinib  
Rociletinib is provided as yellow, film-coated tablets for PO administration in two dosage 
strengths made from the same drug blend. The strengths are achieved by adjusting the total tablet 
weight. The strengths are differentiated by tablet shapes: 125 mg strength is a round tablet and 
250 mg strength tablet is an oval tablet. Each tablet consists of rociletinib HBr drug substance, 
silicified microcrystalline cellulose, croscarmellose sodium, colloidal silicon dioxide, 
copovidone, magnesium stearate and hypromellose based film coat. Excipients used are 
generally regarded as safe. Tablets are packaged along with desiccant in high density 
polyethylene bottles closed with a child-resistant cap. Tablets will be supplied to the study sites 
by the Sponsor. Rociletinib tablets should be stored in their original packaging at 15°C to 30°C 
(59-86°F). 
Child-resistant bottles containing rociletinib tablets are labeled according to applicable 
regulations for investigational products. Patients should be advised not to split or crush tablets. 
Additionally, patients should be advised not to take tablets with chips or other gross visual 
defects. Defective tablets should be returned to the study site. 
5.2 
Description of MPDL3280A 
The MPDL3280A drug product is provided in a single-use, 20-cc USP/Ph. Eur. Type 1 glass vial 
as a colorless-to-slightly yellow, sterile, preservative-free clear liquid solution intended for IV 
administration. The vial is designed to deliver 20 mL (1200 mg) of MPDL3280A solution but 
may contain more than the stated volume to enable delivery of the entire 20 mL volume. The 
MPDL3280A drug product is formulated as 60 mg/mL MPDL3280A in 20 mM histidine acetate, 
120 mM sucrose, 0.04% polysorbate 20, pH 5.8. 
MPDL3280A must be refrigerated at 2°C-8°C (36°F-46°F) upon receipt until use. MPDL3280A 
vials should not be used beyond the expiration date provided by the manufacturer. No 
preservative is used in the MPDL3280A drug product; therefore, each vial is intended for single 
use only. Vial contents should not be frozen or shaken and should be protected from direct 
sunlight. 
For further details, see the MPDL3280A IB. 
5.3 
Preparation and Administration of Study Treatment 
Rociletinib is available as 125 or 250 mg tablets. Patients will self-administer oral rociletinib 
BID at the cohort-assigned dose throughout the treatment period, unless dose reduction is 
required for adverse event management. Patients should take rociletinib as directed by the 
treating physician. Patients will be instructed to take each dose of rociletinib with 8 oz. (240 mL) 
of water and with a meal or within 30 minutes after a meal. (During the PK visit on C1D8 
[Phase 1 only], patients will be more specifically guided to take the morning dose of rociletinib 
within 30 minutes after the start of the meal.) Tablets should be swallowed whole. Missed doses 

Clovis Oncology, Inc. 
Clinical Protocol 
Rociletinib (CO-1686) 
CO-1686-032 
FINAL Version 1.0 
26 May 2015 
 
 
Page 60 of 131 
Confidential 
 
(ie, patient does not take dose within 6 hours of the scheduled time) or vomited doses will not be 
made up, and the patient should resume rociletinib dosing with the next scheduled dose.  
The Investigator or designee will be responsible for distributing the appropriate strength(s) of PO 
rociletinib tablets to all patients. A sufficient number of tablets will be provided to the patient to 
last until the next scheduled visit. Patients will be instructed to record daily doses taken or not 
taken on a patient diary, and will be instructed to bring their rociletinib tablets and diary to the 
next scheduled visit for reconciliation by site personnel. 
On PK sampling days, patients will be instructed to not administer study drug at home, but to 
bring rociletinib and their dosing diaries to the clinic along with breakfast. Patients will be 
instructed when to take their doses of rociletinib in the clinic and when to have their meal, in the 
context of the PK schedule and/or MPDL3280A dose administration for the given visit (see 
Table 2).  
The only dose of MPDL3280A for all patients in this study is a fixed dose of 1200 mg 
administered by IV infusion on the first day of each protocol-specified 21-day treatment cycle 
(see Table 1). MPDL3280A will be delivered in infusion bags with IV infusion lines, 
product-contacting surfaces of polyvinylchloride (PVC) and polyolefin, and 0.2 m in-line filters 
(filter membrane of polyethersulfone). No incompatibilities have been observed between 
MPDL3280A and PVC or polyolefin infusion materials (bags and infusion lines). Administration 
of MPDL3280A will be performed in a setting with emergency medical facilities and staff who 
are trained to monitor for and respond to medical emergencies. 
The initial dose of MPDL3280A will be delivered over 60 ( 15) minutes. If the first infusion is 
tolerated without infusion-associated AEs, the second infusion may be delivered over 30 ( 10) 
minutes. If the 30-minute infusion is well tolerated, all subsequent infusions may be delivered 
over 30 ( 10) minutes. For the first infusion, the patient’s vital signs (heart rate, respiratory rate, 
blood pressure, and temperature) should be determined within 60 minutes before the infusion, 
every 15 [ 5] minutes during the infusion, and 30 ( 10) minutes and 2 hours ( 15 minutes) 
after completion of the infusion. For subsequent infusions, vital signs will be collected within 
60 minutes before the infusion, during the infusion as clinically indicated or if symptoms 
occurred in the prior infusion, and 1 hour ( 10 minutes) after the infusion. 
No premedication will be allowed for the first dose of MPDL3280A. Premedication may be 
administered for subsequent infusions at the discretion of the treating physician after consultation 
with the Medical Monitor. 
5.4 
Blinding/Masking of Treatment 
This is an open-label study; the investigational product will not be blinded or masked. All 
patients enrolled will receive PO rociletinib and IV MPDL3280A. 

Clovis Oncology, Inc. 
Clinical Protocol 
Rociletinib (CO-1686) 
CO-1686-032 
FINAL Version 1.0 
26 May 2015 
 
 
Page 61 of 131 
Confidential 
 
5.5 
Treatment Compliance 
Documentation of dosing will be recorded in a study-specific diary card provided by the Sponsor 
(or designee). Study site personnel will enter the scheduled daily doses of rociletinib and the 
number of tablets to be taken each day. Patients (or legally authorized representative) will be 
asked to record dosing information for PO rociletinib taken at home in the diary card and to 
bring the diary card and all unused tablets with them to scheduled clinic visits. Study site 
personnel will review the dosing information with the patient (or legally authorized 
representative) on scheduled clinic visit days and complete a compliance check and tablet count. 
Study site personnel will record compliance information on the eCRF and retain the diary card in 
the patient’s medical record.  
5.6 
Study Drug Accountability  
All investigational medicinal products (IMPs) required for completion of this study (rociletinib, 
MPDL3280A) will be provided by the Sponsor. Study personnel will maintain accurate records 
of rociletinib and MPDL3280A shipments/receipts, administration, and drug reconciliation. The 
investigational site will acknowledge receipt of IMPs, using the IxRS to confirm the shipment 
condition and content. The study site is responsible for the return or destruction of rociletinib and 
MPDL3280A as required. A drug management system will manage rociletinib and MPDL3280A 
inventory at all sites. The system will be required to manage study treatment requests and 
shipments. 
Any rociletinib and/or MPDL3280A accidentally or deliberately destroyed must be accounted 
for. All bottles or vials must be accounted for before their destruction at the study center. Unused 
bottles or vials should be destroyed locally. If destruction at the site is not possible, supply 
should be returned to the drug depot. During the course of the study and at completion of the 
study, the number of bottles and vials shipped, destroyed, and returned must be reconciled. 
Accurate records of all IMPs received at, dispensed from, returned to, and disposed of by the 
study site should be recorded on the Drug Inventory Log. 
5.7 
Dose Modification Guidelines  
5.7.1 Study Treatment Dose Reductions 
5.7.1.1 Rociletinib Dose Reductions 
From a starting dose of 500 mg BID rociletinib, up to two dose reductions are available 
(Table 7). No dose reduction below 250 mg is permitted. All dose reductions are permanent. 
Table 7: 
Dose Reductions for Rociletinib 
Current Dosage 
Dose Reduction 
500 mg PO BID 
375 mg PO BID 
375 mg PO BID 
250 mg PO BID 
250 mg PO BID 
No further dose reduction allowed 
BID, twice daily; PO, oral. 

Clovis Oncology, Inc. 
Clinical Protocol 
Rociletinib (CO-1686) 
CO-1686-032 
FINAL Version 1.0 
26 May 2015 
 
 
Page 62 of 131 
Confidential 
 
5.7.1.2 
MPDL3280A Dose Reductions 
The only dose of MPDL3280A available on this study is 1200 mg. Dose reductions are not 
permitted. 
5.7.2 Phase 1 – Run-in-Period 
Rociletinib monotherapy will be administered orally BID during the 7-day Run-in-Period. Dose 
reductions of rociletinib during the Run-in-Period are not allowed for reasons other than a DLT. 
Dose delays of rociletinib for up to 48 hours for toxicity management is allowed. Any patient 
who experiences an AE(s) that requires either a delay of treatment for more than a total of 
48 hours or a dose reduction during the 7-day Run-in Period of rociletinib monotherapy will not 
be eligible for combination therapy. Such a patient will only receive monotherapy rociletinib for 
the duration of participation in the study. 
5.7.3 Phase 1 – Cycle 1 
The first dose of MPDL3280A at 1200 mg will be administered by IV on C1D1. Dose reductions 
of rociletinib are not allowed for reasons other than a DLT or a decision by the CSC based on 
emerging safety data. Dose delays of rociletinib are not allowed for reasons other than toxicity. 
Patients are eligible for safety and DLT evaluation of the cohort if they receive at least 75% of 
the planned total dose of each study drug within Cycle 1 or they experience a DLT at any time 
during Cycle 1.  
5.7.4 Beyond DLT Assessment (Phase 1 – Cycle 2+ and Phase 2 – All Cycles) 
For patients who experience a toxicity that is equivalent to a DLT – If the toxicity is assessed as 
being related to rociletinib, the next dose of rociletinib should be held until resolution of the 
toxicity to Grade 1 or to the baseline level (if severity > Grade 1 at baseline) and then reduced to 
the next dose level of rociletinib (Table 7), unless permanent discontinuation of rociletinib is 
required per toxicity management guidelines of the protocol (Sections 6.1 and 6.3). If the toxicity 
is assessed as being related to MPDL3280A, the next dose of MPDL3280A should be held until 
the toxicity has resolved to Grade 1 or to the baseline level (if severity > Grade 1 at baseline), 
unless permanent discontinuation of MPDL3280A is required per toxicity management 
guidelines of the protocol (Sections 6.2 and 6.3). In addition, because there is no available 
antidote for MPDL3280A and discontinuation of MPDL3280A may not have immediate 
therapeutic effect, consideration may be given to holding rociletinib doses temporarily even if 
the toxicity is not attributed to rociletinib. 
Dose holds for toxicity or for reasons unrelated to toxicity (eg, elective surgery or intercurrent 
illness) are allowed for up to 14 days for rociletinib and for up to 42 days (2 cycles) for 
MPDL3280A. Permission for a longer dose hold must be granted by the Sponsor’s Medical 
Monitor; in the absence of such permission, the patient should permanently discontinue all study 
treatment (Section 11.1). 

Clovis Oncology, Inc. 
Clinical Protocol 
Rociletinib (CO-1686) 
CO-1686-032 
FINAL Version 1.0 
26 May 2015 
 
 
Page 63 of 131 
Confidential 
 
Intra-Subject Dose Escalation: For patients in the Dose Finding Phase (Phase 1) who have 
completed 2 cycles of therapy at their original assigned dose with no DLTs, intra-subject dose 
escalation to a higher dose level of rociletinib (if applicable) may be permitted with approval 
from the Sponsor’s Medical Monitor after consideration of cumulative safety data and provided 
that the dose level to which the patient will escalate has already been evaluated and has a DLT 
rate < 33%. Intra-subject dose escalation will begin at the start of a dosing cycle at the 
Investigator’s discretion and requires prior approval by the Sponsor’s Medical Monitor. For 
patients in the Dose Expansion Phase (Phase 2), no intra-subject dose escalation is allowed. 
In cases where a patient must discontinue rociletinib or MPDL3280A for toxicity, monotherapy 
with the other agent may be continued until the patient meets any of the criteria for permanent 
treatment discontinuation (see Section 11).  
A summary of dose modification allowances is shown in Table 8. 
 
Table 8: 
Phase 1 and Phase 2 Dose Modification 
 
Dose Finding Phase (Phase 1) 
Phase 1 and Phase 2 
Run-In 
Cycle 1 
Cycle 2+ 
 
Rociletinib 
Rociletinib 
MPDL3280A 
Rociletinib 
MPDL3280A 
Dose 
Reduction a 
Not allowed 
unless due to 
DLT b 
Not allowed 
unless due to 
DLT or CSC 
decision 
Not allowed 
Allowed for 
toxicity (see 
Table 7 for 
dose 
reductions) 
Not allowed 
Dose Hold 
Allowed up to 
48 hours for 
toxicity 
management b 
Allowed for 
toxicity; must 
receive >75% 
doses to be 
evaluable for 
DLT 
Not allowed 
Allowed up to 
14 days c for 
toxicity or 
reasons 
unrelated to 
toxicity 
Allowed up to 
42 days c for 
toxicity or reasons 
unrelated to 
toxicity 
CSC, Clinical Safety Committee; DLT, dose-limiting toxicity. 
a Dose reductions are permanent.  
b If dose reduction or more than 48-hour delay of rociletinib dosing is required in Run-in-Period, patient will not be eligible for 
combination therapy but rather will continue rociletinib monotherapy.  
c If a longer hold is needed for slowly resolving toxicity, Sponsor approval is required. If either study drug must be discontinued 
for toxicity, monotherapy with the other study drug may be continued. 
 

Clovis Oncology, Inc. 
Clinical Protocol 
Rociletinib (CO-1686) 
CO-1686-032 
FINAL Version 1.0 
26 May 2015 
 
 
Page 64 of 131 
Confidential 
 
5.8 
Treatment of Study Drug Overdose 
There are no known antidotes for overdoses of rociletinib or MPDL3280A. In the event of an 
overdose of MPDL3280A, discontinuation of MPDL3280A may not have immediate therapeutic 
effect. In the event of a known or suspected overdose, the patient should be monitored with 
appropriate hematology and clinical chemistry and should receive supportive therapy, as 
necessary. Please also refer to Section 6 for guidelines on the management of potential study 
drug-related toxicities. 
Decisions regarding dose interruptions or modifications for rociletinib and/or MPDL3280A 
dosing in the case of a suspected overdose will be made by the Investigator in consultation with 
the Medical Monitor based on the clinical evaluation of the patient. 
A plasma sample for PK analysis may be requested by the Medical Monitor on a case-by-case 
basis. This plasma sample should be collected as soon as possible, but within 10 days from the 
date of the last dose of on-study dosing. 
Information regarding the quantity of the excess dose as well as the duration of the overdosing 
should be documented in the appropriate eCRF. 

Clovis Oncology, Inc. 
Clinical Protocol 
Rociletinib (CO-1686) 
CO-1686-032 
FINAL Version 1.0 
26 May 2015 
 
 
Page 65 of 131 
Confidential 
 
6 
MONITORING AND MANAGEMENT OF EXPECTED OR POTENTIAL 
TREATMENT-RELATED TOXICITY 
In general, toxicities should be managed with supportive care and with dose modifications for 
each of the study drugs (Section 5.7) according to attribution of the toxicity. Certain toxicities 
may be more likely to occur with rociletinib or MPDL3280A, and some toxicities may be 
overlapping. This section provides guidance on the monitoring and management of expected or 
potential toxicities associated with rociletinib or MPDL3280A or both rociletinib and 
MPDL3280A. 
6.1 
Rociletinib Expected or Potential Toxicities 
6.1.1 Management of Prolonged QTc 
Electrocardiograms will be performed throughout the study as described (see Table 1 and 
Section 8.4.2.4). Readings for QTc prolongation will be based on the average for the triplicate 
ECGs for each time point. Patients are required to have within-normal-range potassium and 
magnesium at enrollment, and these electrolytes should be maintained within range during 
rociletinib treatment, using supplementation if necessary.  
Guidelines for dose modification and stopping criteria due to QTc prolongation are provided in 
Table 9. 
Table 9: 
Withholding and Stopping Criteria for QTc-Prolongation 
QTc-Prolongationa 
Action and Dose Modification 
QTcF ≥ 501 msec on at least two  
separate ECGsa (Grade 3) 
 
• 
Interrupt study treatment until QTcF prolongation resolves to 
Grade 1 (QTcF > 450-480 msec) or baseline; 
• 
Test serum potassium, calcium, phosphorus and magnesium. 
If abnormal, correct per routine clinical practice to within 
normal limits; 
• 
Review concomitant medication usage for a prolonged QTc; 
• 
Restart at a reduced dose levelb; 
• 
If Grade 3 QTc prolongation recurs after 2 dose 
reductions, permanently discontinue study treatmentb; 
• 
If Grade 4 QTc prolongation (QTcF > 501 or 60 msec 
increase from baseline and polymorphic ventricular 
tachycardia or serious arrythmia) occurs, permanently 
discontinue study treatmentb 
msec, milliseconds; QTcF, QT interval on electrocardiogram corrected using Fridericia’s formula (see Appendix D) 
a Based on average QTc value of triplicate ECGs.  
b If the QTc prolongation resolves to Grade 1 or baseline, the patient may resume study treatment if the Investigator  and 
Medical Monitor agree that the patient will benefit from further treatment. 
 

Clovis Oncology, Inc. 
Clinical Protocol 
Rociletinib (CO-1686) 
CO-1686-032 
FINAL Version 1.0 
26 May 2015 
 
 
Page 66 of 131 
Confidential 
 
6.1.2 Management of Hyperglycemia 
Rociletinib causes hyperglycemia in some people. Clinical experience with rociletinib suggests 
hyperglycemia generally occurs within the first 3 weeks of treatment, leading to the need for 
more intensive glucose monitoring during the first several weeks of the study in order to 
minimize the risk of symptomatic hyperglycemia. Because later onset of hyperglycemia is also 
possible with rociletinib treatment, regular monitoring of glucose and of symptoms of 
hyperglycemia will be required through the end of rociletinib treatment.  
Fasting blood glucose (FBG) will be measured by local laboratories for the following visits: 
Screening/Baseline visit, Day 1 of the Run-in-Period (Phase 1 only), C1D1, C1D4, C1D8, 
C1D15, Day 1 of each cycle beginning with Cycle 2, and at the EOT Visit (Table 1). 
Investigators should use discretion on an individual-patient basis to determine the need for more 
frequent monitoring. 
Diabetes and glucose intolerance are not contraindications to the use of rociletinib. Patients with 
pre-existing diabetes may require more frequent glucose monitoring and/or adjustments of 
diabetic medication. In addition to the scheduled local laboratory tests for FBG (see Table 1), 
patients with pre-existing diabetes should perform home monitoring at least once weekly (if not 
more frequently).  
For patients who are not already monitoring their glucose levels, sites are strongly encouraged to 
implement patient home monitoring of fasting urine glucose for Cycle 1 and Cycle 2. If 
preferred, home monitoring of blood glucose is also acceptable. Patients should be educated to 
contact the site if they have any positive urine glucose test or a home blood glucose reading of 
> 160 mg/dL (> 8.9 mmol/L) and any time they experience symptoms that have correlated with 
rociletinib-induced hyperglycemia, including increases in nausea, vomiting, anorexia, diarrhea, 
and/or fatigue. Symptoms more commonly associated with diabetes, such as polydipsia, 
polyuria, and polyphagia, rarely occur with rociletinib-induced hyperglycemia. Upon reports of 
positive home tests and/or symptoms suggesting hyperglycemia, local laboratory FBG tests 
should be performed. 
Guidelines for management of hyperglycemia, based on the results of laboratory FBG values and 
patient symptoms, are presented in Table 10. Sites are encouraged to follow these guidelines, 
although management of individual patients may be influenced by local practices and the treating 
physician’s judgment.  

Clovis Oncology, Inc. 
Clinical Protocol 
Rociletinib (CO-1686) 
CO-1686-032 
FINAL Version 1.0 
26 May 2015 
 
 
Page 67 of 131 
Confidential 
 
Table 10: 
Management Guidelines for Hyperglycemia 
FBG Result 
Antihyperglycemic 
Interventiona 
Rociletinib Dose Modification 
Grade 2  
(> 160 to 250 mg/dL;  
> 8.9 to 13.9 mmol/L) 
• 
If asymptomatic,b repeat 
test within 1 week; if results 
in this range at least twice 
in 1 week, start 
antihyperglycemicc and 
continue home monitoring; 
• 
Rociletinib may continue without 
interruption or dose reduction 
 
• 
If symptomatic,b start 
antihyperglycemic and 
continue home monitoring.  
Grade 3  
(> 250 to 500 mg/dL;  
> 13.9 to 27.8 mmol/L) 
• 
Start antihyperglycemic and 
continue home monitoring. 
• 
If asymptomatic,b rociletinib may continue 
without interruption or dose reduction; 
• 
If symptomatic,b interrupt rociletinib until 
resolution/improvement in symptoms and 
FBG < 250 mg/dL (< 13.9 mmol/L)c. 
Grade 4  
(> 500 mg/dL;  
> 27.8 mmol/L) 
• 
Start antihyperglycemic and 
continue home monitoring.  
• 
Consider adding a second 
antihyperglycemic 
agent.d 
• 
Interrupt rociletinib dosing until 
resolution/improvement in symptoms and 
FBG < 250 mg/dL (< 13.9 mmol/L).c 
• 
 
FBG, fasting blood glucose 
a Oral antihyperglycemic agent (eg, metformin), which may need to be maintained for duration of rociletinib treatment. Use of 
insulin or agents which increase insulin production (eg, sulphonyl ureas) is generally not recommended because the 
mechanism of rociletinib-induced hyperglycemia is not due to a deficit in insulin production. 
b Increased nausea, vomiting, anorexia, diarrhea, and fatigue have been most common symptoms of hyperglycemia. 
c Per Investigator discretion, rociletinib may be restarted at the same dose. A reduced dose may also be considered if glucose 
levels prove difficult to control. 
d Additional antihyperglycemia agents such as SGLT2 inhibitors (eg, dapagliflozin) or pioglitazone, which increase glucose 
uptake or increase glucose excretion, may be added to metformin. 
 
6.2 
MPDL3280A Expected or Potential Toxicities 
Any toxicities associated or possibly associated with MPDL3280A treatment should be managed 
according to standard medical practice. No reduction of the MPDL3280A dose will be allowed 
(Section 5.7.1.2). Additional tests, such as autoimmune serology or biopsies, may be used to 
determine a possible immunogenic etiology of a toxicity. 
Most immune-related adverse events (irAEs) observed with immunomodulatory agents have 
been mild and self-limiting; however, such events should be recognized early and treated 
promptly to avoid potential major complications. The primary approach to managing Grade 1-2 
irAEs is supportive and symptomatic care. In the case of recurrent Grade 2 events or in severe 
cases, immune-related toxicities may be acutely managed with topical corticosteroids, systemic 
corticosteroids, or tumor necrosis factor alpha (TNF-) inhibitors, as well as delay or permanent 
discontinuation of MPDL3280A.  

Clovis Oncology, Inc. 
Clinical Protocol 
Rociletinib (CO-1686) 
CO-1686-032 
FINAL Version 1.0 
26 May 2015 
 
 
Page 68 of 131 
Confidential 
 
There is no available antidote for MPDL3280A, and as a result, discontinuation of MPDL3280A 
may not have immediate therapeutic effect. In severe cases, immune-related toxicities may be 
acutely managed with topical corticosteroids, systemic corticosteroids, or TNF- inhibitors. In 
addition, consideration may be given to holding rociletinib doses temporarily even if the toxicity 
is not attributed to rociletinib. 
Management of possible infusion reactions, gastrointestinal toxicity (including colitis), 
hepatotoxicity (including hepatitis and elevated transaminases), dermatologic toxicity, 
hypothyroidism, pulmonary toxicity, pericardial and pleural effusions, pancreatic toxicity, and 
ocular toxicity are presented in the following sections. See also Appendix F for precautions for 
anaphylaxis. 
6.2.1 Management of Infusion Reactions 
The management of infusion-related reactions will be according to severity as follows: 
Table 11:  Management Guidelines for Infusion-Related Reactions during Cycle 1 
Description 
Management 
Grade 1  
(mild)  
 
• 
Reduce infusion rate to half the rate being given at the time of event 
onset; 
• 
Once the event has resolved, the Investigator should wait for 30 minutes 
while delivering the infusion at the reduced rate; 
• 
If tolerated, the infusion rate may then be increased to the original rate. 
Grade 2  
(moderate)  
 
OR 
 
 
Flushing, fever, throat pain  
• 
Interrupt MPDL3280A infusion; 
• 
Administer aggressive symptomatic treatment; 
• 
Restart only after the symptoms have adequately resolved to baseline 
grade; 
• 
The infusion rate at restart should be half of the infusion rate that was in 
progress at the time of the onset of the infusion-related reaction. 
Grade 3 or 4  
(severe or life-threatening  
[see Appendix F])  
 
• 
Interrupt infusion; 
• 
Initiate aggressive resuscitation and supportive measures; 
• 
Do not re-administer MPDL3280A; 
• 
Manage patient as clinically indicated until the event resolves. 

Clovis Oncology, Inc. 
Clinical Protocol 
Rociletinib (CO-1686) 
CO-1686-032 
FINAL Version 1.0 
26 May 2015 
 
 
Page 69 of 131 
Confidential 
 
6.2.2 Management of Gastrointestinal Toxicity 
Immune-mediated colitis has been associated with the administration of MPDL3280A. 
Treatment guideline is summarized in Table 12. 
Table 12: 
Management Guidelines for Gastrointestinal Toxicity (Diarrhea) 
Description 
Management 
Grade 2  
(4-6 stools/day over 
baseline)  5 days 
 
• Hold MPDL3280A and discontinue NSAIDS (or other medication known to 
exacerbate colitis). 
• Investigate for etiology. 
• Restart MPDL3280A once at baseline stool frequency. 
Grade 2  
(4-6 stools/day over 
baseline)  5 days 
  
• Hold MPDL3280A and discontinue NSAIDS (or other medication known to 
exacerbate colitis) while etiology is being investigated. 
• Consider referral to a gastroenterologist. 
• Administer anti-diarrheal agent (eg, Imodium). 
• Consider oral budesonide, mesalamine, or 10 mg oral prednisone equivalent 
per day.  
• Restart MPDL3280A once at baseline stool frequency. 
Grade  3 
 ( 7 stools/day over 
baseline) with peritoneal 
signs, ileus, or fever 
 
OR 
 
Abdominal pain 
Blood or mucus in stool  
 
• Hold MPDL3280A and discontinue NSAIDS (or other medication known to 
exacerbate colitis). 
• Rule out bowel perforation. 
• Consider administering prednisone 60 mg/day or equivalent (oral budesonide 
or methylprednisolone IV). 
• Taper steroids over 1 month. 
• Restart MPDL3280A if diarrhea is resolved as confirmed by sigmoidoscopy 
or colonoscopy and systemic steroid dose is  10mg oral prednisone 
equivalent per day 
• Permanently discontinue MPDL3280A for life-threatening immune-related 
diarrhea or colitis. 
IV, intravenous; NSAID, nonsteroidal anti-inflammatory drugs; TNF, tumor necrosis factor. 
 
If the event is of significant duration or magnitude or is associated with signs of systemic 
inflammation or acute phase reactants (eg, increased C-reactive protein or platelet count or 
bandemia), it is recommended to do the following: 
• Perform sigmoidoscopy (or colonoscopy, if appropriate) with colonic biopsy with three to five 
specimens for standard paraffin block to check for inflammation and lymphocytic infiltrates 
for confirmation of the diagnosis of colitis. If possible, one or two biopsy specimens should be 
snap frozen and stored. 
• Perform laboratory tests to rule out alternate etiology (ie, white blood cells [WBCs] and stool 
calprotectin). 
 

Clovis Oncology, Inc. 
Clinical Protocol 
Rociletinib (CO-1686) 
CO-1686-032 
FINAL Version 1.0 
26 May 2015 
 
 
Page 70 of 131 
Confidential 
 
6.2.3 Management of Hepatotoxicity 
Immune-mediated hepatitis has been associated with the administration of MPDL3280A. 
Eligible patients must have adequate liver function, as manifested by measurements of total 
bilirubin and hepatic transaminase, and liver function will be monitored throughout study 
treatment. 
While on this study, patients presenting with right upper-quadrant abdominal pain and/or 
unexplained nausea or vomiting should have LFTs performed immediately and reviewed before 
administration of the next dose of study drug. 
If LFTs increase, neoplastic, concurrent medications, viral hepatitis, and toxic etiologies should 
be considered and addressed, as appropriate. Imaging of the liver, gall bladder and biliary tree 
should be performed to rule out neoplastic or other causes for increased LFTs. Anti-nuclear 
antibody, perinuclear anti-neutrophil cytoplasmic antibody, anti-liver kidney microsomal 
antibodies, and anti-smooth muscle antibody tests should be performed if an autoimmune 
etiology is considered.  
Patients with LFT abnormalities should be managed according to Table 13. 
 
Table 13: 
Management Guidelines for Hepatotoxicity (LFT Abnormalities) 
Description 
Management 
AST/ALT ( ULN to 
3  ULN) with total 
bilirubin  2  ULN 
• Continue with the standard monitoring plan (ie, LFTs every 3 weeks 
before dosing). 
AST/ALT ( 3  ULN to 
 10  ULN) with total 
bilirubin  2  ULN 
• Continue MPDL3280A. Monitor LFTs at least weekly. Consider 
referral to a hepatologist. 
AST/ALT  10  ULN 
• Hold MPDL3280A; 
• Consider administering IV steroids for 24-48 hours (prednisone 
60 mg/day equivalent) followed by oral prednisone (or equivalent) 
taper over 2-4 weeks; 
• If LFT results do not decrease within 48 hours after initiation of 
systemic steroids, addition of an alternative immunosuppressive agent 
(eg, mycophenolate or TNF- antagonist) to the corticosteroid regimen 
may be considered; 
• Monitor LFTs every 48-72 hours until decreasing and then follow 
weekly; 
• Restart MPDL3280A after discussion with the Medical Monitor if 
AST/ALT  3  ULN with bilirubin  2  ULN and steroid dose is 
 10 mg oral prednisone equivalent per day; 
• Permanently discontinue MPDL3280A for life-threatening immune-
related hepatic events. 
 
 

Clovis Oncology, Inc. 
Clinical Protocol 
Rociletinib (CO-1686) 
CO-1686-032 
FINAL Version 1.0 
26 May 2015 
 
 
Page 71 of 131 
Confidential 
 
Table 13: 
Management Guidelines for Hepatotoxicity (continued) 
AST/ALT  3  ULN 
with bilirubin 
 2  ULN 
• Hold MPDL3280A; 
• Consult hepatologist; 
• Consider administering IV steroids for 24-48 hours (prednisone 
60 mg/day equivalent) followed by oral taper over 1 month; 
• If LFT results do not decrease within 48 hours after initiation of 
systemic steroids, addition of an alternative immunosuppressive agent 
(eg, mycophenolate or TNF- antagonist) to the corticosteroid regimen 
may be considered; 
• Monitor LFTs every 48-72 hours until decreasing and weekly after; 
• Restart MPDL3280A after discussion with the Medical Monitor if 
AST/ALT  3  ULN with bilirubin  2  ULN and steroid dose is 
 10mg oral prednisone equivalent per day. 
ALT, alanine aminotransferase; AST, aspartate aminotransferase; IV, intravenous; LFT, liver function test; TNFα, tumor necrosis 
factor alpha; ULN, upper limit of normal. 
6.2.4 Management of Dermatologic Toxicity 
Treatment-emergent rash (eg, maculopapular or purpura) has been associated with MPDL3280A. 
The majority of cases of rash were mild in severity and self-limited, with or without pruritus. 
A dermatologist should evaluate persistent and/or severe rash or pruritus. A biopsy should be 
considered unless contraindicated. Dermatologic toxicity and rash should be managed according 
to Table 14.  
Table 14: 
Management Guidelines for Rash 
Description 
Management 
Grade 1 
mild  
 10% BSA 
• Continue MPDL3280A. Symptomatic therapy with antihistamine PRN; 
• Consider topical steroids and/or other symptomatic therapy (eg, 
antihistamines). 
Grade 2 
moderate  
10%-30% BSA 
 
• Continue MPDL3280A; 
• Consider dermatologist referral; 
• Administer topical steroids; 
• Consider higher potency topical steroids if rash unresolved. 
Grade 3 
severe  
 30% BSA 
 
• Hold MPDL3280A; 
• Consult dermatologist; 
• Administer oral prednisone 10 mg or equivalent. If rash unresolved after 
48-72 hours, administer oral prednisone 60 mg or equivalent; 
• Restart MPDL3280A if rash resolved and systemic dose is  10 mg oral 
prednisone equivalent per day; 
• Permanently discontinue MPDL3280A for life-threatening 
immune-related dermatologic toxicity. 
 BSA, body surface area; PRN, as needed. 

Clovis Oncology, Inc. 
Clinical Protocol 
Rociletinib (CO-1686) 
CO-1686-032 
FINAL Version 1.0 
26 May 2015 
 
 
Page 72 of 131 
Confidential 
 
6.2.5 Management of Endocrine Toxicity (Hypothyroidism) 
Hypothyroidism has been associated with the administration of MPDL3280A. 
Patients with unexplained symptoms such as fatigue, myalgias, impotence, mental status 
changes, or constipation should be investigated for the presence of thyroid, pituitary, or adrenal 
endocrinopathies, as well as for hyponatremia or hyperkalemia. An endocrinologist should be 
consulted if an endocrinopathy is suspected. Thyroid-stimulating hormone (TSH) and free T4 
levels should be obtained to determine whether thyroid abnormalities are present. TSH, 
prolactin, and a morning cortisol level will help to differentiate primary adrenal insufficiency 
from primary pituitary insufficiency. 
Hypothyroidism should be managed according to Table 15. 
Table 15: 
Management Guidelines for Hypothyroidism 
Description 
Management 
TSH elevated, asymptomatic 
• Continue MPDL3280A; 
• Start thyroid replacement hormone (as per institutional guidelines); 
• Monitor TSH weekly. 
TSH elevated, symptomatic 
• Hold MPDL3280A; 
• Consider referral to an endocrinologist; 
• Start thyroid replacement hormone (as per institutional guidelines); 
• Monitor TSH weekly; 
• Restart MPDL3280A when symptoms are controlled by thyroid replacement 
and TSH levels are decreasing. 
TSH, thyroid-stimulating hormone. 
6.2.6 Management of Pericardial and Pleural Effusions 
Pericardial involvement with associated effusions is common in patients with NSCLC and have 
the theoretical potential to be exacerbated by inflammation associated with antitumor immunity 
following PD-L1 blockade. Patients presenting with dyspnea, chest pain, or unexplained 
tachycardia should be evaluated for the presence of a pericardial effusion. Patients with 
preexisting pericardial effusion should be followed closely for pericardial fluid volume 
measurements and impact on cardiac function. When intervention is required for pericardial 
effusions, appropriate workup includes cytology, lactate dehydrogenase (LDH), glucose, 
cholesterol, and cell count. For patients with a pericardial effusion causing end-diastolic right 
ventricular collapse, treatment may be restarted following the placement of a pericardial window, 
demonstration of hemodynamic stability, and resolution of right ventricular dysfunction. 
6.2.7 Management of Potential Pancreatic Toxicity 
Symptoms of abdominal pain associated with elevations of amylase and lipase, suggestive of 
pancreatitis, have been associated with the administration of other immunomodulatory agents. 

Clovis Oncology, Inc. 
Clinical Protocol 
Rociletinib (CO-1686) 
CO-1686-032 
FINAL Version 1.0 
26 May 2015 
 
 
Page 73 of 131 
Confidential 
 
The differential diagnosis of acute abdominal pain should include pancreatitis. Appropriate 
workup should include an evaluation for obstruction, as well as serum amylase and lipase tests. 
Pancreatic toxicity should be managed according to Table 16. 
Table 16: 
Management Guidelines for Amylase/Lipase Abnormalities 
Description 
Management 
Amylase/lipase 
(> ULN and ≤ 2  ULN) and 
asymptomatic 
• Continue MPDL3280A; 
• Monitor amylase/lipase levels prior to dosing. 
Amylase/lipase 
( 2  ULN to ≤ 5  ULN) and 
asymptomatic 
 
• Continue MPDL3280A; 
• Monitor amylase/lipase weekly; 
• Consider oral prednisone 10 mg daily or equivalent for prolonged 
elevation (eg, more than 3 weeks). 
Amylase/lipase 
(> 5  ULN) and asymptomatic 
 
• Hold MPDL3280A; 
• Monitor amylase/lipase every other day and consider oral prednisone 
60 mg daily or equivalent; 
• Consult a gastroenterologist; 
• Resume MPDL3280A dosing when lipase/amylase levels are less than 
2  ULN. 
Autoimmune pancreatitis 
(abdominal pain and raised 
amylase/lipase levels) 
 
• Hold MPDL3280A; 
• Consult a gastroenterologist; 
• Consider administering IV steroids (prednisone equivalent of 60 mg/day) 
followed by taper over 2-4 weeks; 
• Resume MPDL3280A when enzyme levels are less than 2  ULN and 
patient is asymptomatic; 
• Permanently discontinue MPDL3280A for life threatening immune related 
pancreatitis. 
IV, intravenous; ULN, upper limit of normal. 

Clovis Oncology, Inc. 
Clinical Protocol 
Rociletinib (CO-1686) 
CO-1686-032 
FINAL Version 1.0 
26 May 2015 
 
 
Page 74 of 131 
Confidential 
 
6.2.8 Management of Potential Ocular Toxicity 
An ophthalmologist should evaluate visual complaints. Uveitis or episcleritis may be treated with 
topical corticosteroid eye drops. MPDL3280A should be permanently discontinued for immune-
mediated ocular disease that is unresponsive to local immunosuppressive therapy. 
Ocular toxicity should be managed according to Table 17. 
Table 17: 
Management Guidelines for Ocular Toxicities 
Description 
Management 
Symptomatic: autoimmune 
uveitis, iritis, or episcleritis 
• Hold MPDL3280A; 
• Consult ophthalmologist and start topical corticosteroid eye drops; 
• MPDL3280A may be restarted following resolution of the events and 
discussions with the Medical Monitor; 
• Permanently discontinue MPDL3280A for immune-mediated ocular 
disease that is unresponsive to local immunosuppressive therapy. 
6.3 
Overlapping Expected or Potential Toxicities 
Guidelines for the management of specific expected or potential overlapping toxicities for 
rociletinib and MPDL3280A are described in Table 18. 
 

Clovis Oncology, Inc. 
Clinical Protocol 
Rociletinib (CO-1686) 
CO-1686-032 
FINAL Version 1.0 
 
 
26 May 2015 
 
 
Page 75 of 131 
Confidential 
 
Table 18: 
Management of Overlapping Toxicities 
Toxicity 
Attribution to both agents 
Rash/Skin Toxicity: 
 
Grade 2: continue both agents; initiate supportive care. 
Grade 3:  
▪ 
Obtain dermatology consult; 
▪ 
Hold rociletinib and MPDL3280A until resolved to < Grade 1, then reinitiate rociletinib at a dose agreed upon with the 
Sponsor’s Medical Monitor; (dose delays longer than 14 days also require discussion with the Medical Monitor); 
▪ 
Restart MPDL3280A if rash does not occur within 14 days of rociletinib re-initiation; 
▪ 
Hold rociletinib and permanently discontinue MPDL3280A if the patient experiences recurrent Grade  3 skin toxicity. 
When rash is Grade 1, restart rociletinib at previous dose. If Grade  3 rash recurs, rociletinib should be discontinued 
permanently. 
Grade 4: Permanently discontinue MPDL3280A. Hold rociletinib until rash is Grade 1 and restart at one dose level lower 
(dose delays longer than 14 days require discussion with the Medical Monitor). If Grade  3 rash recurs, rociletinib should 
be discontinued. 
Diarrhea: 
 
Grade 2: Supportive care unless > 48 to 72 hrs. Then reduce dose of rociletinib and hold MPDL3280A until resolves to 
< Grade 1. 
Grade 3: Hold rociletinib and MPDL3280A Obtain gastroenterology consult, discontinue NSAIDs or medications known to 
exacerbate colitis, Initiate steroid treatment. If resolves to < Grade 1, then restart rociletinib at next lower dose. If no 
recurrent symptoms, within 14 days resume MPDL3280A as long as steroid dose is  10 mg oral prednisone equivalent per 
day (dose delays longer than 14 days require discussion with the Medical Monitor). 
Grade 4: MPDL3280A should be permanently discontinued. Hold rociletinib until diarrhea is Grade 1 and restart at one 
dose level lower. If Grade  3 diarrhea recurs, rociletinib should be permanently discontinued (dose delays longer than 14 
days require discussion with the Medical Monitor). 
Nausea/Vomiting: 
 
Grade1-2: Continue treatment. Begin maximum supportive care and adequate anti-emetic treatments (see Section 7.6.1 for 
guidance on avoiding QT-prolonging concomitant medication). 
Grade ≥ 3:  
▪ 
Begin/continue maximum supportive care and adequate combination anti-emetic treatments (see Section 7.6.1 for 
guidance on avoiding QT-prolonging concomitant medication). Consider gastroenterology consult; 
▪ 
Hold both rociletinib and MPDL3280A until < Grade 1. Restart rociletinib at next lower dose. If no recurrent 
symptoms, restart MPDL3280A; 
▪ 
If Grade  3 nausea/vomiting recurs, MPDL3280A should be discontinued. 
 

Clovis Oncology, Inc. 
Clinical Protocol 
Rociletinib (CO-1686) 
CO-1686-032 
FINAL Version 1.0 
 
 
26 May 2015 
 
 
Page 76 of 131 
Confidential 
 
Table 18: 
Management of Overlapping Toxicities (continued) 
Toxicity 
Attribution to both agents 
Ocular Toxicity:  
 
Grade ≥ 2:  
▪ 
Hold both study drugs until < Grade 1 (dose delays longer than 14 days require discussion with the Medical Monitor); 
▪ 
Obtain ophthalmology consult; uveitis or episcleritis may be treated with topical corticosteroid eye drops; 
▪ 
Reintroduce rociletinib at a reduced dose when symptoms resolved to Grade ≤ 1. If no recurrent symptoms, restart 
MPDL3280A; MPDL3280A should be permanently discontinued for immune-mediated ocular disease that is 
unresponsive to local immunosuppressive therapy. 
Laboratory abnormalities 
Grade  3 Laboratory abnormalities related to study drug that are asymptomatic and deemed by the Investigator not to be 
clinically significant 
▪ 
After discussion between Investigator and Medical Monitor, rociletinib dosing may be delayed, and treatment 
subsequently resumed at the current dose level or at a reduced dose. If abnormality persists > 7 days, MPDL3280A 
dosing may also be held and subsequently resumed at the same dose level when toxicity resolves to baseline grade plus 
one. 
Liver toxicities 
Grade  3 AST, ALT, or bilirubin abnormalities (or AST or ALT  10  ULN in patients with hepatic metastases) related to 
study drug that are asymptomatic and deemed by the Investigator not to be clinically significant 
▪ 
Hold both study drugs until recovery Grade  1; 
▪ 
Initiate systemic steroids IV for 48 hours followed by oral taper; 
▪ 
Monitor LFTs QOD until decreasing, then weekly; 
▪ 
If resolved to baseline grade plus one (eg, if baseline Grade 1, then Grade 2) resume MPDL3280A dosing; 
▪ 
If AE persists permanently discontinue MPDL3280A. 
Other Grade  3 
non-hematologic or Grade 4 
hematologic toxicity 
▪ 
Hold rociletinib and MPDL3280A until recovery to Grade  1 and then restart rociletinib at a reduced dose and 
MPDL3280A at the same dose. 
▪ 
If the Grade 4 AE recurs (a second time), then MPDL3280A should be discontinued. 
▪ 
If the Grade 4 AE recurs (a third time), then rociletinib should be discontinued. 
 
 

Clovis Oncology, Inc. 
Clinical Protocol 
Rociletinib (CO-1686) 
CO-1686-032 
FINAL Version 1.0 
 
 
26 May 2015 
 
 
Page 77 of 131 
Confidential 
 
Table 18: 
Management of Overlapping Toxicities (continued) 
Pulmonary toxicity  
Incidental radiographic findings of ground glass opacities (GGO) or non-infectious infiltrate in absence of symptoms: 
▪ 
Hold rociletinib and MPDL3280A and re-evaluate after 1 week; 
▪ 
If no worsening in GGO/infiltrates and patient is still asymptomatic, resume treatment with rociletinib. Re-evaluate 
after additional 1 week. If GGO/infiltrates are still present and not worsened, perform pulmonary function tests. If 
patient is confirmed asymptomaic, resume treatment with MPDL3280A. 
▪ 
If GGO/infiltrates worsen and patient is still asymptomatic, continue to hold rociletinib and MPDL3280A and refer 
patient for bronchoscopy and pulmonary function tests. Consider starting low-dose oral prednisone 10 mg or equivalent 
per day. Re-evaluate after 1 week and resume rociletinib if GGO/infiltrates improve. Re-evaluate after additional 
1 week and resume treatment with MPDL3280A under the same conditions. 
▪ 
Prior to reintroduction of rociletinib, discuss appropriate dose with Medical Monitor.  
 
Symptomatic presentation (eg, hypoxia, cough;Grade 2+): 
▪ 
Hold rociletinib and MPDL3280A dosing and investigate for presence of radiographic changes.  
▪ 
Rule out alternative causes (eg, lymphangitic carcinomatosis, infection, heart failure, chronic obstructive pulmonary 
disease, pulmonary embolism, or hypertension). Diagnostic evaluation may include oxygen saturation (ie, arterial blood 
gas), high-resolution CT scan of the chest, bronchoscopy with bronchoalveolar lavage, pulmonary function tests (with 
DLCO), and pulmonary function testing with a pulmonary embolism protocol.  
▪ 
Grade ≥ 3 dyspnea or hypoxia may require corticosteroid treatment. MPDL3280A should be interrupted if 
corticosteroids are initiated.  
▪ 
Delay rociletinib and MPDL3280A re-administration if GGOs are observed. Administer steroids if pneumonitis or 
organizing pneumonia is documented. 
▪ 
If bronchoscopy is consistent with immune-related etiology, start oral prednisone 60 mg or equivalent per day, followed 
by a taper over 2 weeks. 
▪ 
Rociletinib dosing may be restarted at a reduced dose after resolution of symptoms and steroid use is no more than 
10 mg prednisone equivalent per day. If no recurrent symptoms develop within 14 days, MPDL3280A dosing may be 
reinitiated.  
▪ 
Discussion between the Investigator and Medical Monitor and approval to restart dosing is required before rociletinib or 
MPDL3280A are restarted. 
▪ 
Permanently discontinue MPDL3280A for life-threatening immune-related pulmonary events. 
 
 

Clovis Oncology, Inc. 
Clinical Protocol 
Rociletinib (CO-1686) 
CO-1686-032 
FINAL Version 1.0 
 
 
26 May 2015 
 
 
Page 78 of 131 
Confidential 
 
Table 18: 
Management of Overlapping Toxicities (continued) 
Toxicity 
Attribution to both agents 
Amylase/Lipase 
Grade ≥ 3 amylase/lipase elevation 
▪ 
Delay MPDL3280A and rociletinib for asymptomatic Grade ≥ 3 amylase and/or lipase elevations and monitor QOD 
until decreasing; for Grade 4 elevations consider 10 mg prednisone daily; 
▪ 
If symptomatic, MPDL3280A and rociletinib should be held. Methylprednisolone or oral steroids (prednisone 
equivalent of 60 mg/day) should be administered. Rociletinib dosing may be restarted when symptoms resolve and the 
amylase/lipase elevation is Grade  1. If no recurrent symptoms after 14 days then MPDL3280A dosing may be 
reinitiated at the same dose level. 
▪ 
If the Grade ≥ 3 amylase/lipase elevation recurs with symptoms before MPDL3280A re-initiation then rociletinib 
should be permanently discontinued.  
▪ 
If the Grade ≥ 3 amylase/lipase elevation recurs with symptoms after MPDL3280A re-initiation then rociletinib should 
be held until amylase/lipase elevation is Grade  1 and the MPDL3280A permanently discontinued. 
▪ 
MPDL3280A should be permanently discontinued for life-threatening, immune-related pancreatitis. 
Hypothyroidism 
▪ 
No change in MPDL3280A dosing will be implemented for asymptomatic TSH elevation; start thyroid replacement 
hormone and monitor TSH weekly; 
▪ 
Delay MPDL3280A for symptomatic TSH elevation; start thyroid replacement hormone and monitor TSH weekly; 
resume MPDL3280A when symptoms improve and TSH is decreasing. 
AE, adverse event; ALT, alanine aminotransferase; AST, aspartate aminotransferase; IV, intravenous; NSAID, nonsteroidal anti-inflammatory drug; QOD, every other day; TSH, 
thyroid-stimulating hormone; ULN, upper limit of normal. 
 

Clovis Oncology, Inc. 
Clinical Protocol 
Rociletinib (CO-1686) 
CO-1686-032 
FINAL Version 1.0 
 26 May 2015 
 
 
Page 79 of 131 
Confidential 
 
7 
PRIOR AND CONCOMITANT THERAPIES 
Concomitant therapy includes any prescription medications or over-the-counter preparations 
used by a patient between the 28 days prior to the first dose of study treatment through 28 days 
after the last dose of study treatment, or the date of administration of subsequent anticancer 
therapy, whichever is earlier. All concomitant medications should be reported to the Investigator 
and recorded on the appropriate eCRF. 
7.1 
Anticancer or Experimental Therapy 
No other anticancer therapies (including chemotherapy, radiation, and hormonal treatment 
[except corticosteroids and megestrol acetate], antibody or other immunotherapy or other 
experimental drugs) of any kind will be permitted while the patient is participating in the study.  
Palliative radiation therapy intended to provide relief of cancer-related symptoms is permitted 
while the patient is on study treatment with approval from the Sponsor’s Medical Monitor. 
Treatment should be held while the patient is undergoing radiotherapy.  
Additionally, a patient who continues treatment post-progression may undergo radiation or other 
procedures to specific lesions post-progression, if the patient continues to benefit from treatment 
overall. See Section 8.2.1 for more details. 
7.2 
Hematopoietic Growth Factors and Blood Products 
Erythropoietin, darbepoetin alfa, and/or hematopoietic colony-stimulating factors for treatment 
of cytopenias should be administered according to institutional guidelines. Prophylactic use of 
these agents is not permitted. 
Transfusion thresholds for blood product support will be in accordance with institutional 
guidelines. 
7.3 
Medications for Treatment of Infusion Reactions 
Patients who experience infusion-associated symptoms may be treated symptomatically with 
acetaminophen, ibuprofen, diphenhydramine, and/or famotidine or another H2 receptor 
antagonist, as per standard practice. Serious infusion-associated events manifested by dyspnea, 
hypotension, wheezing, bronchospasm, tachycardia, reduced oxygen saturation, or respiratory 
distress should be managed with supportive therapies as clinically indicated (eg, supplemental 
oxygen and 2-adrenergic agonists). 
7.4 
Systemic corticosteroids and TNF- inhibitors 
Systemic corticosteroids and TNF- inhibitors may attenuate potential beneficial immunologic 
effects of treatment with MPDL3280A but may be administered at the discretion of the treating 
physician after consultation with the Medical Monitor. If feasible, alternatives to corticosteroids 
should be considered. Premedication may be administered for Cycles  2 at the discretion of the 

Clovis Oncology, Inc. 
Clinical Protocol 
Rociletinib (CO-1686) 
CO-1686-032 
FINAL Version 1.0 
 26 May 2015 
 
 
Page 80 of 131 
Confidential 
 
treating physician after consultation with the Medical Monitor. The use of inhaled corticosteroids 
and mineralocorticoids (eg, fludrocortisone) for patients with orthostatic hypotension or 
adrenocortical insufficiency is allowed. Megestrol administered as an appetite stimulant is 
acceptable while the patient is enrolled in the study. 
7.5 
Other Concomitant Medications 
Influenza vaccination should be given during influenza season only (approximately October to 
March). Patients must not receive live, attenuated influenza vaccine (eg, FluMist) within 
4 weeks prior to first day of study treatment or at any time during the study but may receive 
inactivated vaccine. 
Therapies considered necessary for the patient’s well-being may be given at the discretion of the 
Investigator and should be documented on the eCRF. Other concomitant medications, except for 
analgesics, chronic treatments for concomitant medical conditions, or agents required for 
life-threatening medical problems, should be avoided. 
Prophylactic antibiotics (eg, to prevent urinary tract infection or chronic obstructive pulmonary 
disease exacerbation) are allowed. Herbal and complementary therapies should not be 
encouraged because of unknown side effects and potential drug interactions, but any taken by the 
patient should be documented appropriately on the eCRF. 
7.6 
Excluded Therapies Concurrent with Rociletinib  
7.6.1 Drugs that prolong QTc interval 
Medications known to produce QT prolongation should be avoided during treatment of patients 
with rociletinib. See http://crediblemeds.org/ for the most up-to-date reference lists of 
QT-prolonging medications. Please note that the lists contain common supportive medications, 
such as anti-emetics (ondansetron [and other 5HT3 antagonists], metoclopramide, hydroxyzine), 
antibiotics (azithromycin, ciprofloxacin, metronidazole) and anti-depressants (escitalopram), 
which should not be used in combination with rociletinib.  
Medications to consider for nausea that are not associated with QT prolongation include: 
• Steroids (dexamethasone, methylprednisolone) 
• Benzodiazepines 
• Aprepitant  
• Select anticholinergic agents (scopolamine) 
• Trimethobenzamide  
• Cannabinoids 

Clovis Oncology, Inc. 
Clinical Protocol 
Rociletinib (CO-1686) 
CO-1686-032 
FINAL Version 1.0 
 26 May 2015 
 
 
Page 81 of 131 
Confidential 
 
Palonosetron is currently not listed on crediblemeds.org and a thorough QTc study showed no 
QTc effect. However, as rare cases of QTc prolongation have been reported, a more frequent 
ECG monitoring schedule should be adopted if used with rociletinib. 
If a drug that has the potential to cause QT prolongation is indicated to control AEs (eg, 5HT3 
inhibitor for nausea/vomiting), and the investigator believes that the patient is benefiting from 
rociletinib therapy, then additional ECGs should be performed to monitor for potential QTC 
changes. The use of such concomitant medications and an appropriate ECG monitoring plan 
should be agreed between the Investigator and Sponsor.  
7.6.2 CYP450 Isozyme Inhibitors and Inducers  
Caution should be exercised in patients receiving oral rociletinib and requiring concomitant 
medication with warfarin (Coumadin), NSAIDs, or clopidogrel, as rociletinib moderately 
inhibited CYP2C8, CYP2C9, and CYP2C19 activities in vitro. Patients taking warfarin who are 
enrolled in the study are required to have international normalized ratio (INR) monitored 
regularly per standard clinical practice. Preliminary data from an ongoing definitive CYP 
inhibition study revealed that rociletinib also moderately inhibited CYP3A4. As such, caution 
should be exercised in patients receiving rociletinib and the following CYP3A4 substrates with 
narrow therapeutic range: alfentanil, astemizole, cisapride, cyclosporine, dihydroergotamine, 
ergotamine, fentanyl, pimozide, quinidine, sirolimus, tacrolimis, and terfenadine.  
7.6.3 P-gp Substrates, Inhibitors and Inducers 
Because rociletinib is a P-gp inhibitor in vitro, caution should be exercised in patients receiving 
PO rociletinib and requiring concomitant medication with digoxin, a P-gp substrate. Patients 
taking digoxin who are enrolled in the study are required to have digoxin levels monitored 
regularly via standard clinical practice. 
Rociletinib is a P-gp substrate and thus, P-gp inhibitors have the potential to increase rociletinib 
exposure. As such, caution should be exercised in patients receiving rociletinib and the following 
P-gp inhibitors: amiodarone, azithromycin, captopril, carvedilol, clarithromycin, conivaptan, 
cyclosporine, diltiazem, dronedarone, erythromycin, felodipine, itraconazole, ketoconazole, 
lopinavir and ritonavir, quercetin, quinidine, ranolazine, verapamil. 
Conversely, P-gp inducers have the potential to decrease rociletinib exposure. Caution should be 
exercised in patients receiving rociletinib and the following P-gp inducers: avasimibe, 
carbamazepine, phenytoin, rifampin, St. John’s wort, and tipranavir/ritonavir. 
7.6.4 Proton Pump Inhibitors 
Because rociletinib is absorbed optimally in an acidic environment, proton pump inhibitors or H2 
blockers should be used with caution. If gastric acid blockade is required, short acting antacids 
are preferred.  

Clovis Oncology, Inc. 
Clinical Protocol 
Rociletinib (CO-1686) 
CO-1686-032 
FINAL Version 1.0 
 26 May 2015 
 
 
Page 82 of 131 
Confidential 
 
7.7 
Excluded Therapies Concurrent with MPDL3280A 
The following therapies are excluded while patients are receiving MPDL3280A and for 
10 weeks after the last dose of MPDL3280A. 
7.7.1 Denosumab 
Patients who are receiving a RANKL inhibitor (denosumab) prior to enrollment must be willing 
and eligible to receive a bisphosphonate instead; denosumab could potentially alter the activity 
and the safety of MPDL3280A. 
7.7.2 Immunomodulatory Agents 
Patients are not allowed to receive immunostimulatory agents, including but not limited to IFN-
, IFN-, or IL-2. These agents, in combination with MPDL3280A, could potentially increase 
the risk for autoimmune conditions. 
Patients should also not receive immunosuppressive medications, including but not limited to 
cyclophosphamide, azathioprine, methotrexate, and thalidomide. These agents could potentially 
alter the activity and the safety of MPDL3280A. Systemic corticosteroids and anti-TNF- agents 
may attenuate potential beneficial immunologic effects of treatment with MPDL3280A but may 
be administered at the discretion of the treating physician after consultation with the Medical 
Monitor. If feasible, alternatives to these agents should be considered. 

Clovis Oncology, Inc. 
Clinical Protocol 
Rociletinib (CO-1686) 
CO-1686-032 
FINAL Version 1.0 
 26 May 2015 
 
 
Page 83 of 131 
Confidential 
 
8 
STUDY PROCEDURES 
Table 1 summarizes the procedures and assessments to be performed for all patients.  
Unless otherwise specified, all procedures and assessments in Cycle 2+ are to be completed 
within ± 3 days of the scheduled time points relative to C1D1 of combination treatment with PO 
rociletinib and IV MPDL3280A. Perform assessments scheduled for C1D4 on that day (ie, no 
window) and assessments for C1D8 and C1D15 within ± 2 days of the scheduled time points. 
8.1 
Screening Period  
After written informed consent, patients will undergo screening assessments within 28 days 
before the first dose of study drug. Some assessments are required within 7 days (serum 
pregnancy test) or 14 days prior to the first dose of study treatment (see Table 1). A mandatory 
fresh tumor biopsy will be collected within 60 days prior to the first day of study treatment. If a 
biopsy was performed outside of the protocol within this 60-day period, and no intervening 
treatment was given, a repeat biopsy is not required if adequate tumor tissue can be provided to 
the Sponsor during the Screening Period. Other assessments performed before the patient signing 
of informed consent for this protocol are acceptable for the screening purposes of this protocol 
only if confirmed to have been standard of care. Please refer to Table 1 for details on 
assessments to be performed during the Screening Period. 
Procedures required on Day 1 of Run-in-Period (Phase 1) or C1D1 (Phase 2) may be omitted if 
completed ≤ 3 days earlier during the Screening Period. 
8.2 
Treatment Period  
Before enrollment of a patient, all eligibility criteria must be satisfied, and enrollment must be 
approved by the Sponsor’s medical monitoring team. 
The Treatment Period will consist of 21-day combination treatment cycles, with MPDL3280A 
administered by IV infusion on the first day of each cycle, beginning with C1D1, and rociletinib 
administered PO BID continuously. During Phase 1 of the study only, the Treatment Period will 
also include a 7-day Run-in Period of rociletinib monotherapy prior to C1D1 of combination 
treatment with rociletinib and MPDL3280A. Study visits will be scheduled as indicated in 
Table 1. Additional clinic visits will also occur as clinically indicated.  
During the Treatment Period, tumor assessments will be conducted every 2 cycles (6 weeks 
±1 week) through Cycle 6 (ie, at the end of Cycles 2, 4, and 6); every 3 cycles (9 weeks 
±1 week) after Cycle 6 (ie, at the end of Cycles 9, 12, etc); and at the EOT Visit. The frequency 
of tumor assessments may be further reduced after 2 years with approval of the Medical Monitor 
(see Section 8.4.3 for details). Tumor scans will be evaluated locally for response evaluation and 
treatment decision-making.  
Patients will be allowed to continue on study as long as they experience no unacceptable 
toxicities and they continue to receive clinical benefit from the study treatment as assessed by the 

Clovis Oncology, Inc. 
Clinical Protocol 
Rociletinib (CO-1686) 
CO-1686-032 
FINAL Version 1.0 
 26 May 2015 
 
 
Page 84 of 131 
Confidential 
 
Investigator (with agreement from the Sponsor’s Medical Monitor) or until the patient meets any 
of the withdrawal criteria (see Section 11 for details and exceptions). 
8.2.1 Post-Progression Treatment 
Patients may continue to receive treatment with rociletinib and/or MPDL3280A after 
radiographic progression of disease if, in the opinion of the Investigator and approved by the 
Sponsor, the patient is still benefiting from treatment. This must be discussed with the Sponsor’s 
Medical Monitor and will be reviewed on a case-by-case basis. If a patient continues treatment 
post-progression, all study assessments including efficacy assessments, safety assessments, and 
blood collection for biomarker analysis, should continue per protocol. The patient should be 
discontinued from treatment once it is clear that no further clinical benefit can be achieved.  
The criteria below are required for treatment post-progression:  
• Evidence of clinical benefit as assessed by the Investigator;  
• Absence of symptoms and signs (including worsening of laboratory values [eg, new or 
worsening hypercalcemia]) indicating unequivocal progression of disease;  
• No decline in ECOG performance status that can be attributed to disease progression;  
• Absence of tumor growth at critical anatomical sites (eg, leptomeningeal disease) that cannot 
be managed by protocol-allowed medical interventions;  
• Patients for whom approved therapies exist must provide written consent to acknowledge 
deferring these treatment options in favor of continuing study treatment at the time of initial 
apparent progression; 
• Written Sponsor approval for treatment post-progression; 
• Patients in whom radiographic disease progression is confirmed at a subsequent tumor 
assessment may be considered for continued study treatment at the discretion of the 
Investigator if they continue to meet the criteria above and have evidence of clinical benefit. 
8.2.2 End-of-Treatment Visit 
Patients will be asked to return to the clinic for the EOT Visit 28 days (+7 days) after the last 
dose of study treatment, or before the patient initiates another anticancer agent (if sooner), to 
assess safety of the patients. Safety evaluation assessments for the EOT Visit are outlined in 
Table 1. All AEs (including SAEs and protocol-defined events of special interest), regardless of 
attribution, will be recorded until 28 days after the last dose of study treatment or until initiation 
of another anticancer therapy, whichever occurs first. Ongoing AEs considered related to study 
treatment and all SAEs, regardless of causality, will be followed until the event has resolved to 
baseline grade, the event is assessed by the Investigator as stable, new anticancer treatment is 
initiated, the patient is lost to follow up, the patient withdraws consent, or it is determined that 
the study treatment or participation is not the cause of the AE.  

Clovis Oncology, Inc. 
Clinical Protocol 
Rociletinib (CO-1686) 
CO-1686-032 
FINAL Version 1.0 
 26 May 2015 
 
 
Page 85 of 131 
Confidential 
 
Tumor assessment scans do not need to be repeated if radiographic disease progression has been 
documented previously or the last scans were performed < 2 weeks before the last dose of study 
treatment or the patient had disease progression at the last scan. For patients who provide 
additional consent, an optional fresh tumor biopsy will be collected at the time of permanent 
treatment discontinuation due to disease progression (at the time the Investigator believes the 
patient is no longer deriving clinical benefit from study treatment, if treatment beyond 
radiographic disease progression is approved). This optional biopsy and associated blood 
samples scheduled for the EOT Visist (see Table 2) should occur as close as possible to the date 
of the decision to permanently discontinue study.  
8.3 
Follow-Up Period 
During the Follow-Up-Period, all patients will be contacted by the site every 12 weeks 
(± 1 week) for the collection of information on all subsequent anticancer therapy and for the 
monitoring of survival status until the patient’s death, patient withdrawal of consent, or a 
decision by the Sponsor to cease data collection and close the study, whichever comes first. 
These assessments may be performed during routine clinic visits or by telephone contact.  
8.4 
Methods of Data Collection 
8.4.1 Patient History 
Patient information collected during screening will include basic demographics; medical history, 
including smoking status, medical conditions, and oncology history including date of cancer 
diagnosis, prior cancer treatment, and any surgical procedures. For patients being considered for 
enrollment in the study, screening assessments will not begin until patient tumor EGFR mutation 
status is determined through local assessments. 
8.4.2 Safety Evaluations 
8.4.2.1 Adverse Event Assessment 
The Investigator has the responsibility for assessing the safety of the patients and patient 
compliance with the protocol to ensure study integrity. Patients will be monitored for AEs from 
the time of the first dose of study drug is administered through 28 days after the last dose of 
study drug. Study procedure-related AEs that occur after signing of the Informed Consent Form 
(ICF) and before administration of rociletinib and MPDL3280A will also be collected. All 
ongoing AEs related to study treatment and all SAEs, and all protocol-defined events of special 
interest (Section 9.6) will be followed until resolution or stabilization. Adverse events and 
laboratory abnormalities will be graded according to the NCI CTCAE grading system (v4.03). 
Complete details for monitoring and managing AEs, including the definition of study drug-
related AEs, are provided in Section 9. 

Clovis Oncology, Inc. 
Clinical Protocol 
Rociletinib (CO-1686) 
CO-1686-032 
FINAL Version 1.0 
 26 May 2015 
 
 
Page 86 of 131 
Confidential 
 
8.4.2.2 Clinical Laboratory Investigations 
Blood for safety evaluations will be analyzed by a local laboratory to inform patient treatment 
decisions, and results must be reviewed by the Investigator before administration of rociletinib 
and/or MPDL3280A. Additional tests may be performed at the Investigator’s discretion. The 
panels of laboratory tests to be performed are shown below: 
Hematology: Hematology assessments include hemoglobin, hematocrit, WBC and differential 
(with ANC), reticulocyte count, and platelet count. Hematology results must be reviewed by the 
Investigator before administration of rociletinib and/or MPDL3280A. 
Patients known to require concomitant therapy with anticoagulants such as warfarin should also 
have INR monitored throughout the study. 
Serum Chemistry: Serum chemistry assessments include total protein, albumin, creatinine, 
BUN or urea, total bilirubin, alkaline phosphatase, ALT, AST, total cholesterol, fasting glucose, 
sodium, potassium, magnesium, chloride, calcium, phosphorus and uric acid.  
In addition separate assessments of fasting glucose; hemoglobin A1c; TSH and free T3 and T4; 
will be performed as described in Table 1.  
Urinalysis: Urinalysis will be performed on freshly voided clean sample by dipstick for protein, 
glucose, blood, pH, and ketones per the schedule of evaluations. If dipstick findings are 
abnormal, then a microscopic evaluation will be performed to assess the abnormal findings. 
Urinalysis is scheduled at screening only. 
Serum ß-hCG Pregnancy Test (Local Lab): Performed on females of childbearing potential 
 7 days before first day of study treatment and at the EOT Visit. If the serum pregnancy test 
results are not available on first day of study treatment, a urine pregnancy test can be performed 
on first day of study treatment to confirm that the patient is not pregnant before dosing. A 
negative result must be confirmed by a physician before the first dose of either study drug can be 
administered. Both values should be entered in the eCRF. 
Laboratory reports will be reviewed by the Investigator or delegated physician who will then 
comment on out-of-range parameters and assess clinical significance. Clinically significant 
abnormalities and associated panel results, as well as results of any additional tests performed as 
follow up to the abnormalities, will be documented on the eCRF as an AE. 
8.4.2.3 Vital Signs 
Vital signs will be measured at all clinic visits as outlined in Table 1. Vital signs include body 
temperature, heart rate, respiratory rate, and blood pressure. All vital signs will be obtained after 
the patient has been resting for at least 5 minutes.  
Weight will also be measured at all clinic visits as part of physical examinations (see 
Section 8.4.2.6). 

Clovis Oncology, Inc. 
Clinical Protocol 
Rociletinib (CO-1686) 
CO-1686-032 
FINAL Version 1.0 
 26 May 2015 
 
 
Page 87 of 131 
Confidential 
 
For the first infusion of MPDL3280A, vital signs should be measured within 60 minutes before, 
every 15 (± 5) minutes during the infusion, and 30 (± 10) minutes after the infusion. For 
subsequent infusions, vital signs will be collected within 60 minutes before the infusion, during 
the infusion if clinically indicated or if symptoms occurred in the prior infusion, and 1 hour (± 10 
minutes) after the infusion. 
8.4.2.4 12-Lead Electrocardiograms 
Triplicate serial 12-lead ECGs (10-sec ECG tracings collected in triplicate > 2 min apart) will be 
taken at time points specified in Table 1 and as clinically indicated. The average of triplicates 
should be recorded. 
Electrocardiograms should be performed after the patient has been resting for at least 5 min. The 
12-lead ECGs collected will be read locally to facilitate patient management and analyzed at a 
central ECG laboratory. Details on recording ECGs and their interpretation will be included in 
the Investigator’s file.  
8.4.2.5 Echocardiogram (ECHO) or Multigated Acquisition (MUGA) Scan 
An ECHO or MUGA scan will be performed at screening only for patients with a known history 
of pericardial effusions, or for whom the Investigator suspects has the potential for a pericardial 
effusion, and otherwise as clinically indicated. 
8.4.2.6 Physical Examinations 
Physical examinations will be performed at every clinic visit as outlined in Table 1.  
Complete physical examinations will include height (at screening only), weight (the patient 
should be in light indoor clothes; no shoes), and the evaluation of head, eyes, ears, nose and 
throat (HEENT) and cardiovascular, dematologic, musculoskeletal, respiratory, gastrointestinal, 
and neurologic systems.  
Limited physical examinations will include weight, an assessment of all baseline abnormalities 
and recording of associated changes, questioning of the patient about any skin or vision changes, 
and any other symptom-directed examination. 
8.4.2.7 ECOG Performance Status 
ECOG performance status (Appendix C) will be assessed at time points specified in Table 1. 
ECOG performance status should be assessed by the same study personnel at each visit, if 
possible. Care will be taken to accurately score performance status, especially during screening 
for study eligibility purposes. Additional consideration should be given to borderline ECOG 
performance status to avoid enrolling patients with significant impairment. 

Clovis Oncology, Inc. 
Clinical Protocol 
Rociletinib (CO-1686) 
CO-1686-032 
FINAL Version 1.0 
 26 May 2015 
 
 
Page 88 of 131 
Confidential 
 
8.4.2.8 Pulmonary Function Tests  
Patients are required to have a pulmonary function evaluation conducted at baseline and as 
clinically indicated. Pulmonary function tests must include an assessment of DLCO. 
8.4.3 Efficacy Evaluations 
8.4.3.1 Tumor Assessments 
Tumor assessments will be performed at screening and during the Treatment Period until 
permanent discontinuation of all study treatment (patients who continue treatment with 
rociletinib and/or MPDL3280A after a radiographic progression should continue to be scanned 
according to the protocol until they permanently discontinue all study treatment). 
The frequency of tumor assessments will be every 2 cycles (6 weeks ± 1 week) through Cycle 6 
(ie, at the end of Cycles 2, 4, and 6); every 3 cycles (9 weeks ± 1 week) after Cycle 6 (ie, at the 
end of Cycles 9, 12, etc); and at the EOT Visit. The frequency of tumor assessments may be 
further reduced after 2 years with the approval of the Medical Monitor. Tumor assessments at the 
EOT Visit are not required if radiographic disease progression has been documented previously 
or the last tumor assessments were performed < 2 weeks before the last dose of study treatment. 
If an initial complete response (CR) or PR is noted, confirmatory scans must be performed 4 to 
6 weeks later.  
Scans will be evaluated locally for response evaluation and patient treatment decisions. Tumor 
response will be evaluated using RECIST v1.1 (Appendix A) and modified RECIST 
incorporating irRC (Appendix B). 
Tumor assessments should consist of clinical examination and appropriate imaging techniques 
(preferably CT scans of the chest, abdomen, and pelvis with ≤5 mm slice thickness); other 
studies (MRI and X-ray) may be performed if required. Brain imaging is required at baseline. 
Patients with brain lesions at baseline will require repeat brain imaging as part of the follow-up 
tumor assessments. Patients without baseline brain lesions do not require brain imaging on study 
unless clinically indicated. The same methods used to detect lesions at baseline are to be used to 
follow the same lesions throughout the clinical study.  
8.4.4 Pharmacokinetic Evaluations  
Blood samples for PK profile analysis of rociletinib (and its metabolites) and MPDL3280A, will 
be collected at visits and time points described in Table 1 and Table 2. Central laboratories will 
be used for bioanalysis of these samples. Please refer to the laboratory manual for details on 
collection and processing of blood PK samples. 
On scheduled PK sampling days, patients should be instructed to not administer study drug at 
home, but to bring rociletinib to the clinic along with breakfast. After a predose PK blood draw, 
patients will eat breakfast and take the morning dose of rociletinib within 30 minutes after 
starting their meal. On days of MPDL3280A infusions, patients will be administered IV 

Clovis Oncology, Inc. 
Clinical Protocol 
Rociletinib (CO-1686) 
CO-1686-032 
FINAL Version 1.0 
 26 May 2015 
 
 
Page 89 of 131 
Confidential 
 
MPDL3280A approximately 2 hours after the morning rociletinib dose. Times of the PK blood 
draws, meals, and administrations of study drugs in the clinic should be recorded. 
Additional unscheduled PK blood samples will be collected at the time of fresh tumor biopsy and 
may also be collected when a patient experiences an AE for which the Investigator would like to 
have PK data to help understand the safety observation.  
8.4.5 Pharmacodynamic Evaluations 
A mandatory fresh tumor tissue biopsy specimen will be collected within 60 days prior to the 
first day of study treatment for all patients. In addition, an optional fresh tumor biopsy may be 
collected at time of disease progression (or patient is considered by the Investigator to no longer 
benefit from study treatment, if treatment is continued beyond a radiographic progression). 
The baseline tissue biopsy specimen from screening will be used for a retrospective confirmation 
of EGFR mutation status by a central laboratory. The baseline biopsy as well as the optional 
tissue biopsy collected at disease progression will also be used to investigate mechanisms of 
response, primary resistance, and acquired resistance to rociletinib and MPDL3280A. 
Immunohistochemistry (IHC) using exploratory biomarkers of the EGFR and PD-L1 pathway 
signaling such as PD-L1, CD8, and MHC Class II may be performed. Samples may also be 
assessed for genomic alterations (eg, mutations, amplifications, and fusions) in a panel of 
established cancer genes by next generation sequencing (NGS). A subset of specimens may also 
be characterized using additional genomic (whole exome), transcriptional (whole transcriptome, 
RNA-Seq), or protein-based approaches. 
Blood samples will be collected for pharmacogenomic and pharmacodynamic analyses to 
investigate mechanisms of response, primary resistance, and acquired resistance to rociletinib 
and MPDL3280A. The pharmacogenomic blood sample will be collected predose on Day 1 of 
the Run-in-Period for Phase 1, and on C1D1 of Phase 2 for genomic DNA purification. The 
DNA sample may be evaluated by NGS, and molecular alterations in germline and tumor DNA 
may be compared so that molecular alterations unique to the tumor can be unambiguously 
identified. Pharmacodynamic blood samples will be collected as outlined in Table 2. 
Pharmacodynamic blood samples will be processed to plasma and/or serum and PBMCs to 
evaluate markers which may include (but are not necessarily limited to) IGF-1, insulin, 
c-peptide, and T-cell receptor diversity. Cell-free DNA will be purified from plasma samples and 
evaluated for EGFR mutation status and possibly also for similar DNA analyses as described for 
tumor biopsies (eg, targeted cancer panel NGS), if sufficient DNA is available. 
Changes in biomarker status will be investigated for associations with rociletinib and/or 
MPDL3280A exposure, safety, and clinical activity. 
Please refer to the Laboratory Manual for details on collecting and processing pharmacodynamic 
samples. 

Clovis Oncology, Inc. 
Clinical Protocol 
Rociletinib (CO-1686) 
CO-1686-032 
FINAL Version 1.0 
 26 May 2015 
 
 
Page 90 of 131 
Confidential 
 
8.4.6 Patient Diary  
Patient diary cards will be provided to patients at the beginning of the Run-in-Period (Phase 1 
only) and on Day 1 of every treatment cycle when rociletinib study drug is dispensed to the 
patient. Patients will use diary cards to note the date, time, and dose of rociletinib administration. 
At each clinic visit, patients will bring the diary with them to the clinic, along with the study 
drug bottle and any unused study drug, for study staff to review. 

Clovis Oncology, Inc. 
Clinical Protocol 
Rociletinib (CO-1686) 
CO-1686-032 
FINAL Version 1.0 
 26 May 2015 
 
 
Page 91 of 131 
Confidential 
 
9 
ADVERSE EVENT REPORTING 
9.1 
Definition of an Adverse Event (AE) 
Patients will be monitored for AEs from the time the first dose of study drug is administered 
through 28 days after the last dose of study treatment. Study procedure-related AEs that occur 
after signing of the ICF and before administration of study drug will also be collected. 
An AE is defined as any untoward medical occurrence in a patient administered a medicinal 
product that does not necessarily have a causal relationship with this treatment. An AE can, 
therefore, be any unfavorable and unintended sign (including an abnormal laboratory finding), 
symptom, or disease temporally associated with the use of an investigational product, whether or 
not related to the IMP. This includes an exacerbation of pre-existing conditions or events, 
intercurrent illnesses, drug interaction, or the significant worsening of the indication under 
investigation that is not recorded elsewhere on the eCRF under specific efficacy assessments. 
Anticipated fluctuations of pre-existing conditions, including the disease under study, that do not 
represent a clinically significant exacerbation or worsening are not considered AEs. 
It is the responsibility of the Investigator to document all AEs that occur during the study. AEs 
should be elicited by asking the patient a non-leading question (eg, “Have you experienced any 
new or changed symptoms since we last asked/since your last visit?”). AEs will be reported on 
the AE eCRF. Symptoms reported spontaneously by the patient during the physical examination 
will also be documented on the AE eCRF (not on the physical examination eCRF, which is 
reserved for physical signs or findings). 
9.2 
Definition of a Serious Adverse Event (SAE) 
An SAE is any untoward medical occurrence that occurs at any dose of rociletinib and 
MPDL3280A that: 
• Results in death. Death may occur as a result of the underlying disease process. Nevertheless, 
any event resulting in death during the reporting period must be treated as an SAE and 
reported as such. All deaths occurring within 28 days of the last administration of rociletinib 
and/or MPDL3280A should be reported as SAEs; 
• Is life-threatening (patient is at immediate risk of death from the event as it occurred); 
• Requires in-patient hospitalization (formal admission to a hospital for medical reasons) or 
prolongation of existing hospitalization; 
• Results in persistent or significant disability/incapacity; 
• Results in a congenital anomaly/birth defect. 
Important medical events that may not result in death, are not life-threatening, or do not require 
hospitalization may be considered SAEs when, based on appropriate medical judgment, they 
may jeopardize the patient and may require medical or surgical intervention to prevent one of the 
outcomes listed in this definition. Examples of such events include allergic bronchospasm 

Clovis Oncology, Inc. 
Clinical Protocol 
Rociletinib (CO-1686) 
CO-1686-032 
FINAL Version 1.0 
 26 May 2015 
 
 
Page 92 of 131 
Confidential 
 
requiring intensive treatment in an emergency room or at home, blood dyscrasias or seizures that 
do not result in in-patient hospitalization, or the development of drug dependency or drug abuse. 
9.3 
Events or Outcomes Not Qualifying as SAEs 
The following are not considered SAEs: 
• Pre-planned or elective hospitalization including social and/or convenience situations (eg, 
respite care); 
• Overdose of either rociletinib or MPDL3280A or concomitant medication unless the event 
meets SAE criteria (eg, hospitalization). However, the event should still be captured as a 
non-serious AE on the appropriate eCRF page; 
• Events of progression of the patient’s underlying cancer as well as events clearly related to 
progression of the patient’s cancer (signs and symptoms of progression) should not be 
reported as a SAE unless the outcome is fatal during the study or within the safety reporting 
period. If the event has a fatal outcome during the study or within the safety reporting period, 
then the event of Progression of Disease must be recorded as an AE and as a SAE with CTC 
Grade 5 (fatal outcome) indicated; 
• Diagnosis of progression of disease or hospitalization due to signs and symptoms of disease 
progression alone should not be reported as SAEs. 
9.4 
Clinical Laboratory Assessments as AEs and SAEs 
It is the responsibility of the Investigator to assess the clinical significance of all abnormal values 
as defined by the list of reference ranges from the local laboratory. In some cases, significant 
changes in lab values within the normal range will require similar judgment. 
An abnormal laboratory value that is not already associated with an AE is to be recorded as an 
AE only if any one of the following criteria is met: 
• An action on the study drug is made as a result of the abnormality; 
• Intervention for management of the abnormality is required; 
• At the discretion of the Investigator should the abnormality be deemed clinically significant. 
9.5 
Pregnancy or Drug Exposure During Pregnancy 
If a patient becomes pregnant during the study, the Investigator is to stop dosing with study 
drug(s) immediately. 
A pregnancy is not considered to be an AE or SAE; however, it must be reported to the Sponsor 
using the Pregnancy Report Form within the same timelines as an SAE (Section 9.9). This 
applies to female patients as well as female partners of male patients. 

Clovis Oncology, Inc. 
Clinical Protocol 
Rociletinib (CO-1686) 
CO-1686-032 
FINAL Version 1.0 
 26 May 2015 
 
 
Page 93 of 131 
Confidential 
 
A pregnancy should be followed through to outcome, whenever possible. Once the outcome of 
the pregnancy is known, the Pregnancy Outcome Report Form should be completed and reported 
to the Sponsor. 
AEs or SAEs that occur during pregnancy will be assessed and processed according to the AE or 
SAE processes using the appropriate AE or SAE forms. 
9.6 
Adverse Events of Special Interest for MPDL3280A 
The conditions listed below are of special interest and should be recorded within 24-48 hours of 
their occurrence. 
Conditions suggestive of an autoimmune disorder: 
• Pneumonitis; 
• Hypoxia or Dyspnea ≥ Grade 3; 
• Colitis; 
• Endocrinopathies: diabetes mellitus, pancreatitis, or adrenal insufficiency; 
• Vasculitis; 
• Hepatitis; 
• Transaminitis: AST or ALT > 3 × ULN and bilirubin > 2 × ULN or AST/ALT > 10 × ULN;  
• Systemic lupus erythematosus; 
• Guillain barre syndrome; 
• Myasthenia gravis; 
• Pericardial effusion; 
• Skin Reactions: vitiligo or pemphigoid; 
• Events suggestive of hypersensitivity, cytokine release, influenza-like illness, SIRS, or 
infusion reaction syndromes. 
9.7 
Recording of AEs and SAEs 
Any AE from the time the first dose of either study drug through 28 days after the last dose of 
study drug will be recorded on the AE eCRF. Study procedure-related AEs that occur after 
signing of the ICF and before first dose of either study drug will also be captured on the AE 
eCRF. Any other AE that occurs before first dose of study drug should be recorded on the 
Medical History eCRF. In order to avoid vague, ambiguous, or colloquial expressions, the AE 
should be recorded in standard medical terminology rather than the patient’s own words. 
Whenever possible, the Investigator should combine signs and symptoms that constitute a single 
disease entity or syndrome. For example, fever, headache, and nasal discharge may be reported 
as coryza, if that is a reasonable diagnosis. The existence of an AE may be concluded from a 

Clovis Oncology, Inc. 
Clinical Protocol 
Rociletinib (CO-1686) 
CO-1686-032 
FINAL Version 1.0 
 26 May 2015 
 
 
Page 94 of 131 
Confidential 
 
spontaneous report of the patient; from the physical examination; or from special tests such as 
the ECG, laboratory assessments, or other study-specified procedure. 
Each AE is to be evaluated for duration, severity, seriousness, and causal relationship to each 
study drug. The action taken and the outcome must also be recorded. 
SAEs that occur during the study or within 28 days after receiving the last dose of either study 
drug, whether or not related to rociletinib or MPDL3280A, must be immediately reported to the 
Sponsor/designee SAE contact (Section 9.9). 
9.7.1 Intensity of Adverse Events 
The severity of the AE will be graded according to the NCI CTCAE v4.03 grading scale. For 
AEs not covered by NCI CTCAE v4.03, the severity will be characterized as mild, moderate, 
severe, or life-threatening according to the following definitions: 
• Mild (Grade 1) events are usually transient and do not interfere with the patient’s daily 
activities; 
• Moderate (Grade 2) events introduce a low level of inconvenience or concern to the patient 
and may interfere with daily activities; 
• Severe (Grade 3) events interrupt the patient’s usual daily activities and hospitalization (or 
prolongation of hospitalization) may be required; 
• Life-threatening (Grade 4) events require urgent intervention to prevent death. 
9.7.2 Causal Relationship of Adverse Events to Investigational Study Drugs 
Medical judgment should be used to determine the cause of the AE considering all relevant 
factors such as, but not limited to, the underlying study indication, coexisting disease, 
concomitant medication, relevant history, pattern of the AE, temporal relationship to the study 
medication, dechallenge or rechallenge. 
Not Related  
• An AE that is clearly due to extraneous causes (eg, concurrent disease, concomitant 
medications, disease under study); 
• It does not correspond to a reasonable temporal sequence from administration of study drug; 
• It does not correspond to a known pattern of response to study drug; 
• It does not reappear or worsen when study drug is restarted; 
• An alternative explanation is likely but not clearly identifiable. 
 

Clovis Oncology, Inc. 
Clinical Protocol 
Rociletinib (CO-1686) 
CO-1686-032 
FINAL Version 1.0 
 26 May 2015 
 
 
Page 95 of 131 
Confidential 
 
Possibly Related  
• An AE that is difficult to assign to alternative causes; 
• It corresponds to a strong or reasonable temporal sequence from administration of study 
drug; 
• It could not be reasonably explained by the patient’s clinical state, concurrent disease, or 
other concomitant therapy administered to the patient; 
• It corresponds to a known response pattern to study drug; 
• It is confirmed with a positive rechallenge or supporting laboratory data. 
9.7.3 Outcome and Action Taken 
The Investigator will record the action taken and outcome for each AE according to the 
following criteria: 
• Action Taken with Study Drug: 
▪ None; 
▪ Rociletinib dose reduced; 
▪ Rociletinib temporarily interrupted; 
▪ Rociletinib permanently discontinued; 
▪ MPDL3280A temporarily interrupted; 
▪ MPDL3280A permanently discontinued; 
▪ Other (specify). 
• Outcome: 
▪ Recovered; 
▪ Recovered with sequelae; 
▪ Improved; 
▪ Ongoing; 
▪ Death; 
▪ Lost to follow up. 
9.8 
Follow-Up of AEs and SAEs 
All AEs occurring during the study are to be followed up in accordance with good medical 
practice until resolved; judged no longer clinically significant; or, if a chronic condition, until 
fully characterized through 28 days after the last dose of rociletinib and/or MPDL3280A. All 
ongoing AEs related to study treatment, all SAEs, and all protocol-defined events of special 
interest (Section 9.6) will be followed until the event has resolved to baseline grade, the event is 
assessed by the Investigator as stable, new anticancer treatment is initiated, the patient is lost to 

Clovis Oncology, Inc. 
Clinical Protocol 
Rociletinib (CO-1686) 
CO-1686-032 
FINAL Version 1.0 
 26 May 2015 
 
 
Page 96 of 131 
Confidential 
 
follow up, the patient withdraws consent, or it is determined that the study treatment or 
participation is not the cause of the adverse event. 
9.9 
Regulatory Aspects of SAE Reporting 
All SAEs, regardless of relationship to study drug, must be reported to the safety contract 
research organization (CRO) within 24 hours of knowledge of the event, according to the 
procedures below. It is important that the Investigator provide an assessment of relationship of 
the SAE to study treatment at the time of the initial report. The Clinical Trial Serious Adverse 
Event Report Form must be used for reporting SAEs. 
While not considered an SAE, pregnancy occurring in a female patient or in the female partner 
of a male patient must also be reported to the CRO as soon as the event is known by the clinical 
site. If the pregnancy occurs in a female patient, study drug should be stopped immediately. 
Notification to the CRO should take place via facsimile or email utilizing the Pregnancy Report 
Form. 
Further details on SAE/pregnancy reporting can be found in the Investigator’s file. 
The Sponsor or its designee is responsible for submitting reports of AEs associated with the use 
of the drug that are both serious and unexpected to the US Food and Drug Administration 
(FDA), according to 21 Code of Federal Regulations (CFR) 312.32; to the Japanese 
Pharmaceuticals and Medical Devices Agency; to the European regulatory authorities according 
to the European Commission Clinical Trials Directive (2001/20/EC); and to other regulatory 
authorities, according to national law and/or local regulations. All investigators participating in 
ongoing clinical studies with the study medication will receive copies of these reports for prompt 
submission to their IRB or IEC. In accordance with the European Commission Clinical Trials 
Directive (2001/20/EC), the Sponsor or its designee will notify the relevant ethics committees in 
concerned member states of applicable suspected unexpected serious adverse reactions 
(SUSARs) as individual notifications or through periodic line listings. The Sponsor or its 
designee will submit all safety updates and periodic reports to the regulatory authorities as 
required by applicable regulatory requirements.  

Clovis Oncology, Inc. 
Clinical Protocol 
Rociletinib (CO-1686) 
CO-1686-032 
FINAL Version 1.0 
 26 May 2015 
 
 
Page 97 of 131 
Confidential 
 
10 
STATISTICAL METHODS 
10.1 Analysis Populations 
The following analysis populations are defined for the study: 
Tumor evaluable population—all patients who received at least one dose of rociletinib or 
MPDL3280A, have at least one measureable tumor lesion at baseline, and have at least one 
post-baseline tumor assessment as determined by the Investigator. 
Safety population—all patients who have received at least one dose of rociletinib or 
MPDL3280A. 
10.2 Statistical Methods 
10.2.1 General Considerations 
Data will be summarized using descriptive statistics (number of patients, mean, median, standard 
deviation, minimum, and maximum) for continuous variables and using frequencies and 
percentages for discrete variables. Data will be presented by dose cohorts, as appropriate. 
Kaplan-Meier methodology will be used to summarize time to event variables. 
All data will be used to their maximum possible extent but without any imputations for missing 
data. 
All statistical analyses will be conducted with the Statistical Analysis Software (SAS®) system. 
10.2.2 Patient Disposition  
The frequency and percentage of patients in each analysis population will be presented. The 
primary reason for discontinuation of rociletinib and/or MPDL3280A will be summarized. 
10.2.3 Baseline Characteristics  
Baseline characteristics and demographic data will be summarized for the safety population. 
10.2.4 Efficacy Analyses  
The efficacy endpoints of ORR, DoR, DCR, and PFS will be evaluated using RECIST v1.1 
(Appendix A:) and modified RECIST incorporating irRC (Appendix B). Efficacy endpoints 
evaluated by the Investigator will be presented for the subgroup of patients determined to be 
tumor evaluable by the Investigator.  
Progression-free survival and OS will also be presented for the safety population.  

Clovis Oncology, Inc. 
Clinical Protocol 
Rociletinib (CO-1686) 
CO-1686-032 
FINAL Version 1.0 
 26 May 2015 
 
 
Page 98 of 131 
Confidential 
 
10.2.4.1 Primary Endpoint (Phase 2) 
The primary endpoint of the Dose Expansion Phase (Phase 2) of the study is ORR per RECIST 
as assessed by the Investigator. 
The ORR is the best overall response recorded from the start of the treatment until disease 
progression or recurrence. 
The frequency and percentages of patients with a best overall response of CR, PR, stable disease 
(SD), or PD will be summarized. The confirmed response rate will also be summarized with 
frequencies and percentages. 
10.2.4.2 Secondary Efficacy Endpoints 
10.2.4.2.1 Overall Response Rate (ORR) based on Modified Response Criteria 
The ORR based on the modified response criteria is the best overall response recorded from the 
start of the treatment until disease progression or recurrence as assessed by the Investigator using 
the modified RECIST criteria. 
The frequency and percentages of patients with a best overall response of CR, PR, SD, or PD 
will be summarized. 
10.2.4.2.2 Duration of Response (DOR) 
Duration of response for CR and PR will be measured from the date that any of these best 
responses is first recorded until the first date that PD is objectively documented. For patients who 
continue treatment post-progression, the first date of progression will be used for the analysis. 
Patients without a documented event of radiographic progression will be censored on the date of 
the most recent tumor assessment. 
10.2.4.2.3 Disease Control Rate (DCR) 
Disease control rate is defined as the percentage of patients who have achieved CR, PR, or SD 
lasting at least 12 weeks.  
10.2.4.2.4 Progression-Free Survival (PFS) 
Progression-free survival (PFS) will be calculated as 1+ the number of days from the first dose of 
study drug to documented radiographic progression, as determined by the Investigator or death 
due to any cause, whichever occurs first. Patients without a documented event of radiographic 
progression will be censored on the date of their last adequate tumor assessment (ie, radiologic 
assessment) or date of first dose of study drug if no tumor assessments have been performed.  
For patients who continue treatment post-progression, the first date of progression will be used 
for the analysis of PFS. 

Clovis Oncology, Inc. 
Clinical Protocol 
Rociletinib (CO-1686) 
CO-1686-032 
FINAL Version 1.0 
 26 May 2015 
 
 
Page 99 of 131 
Confidential 
 
10.2.4.2.5 Overall Survival 
Overall survival (OS) will be calculated as 1+ the number of days from the first dose of study 
drug to death due to any cause. Patients without a documented date of death will be censored on 
the date the patient was last known to be alive. 
10.2.4.2.6 Exploratory Sub-Group Analyses  
For Phase 2 of the study, accrual to Groups A and B will take place independently. 
In Group B, T790M+ and T790M– patients will be enrolled concurrently. Exploratory subgroup 
analyses will be performed. 
There are no planned statistical analyses between Group A and B or the sub-groups within 
Group B. 
10.2.4.2.7 PK Analyses  
Blood sampling for PK analyses of both rociletinib and MPDL3280A will be conducted in all 
patients treated with rociletinib and MPDL3280A. PK parameters, including AUC0-24, Cmax, Cmin, 
and tmax will be estimated for rociletinib, and Cmax, and Cmin for MPDL3280A using non-
compartmental models. Comparisons across dose levels will be made to assess proportionality. 
10.2.4.2.8 Pharmacodynamics Analyses 
Tumor tissue, plasma, and blood specimens will be used for pharmacodynamic assessment of 
rociletinib and/or MPDL3280A activity, to evaluate the concordance of mutant EGFR detection 
between tissue and plasma, and to explore biomarkers that may be predictive of response or 
resistance to rociletinib and/or MPDL3280A. Biomarkers and changes in biomarker status will 
be investigated for associations with rociletinib and/or MPDL3280A exposure, safety, and 
clinical activity. Given the limited sample size, no formal statistical analysis is planned. 
10.2.5 Safety Analyses  
The safety analyses will be performed using the safety population. 
Safety data analysis will be conducted on all patients receiving at least one dose of rociletinib or 
MPDL3280A. The number and percentage of patients experiencing one or more AEs will be 
summarized by dose level group, relationship to study drug, and severity. AEs will be coded 
using MedDRA terminology. Listings of patients who experienced DLT during Cycle 1, dose 
reductions, dosing interruptions, withdrawal due to an AE, SAEs and/or death will be presented. 
Laboratory parameters will be summarized using descriptive statistics, by post-dosing shifts 
relative to baseline, and data listings of clinically significant abnormalities. Vital signs, ECOG 
performance status, and ECG data will be summarized by changes from baseline values at each 
dose level using descriptive statistics.  

Clovis Oncology, Inc. 
Clinical Protocol 
Rociletinib (CO-1686) 
CO-1686-032 
FINAL Version 1.0 
 26 May 2015 
 
 
Page 100 of 131 
Confidential 
 
A mTPI method will be used to identify the MTD or MAD and the RP2D. The mTPI, a 
model-based approach that has a pre-specified decision matrix that recommends escalating, 
reducing or maintaining the same dose or stopping dose escalation, based on the toxicities 
observed in the dose level under evaluation, reduces the risk of exposing patients to doses above 
the MTD compared with 3+3 design in which there is a 71% chance of escalation if the true but 
unknown rate of DLT is 20% and less than 50% chance of escalation if the true but unknown rate 
of DLT is higher than 30%. 
10.2.5.1 Extent of Exposure 
The following will be summarized by dose group:  
• Number of weeks of treatment initiated; 
• Number of dose reductions or interruptions. 
The number of weeks of treatment initiated will be investigated by summarizing the number of 
weeks started by each patient for each study drug. The number of patients with at least one dose 
reduction or interruption will be summarized with frequencies and percentages separately for 
each study drug and for the combination. 
10.2.5.2 Adverse Events 
Adverse event (AE) coding will be performed using MedDRA terminology. The severity of the 
toxicities will be graded according to the NCI CTCAE v4.03 whenever possible. Treatment-
emergent AEs are defined as AEs with an onset date on or after the date of first dose of 
rociletinib or MPDL3280A until the date of the last dose of either study drug plus 28 days. AEs 
will be considered treatment-emergent if all or part of the date of onset of the AE is missing and 
it cannot be determined if the AE meets the definition for treatment-emergent. 
The number and percentage of patients who experienced treatment-emergent AEs for each 
system organ class and preferred term will be presented by dose group. Multiple instances of the 
treatment-emergent AEs in each System Organ Class and multiple occurrences of the same 
Preferred Term are counted only once per patient. The number and percentage of patients with at 
least one treatment-emergent AE will also be summarized by dose group. 
Separate tables will present the following by dose group and study phase: 
• All treatment-emergent AEs; 
• Treatment-emergent AEs by CTCAE grade; 
• Grade 3 or greater treatment-emergent AEs; 
• Grade 3 or greater treatment-related, treatment-emergent AEs; 
• Treatment-related, treatment-emergent AEs; 
• Dose-limiting toxicity AEs; 
• Serious treatment-emergent AEs; 

Clovis Oncology, Inc. 
Clinical Protocol 
Rociletinib (CO-1686) 
CO-1686-032 
FINAL Version 1.0 
 26 May 2015 
 
 
Page 101 of 131 
Confidential 
 
• Serious treatment-related, treatement-emergent AEs; 
• Treatment-emergent AEs with an outcome of death; 
• Treatment-emergent AEs leading to discontinuation of either study drug; 
• Treatment-emergent AEs resulting in interruption or reduction of either study drug. 
The incidence of treatment-emergent AEs will be summarized by relationship to oral study drug 
using “treatment-related” and “not treatment-related” categories. If a patient experiences 
multiple occurrences of the same AE with different relationship categories, the patient will be 
counted once as a relationship category of treatment-related. 
If a patient experiences multiple occurrences of the same AE with different intensity toxicity 
grades, the patient will be counted once for the maximum (most severe) toxicity grade. AEs with 
a missing intensity will be presented in the summary table with a toxicity grade of “Missing.” 
For each toxicity grade, the number and percentage of patients with at least one 
treatment-emergent AE of the given grade will be summarized. 
Non-treatment-emergent AEs (pre-treatment and post-treatment) will be presented in the data 
listings.  
10.2.5.3 Clinical Laboratory Evaluations 
Clinical laboratory evaluations include the continuous variables for hematology, serum 
chemistry, and urinalysis. Laboratory values will be presented in International System of Units. 
The baseline laboratory value will be defined as the last value before or on the day of the first 
dose of either study drug. The on-treatment period will be defined as the day after the first dose 
of either study drug to 28 days after the last dose of rociletinib or MPDL3280A. Laboratory 
values collected during the on-treatment period will be included in the summary tables. The 
laboratory values collected after the on-treatment period will only be presented in the data 
listings.  
The summary of laboratory data will include descriptive statistics (N, mean, standard deviation, 
minimum, median, and maximum) of the maximum, minimum, and last value during the 
treatment period by dose group and study phase. Summaries using descriptive statistics of the 
change from baseline to the maximum, minimum, and last value during the on-treatment period 
will also be given by dose group and study phase. Separate listings will be produced for 
clinically significant laboratory abnormalities (ie, those that meet Grade 3 or 4 criteria according 
to CTCAE) by dose group.  
10.2.5.4 Vital Sign Measurements 
The baseline vital sign measurement will be defined as the last value before or on the day of the 
first dose of either study drug. The on-treatment period will be defined as the day after the first 
dose of either study drug to 28 days after the last dose of rociletinib or MPDL3280A Vital sign 
measurements collected during the on-treatment period will be included in the summary tables. 

Clovis Oncology, Inc. 
Clinical Protocol 
Rociletinib (CO-1686) 
CO-1686-032 
FINAL Version 1.0 
 26 May 2015 
 
 
Page 102 of 131 
Confidential 
 
The vital sign measurements collected after the on-treatment period will only be presented in the 
data listings.  
The summary of vital sign data will include descriptive statistics (N, mean, standard deviation, 
minimum, median, and maximum) of the maximum, minimum, and last value during the 
on-treatment period by dose group and study phase. Summaries using descriptive statistics of the 
change from baseline to the maximum, minimum, and last value during the on-treatment period 
will also be given by dose group.  
10.2.5.5 12-Lead Electrocardiograms  
Electrocardiogram (ECG) intervals will be stratified into categories indicative of potential 
clinical significance. Each patient’s maximum QT and QTC intervals from the pretreatment visit 
and treatment period visits will be classified as ≤ 450 ms, > 450 to ≤ 480 ms, > 480 to ≤ 500 ms, 
and > 500 ms. For each patient’s maximum change from the pretreatment ECG visit for QT and 
QTC, intervals will be classified into < 30 ms, ≥ 30 to < 60 ms, and ≥ 60 ms. The number and 
percentage of patients in each classified category will be presented. Additional endpoints will 
include abnormal T waves and U waves and other ECG intervals and diagnostic parameters.  
Descriptive statistics will be used to summarize other ECG parameters of PR, QRS, QT, and RR 
interval, and the corresponding changes from pretreatment ECG visit at each time point. Plots of 
the mean QT/QTC over time will be provided. 
10.2.5.6 Other Safety Measurements 
Concomitant medications/procedures will be tabulated and summarized. 
10.3 Sample Size Considerations 
Approximately 25 patients will be enrolled into Group A and approximately 50 patients will be 
enrolled into Group B. The CSC will evaluate the safety and efficacy of the combination of 
rociletinib and MPDL3280A on a regular basis in order to ensure that the risk/benefit of the 
combination is at least as beneficial as that of single agent rociletinib. In addition early futility 
rules will be evaluated as described below.  
Within Group A, the expected ORR for single-agent rociletinib in frontline patients is at least 
50%. An early futility rule will be evaluated in the first 5 patients such that if 0 out of the first 5 
patients have a best response of PR or CR, then the true ORR in these patients is likely to be less 
than 50% and thus the evaluation of the combination in frontline patients may be discontinued. 
Within Group B, it is expected that about 30 (60%) of the patients will be T790M+ and thus, 
about 20 patients (40%) will be T790M–. The estimated ORR for single-agent rociletinib is 
greater than 50% in T790M+ patients, so the observed ORR for the combination of rociletinib 
and MPDL3280A is also expected to be greater than 50% in these patients. An early futility rule 
will be evaluated in the first five T790M+ patients such that if 0 out of the first 5 T790M+ 
patients have a best response of PR or CR, then the true ORR in these patients is likely to be less 
than 50% and thus the evaluation of the combination in T790M+ patients may be discontinued. 

Clovis Oncology, Inc. 
Clinical Protocol 
Rociletinib (CO-1686) 
CO-1686-032 
FINAL Version 1.0 
 26 May 2015 
 
 
Page 103 of 131 
Confidential 
 
In T790M– patients, an ORR less than 30% is probably not worthy of further study. The early 
futility rule will be based on the first nine T790M– patients. If 0 out of the first 9 patients have a 
best response of PR or CR, then the true ORR is likely to be less than 30% in these patients and 
thus the evaluation of the combination in T790M– patients may be discontinued. 

Clovis Oncology, Inc. 
Clinical Protocol 
Rociletinib (CO-1686) 
CO-1686-032 
FINAL Version 1.0 
 26 May 2015 
 
 
Page 104 of 131 
Confidential 
 
11 
PATIENT DISPOSITION 
11.1 Permanent Discontinuation of Study Treatment 
A patient must be discontinued from all study treatment if any of the following applies: 
• Consent withdrawal at the patient’s own request or at the request of their legally authorized 
representative; 
• Clinical disease progression where the Investigator believes that the patient will not continue 
to benefit from study treatment (Note: patients will be permitted to continue study treatment 
after a radiographic progression [Appendix A: and Appendix B] if the benefit-risk ratio is 
judged to be favorable and continued treatment is approved by the Medical Monitor); 
• Any event, adverse or otherwise, that, in the opinion of the Investigator, would pose an 
unacceptable safety risk to the patient;  
• Any requirement for dose holds of rociletinib for more than 14 days or dose holds of 
MPDL3280A for more than 42 days, unless permission from the Sponsor’s Medical Monitor 
for longer dose delay is granted; 
• An intercurrent illness that, in the opinion of the Investigator, would affect assessments of the 
clinical status to a significant degree and requires discontinuation of therapy; 
• A positive pregnancy test at any time during the study; 
• Investigator decision. 
In addition, the Sponsor may discontinue the study early for any of the reasons noted in 
Section 12.6. 
The Sponsor (or designee) should be notified of all study terminations as soon as possible. The 
date and reason for cessation of PO rociletinib and/or IV MPDL3280A must be documented in 
the eCRF and source documents. 
To the extent possible, EOT assessments should be performed for all patients who receive 
rociletinib and MPDL3280A. The EOT visit should occur 28 (± 7) days after the last dose of 
rociletinib and MPDL3280A. After stopping protocol-specified treatment, all patients will 
remain in the study and will be followed for safety (through 28 days after last dose; those with 
ongoing SAEs will be followed until either resolution or stabilization has been determined), for 
disease progression (every 8 ± 1 weeks until disease progression), and for survival status and 
subsequent NSCLC therapies (at approximately quarterly intervals until death or Sponsor 
decision). 

Clovis Oncology, Inc. 
Clinical Protocol 
Rociletinib (CO-1686) 
CO-1686-032 
FINAL Version 1.0 
 26 May 2015 
 
 
Page 105 of 131 
Confidential 
 
12 
STUDY ADMINISTRATION 
12.1 Regulatory and Ethical Considerations 
This study will be conducted in compliance with the protocol; Good Clinical Practices (GCPs), 
including International Conference on Harmonisation (ICH) Technical Requirements for 
Registration of Pharmaceuticals for Human Use Guidelines; FDA regulatory requirements; and 
in accordance with the ethical principles of the Declaration of Helsinki. 
12.1.1 Regulatory Authority Approvals 
The Sponsor or designee will submit the study protocol plus all relevant study documents to 
concerned regulatory agencies for approval before the study start. No patient will be admitted to 
the study until appropriate regulatory approval of the study protocol has been received. 
Each investigator must complete a Form FDA 1572 or equivalent and provide the completed 
form according to written instructions to the Sponsor (or designee). Each investigator must 
submit to the Sponsor (or designee) financial disclosure information according to national law 
and/or local regulations. 
Data generated in the US will be handled in accordance with the Health Information Portability 
and Accountability Act (HIPAA). The study will be registered at www.clinicaltrials.gov using 
the Protocol Registration System. 
12.1.2 Institutional Review Board (IRB) 
This protocol and any material to be provided to the patient (such as advertisements, patient 
information sheets, or descriptions of the study used to obtain informed consent) will be 
submitted by the Investigator to an IRB. This also applies to protocol amendments. 
The Sponsor will supply relevant data for the Investigator to submit the study protocol and 
additional study documents to the IRB. The Principal Investigator will submit the study protocol 
for review and approval by an IRB, according to national law and/or local regulations, and will 
provide the IRB with all appropriate materials. 
Verification of the IRB’s unconditional approval of the study protocol and the written ICF will 
be transmitted to the Sponsor. This approval must refer to the study by exact study protocol title 
and number, identify the documents reviewed, and state the date of the review. 
No patient will be admitted to the study until appropriate IRB approval of the study protocol has 
been received, the Investigator has obtained the signed and dated ICF, and the Sponsor is 
notified. 
The Principal Investigator will submit appropriate reports on the progress of the study to the IRB 
at least annually in accordance with applicable national law and/or local regulations and in 
agreement with the policy established by the IRB and Sponsor. 

Clovis Oncology, Inc. 
Clinical Protocol 
Rociletinib (CO-1686) 
CO-1686-032 
FINAL Version 1.0 
 26 May 2015 
 
 
Page 106 of 131 
Confidential 
 
The IRB must be informed by the Principal Investigator of all subsequent study protocol 
amendments and of SAEs or SUSARs occurring during the study that are likely to affect the 
safety of the patients or the conduct of the study. 
12.2 Confidentiality of Information 
The Investigator must assure that patients’ anonymity is strictly maintained and that their 
identities are protected from unauthorized parties. Only patient initials and an identification code 
(ie, not names) should be recorded on any form submitted to the Sponsor and the IRB. The 
Investigator must keep logs on screened and enrolled patients. In addition, the Investigator must 
have a list where the identity of all treated patients can be found. 
The Investigator agrees that all information received from the Sponsor or Roche, including, but 
not limited to, the IB, this protocol, eCRFs, the protocol-specified treatment, and any other study 
information, remain the sole and exclusive property of the Sponsor during the conduct of the 
study and thereafter. This information is not to be disclosed to any third party (except employees 
or agents directly involved in the conduct of the study or as required by law) without prior 
written consent from the Sponsor. The Investigator further agrees to take all reasonable 
precautions to prevent the disclosure by any employee or agent of the study center to any third 
party or otherwise into the public domain. 
12.3 Patient Informed Consent 
All information about the clinical study, including the patient information and the ICF, is 
prepared and used for the protection of the human rights of the patient according to ICH GCP 
guidelines and the Declaration of Helsinki. 
It is the responsibility of the Investigator to obtain signed ICFs from each patient participating in 
this study after adequate explanation of the aims, methods, objectives, and potential hazards of 
the study and before undertaking any study-related procedures. 
The ICF, prepared by the Investigator with the assistance of the Sponsor, must be approved 
along with the study protocol by the IRB and be acceptable to the Sponsor. 
The patient must be provided with the patient information and ICF consistent with the study 
protocol version used and approved by the relevant IRB. The ICF must be in a language fully 
comprehensible to the prospective patient. Patients (and/or relatives, guardians, or legal 
representatives, if necessary) must be given sufficient time and opportunity to inquire about the 
details of the study and to discuss and decide on their participation in the study with the 
investigator concerned. The patient and the person explaining about the study and with whom 
they discuss the informed consent will sign and date the ICF. A copy of the signed ICF will be 
retained by the patient and the original will be filed in the Investigator file unless otherwise 
agreed. 

Clovis Oncology, Inc. 
Clinical Protocol 
Rociletinib (CO-1686) 
CO-1686-032 
FINAL Version 1.0 
 26 May 2015 
 
 
Page 107 of 131 
Confidential 
 
12.4 Study Monitoring 
On behalf of the Sponsor, a CRO monitor will contact and visit the Investigator at the study 
center before the entry of the first patient and at predetermined appropriate intervals during the 
study until after the last patient has completed. The monitor will also perform a study closure 
visit. 
In accordance with ICH GCP guidelines, the Investigator must ensure provision of sufficient 
time, reasonable space, and adequate qualified personnel for the monitoring visits. The visits are 
for the purpose of verifying adherence to the study protocol and the completeness, consistency, 
and accuracy of data entered on the eCRF and other documents. 
The Investigator will make all source data (ie, the various study records, the eCRFs, laboratory 
test reports, other patient records, drug accountability forms, and other pertinent data) available 
for the monitor and allow access to them throughout the entire study period. Monitoring is done 
by comparing the relevant site records of the patients with the entries on the eCRF (ie, source 
data verification). It is the monitor’s responsibility to verify the adherence to the study protocol 
and the completeness, consistency, and accuracy of the data recorded on the eCRFs. 
By agreeing to participate in the study, the Investigator agrees to cooperate with the monitor to 
ensure that any problems detected in the course of the monitoring visits are resolved. Contact 
information for the study monitor is located in the Investigator file. Representatives from the 
Sponsor may also contact and visit the Investigators and monitor data during the study. 
12.5 Electronic Case Report Form (eCRF) 
The data will be collected using an electronic data capture (EDC) system by remote data entry on 
eCRFs. Sites will receive training on the EDC system. All users will be supplied with unique 
login credentials. 
Before study start, the Investigator will prepare a list showing the signature and handwritten 
initials of all individuals authorized to make or change entries on eCRFs. This “study center 
personnel and delegation list” must be kept current throughout the study. 
For each patient enrolled, an eCRF must be completed, reviewed, signed, and dated by the 
Principal Investigator or Co-Investigator within a reasonable time period (< 2 weeks) after data 
collection. This also applies to records for those patients who fail to complete the study. If a 
patient withdraws from the study, the reason must be noted on the eCRF. If a patient is 
withdrawn from the study because of a treatment-limiting AE, thorough efforts should be made 
to clearly document the outcome. 
All laboratory data and investigator observations on the results and any other clinically 
significant test results must be documented on eCRFs. 
Full information regarding EDC and completing eCRFs is included in the Investigator files. All 
questions or comments related to electronic capture should be directed to the assigned monitor. 

Clovis Oncology, Inc. 
Clinical Protocol 
Rociletinib (CO-1686) 
CO-1686-032 
FINAL Version 1.0 
 26 May 2015 
 
 
Page 108 of 131 
Confidential 
 
12.6 Study Termination and Site Closure 
Both the Sponsor and the Investigator reserve the right to terminate the study at any time. Should 
this be necessary, both parties will arrange discontinuation procedures. In terminating the study, 
the Sponsor and the Investigator will assure that adequate consideration is given to the protection 
of the patients’ interests. 
The Sponsor reserves the right to discontinue the study at any time for medical or administrative 
reasons. When feasible, a 30-day written notification will be given. 
The entire study will be stopped if: 
• The protocol-specified treatment is considered too toxic to continue the study; 
• Evidence has emerged that, in the opinion of the Sponsor or the Investigator(s), makes the 
continuation of the study unnecessary or unethical; 
• The stated objectives of the study are achieved; 
• The Sponsor discontinues the development of PO rociletinib or IV MPDL3280A. 
Regardless of the reason for termination, all data available for the patient at the time of 
discontinuation of follow up must be recorded on the eCRF. All reasons for discontinuation of 
treatment must be documented. In terminating the study, the Investigator will ensure that 
adequate consideration is given to the protection of the patients’ interests. 
12.7 Modification of the Study Protocol 
Protocol amendments, except when necessary to eliminate an immediate hazard to patients, must 
be made only with the prior approval of the Sponsor. Agreement from the Investigator must be 
obtained for all protocol amendments and amendments to the informed consent document. The 
IRB must be informed of all amendments and give approval before their implementation. The 
Sponsor will submit any study protocol amendments to the concerned regulatory authorities for 
approval and keep the Investigator(s) updated as detailed in the ICH GCP guidelines. 
12.8 Retention of Study Documents 
The study site will maintain a study file, which should contain, at minimum, the IB, the protocol 
and any amendments, drug accountability records, correspondence with the IRB and the 
Sponsor, and other study-related documents. 
The Investigator agrees to keep records and those documents that include (but are not limited to) 
the identification of all participating patients, medical records, study-specific source documents, 
source worksheets, all original signed and dated ICFs, copies of all eCRFs, query responses, and 
detailed records of drug disposition to enable evaluations or audits from regulatory authorities 
and the Sponsor or its designees. 
The Investigator shall retain records required to be maintained for a period of 5 years after the 
date a marketing application in an ICH region is approved for the drug for the indication for 

Clovis Oncology, Inc. 
Clinical Protocol 
Rociletinib (CO-1686) 
CO-1686-032 
FINAL Version 1.0 
 26 May 2015 
 
 
Page 109 of 131 
Confidential 
 
which it is being investigated or, if no application is to be filed or if the application is not 
approved for such indication, until at least 5 years after the investigation is discontinued. 
However, these documents should be retained for a longer period if required by the applicable 
regulatory requirement(s) or if needed by the Sponsor. In addition, the Investigator must make 
provision for the patients’ medical records to be kept for the same period of time. 
No data should be destroyed without the agreement of the Sponsor. Should the Investigator wish 
to assign the study records to another party or move them to another location, the Sponsor must 
be notified in writing of the new responsible person and/or the new location. The Sponsor will 
inform the Investigator, in writing, when the study-related records are no longer needed. 
Patients’ medical records and other original data will be archived in accordance with the 
archiving regulations or facilities of the investigational site. 
12.9 Clinical Study Report 
A clinical study report will be prepared under the responsibility and supervision of the Sponsor 
and signed by the Sponsor’s chief medical officer, thereby indicating their agreement with the 
analyses, results, and conclusions of the clinical study report. 
12.10 Study Publication 
All data generated from this study are the property of the Sponsor and shall be held in strict 
confidence along with all information furnished by the Sponsor. Independent analysis and/or 
publication of these data by the Investigator(s) or any member of their staff are not permitted 
without the prior written consent of the Sponsor. Written permission to the Investigator will be 
contingent on the review by the Sponsor of the statistical analysis and manuscript, and will 
provide for nondisclosure of the Sponsor confidential or proprietary information. In all cases, the 
parties agree to submit all manuscripts or abstracts to all other parties 30 days before submission. 
This will enable all parties to protect proprietary information and to provide comments based on 
information that may not yet be available to other parties. 
12.11 Quality Assurance Audits 
An audit visit to clinical centers may be conducted by a quality control auditor appointed by the 
Sponsor. The purpose of an audit, which is independent of and separate from routine monitoring 
or quality control functions, is to evaluate study conduct and compliance with the protocol, 
standard operating procedures, ICH GCPs, and the applicable regulatory requirements. The 
Investigator and the Sponsor may also be subject to an inspection by FDA, European Regulatory 
authorities, or other applicable regulatory authorities at any time. 
The auditor and regulatory authorities will require authority from the Investigator to have direct 
access to the patients’ medical records. It is important that the Investigator(s) and their staff 
cooperate with the auditor or regulatory authorities during this audit or inspection. 

Clovis Oncology, Inc. 
Clinical Protocol 
Rociletinib (CO-1686) 
CO-1686-032 
FINAL Version 1.0 
 26 May 2015 
 
 
Page 110 of 131 
Confidential 
 
13 
REFERENCES 
1. Soria J-C, Sequist L, Goldman J, et al. Interim phase 2 results with the irreversible, mutant 
selective, EGFR inhibitor rociletinib (CO-1686). EORTC-NCI-AACR Symposium on 
Molecular Targets and Cancer Therapeutics; November 2014; Barcelona, Spain. 
2. Butte MJ, Keir ME, Phamduy TB, et al. Programmed death-1 ligand 1 interacts specifically 
with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity. 2007;27:111-
22. Epub 2007 Jul 12. 
3. Herbst RS, Soria JC, Kowanetz M, et al. Predictive correlates of response to the anti-PD-L1 
antibody MPDL3280A in cancer patients. Nature 2014;515:563-7. 
4. WHO Fact Sheet N°297. Cancer. October 2011. 
5. Ries L, Eisner M, Kosary C, et al, eds. Cancer Statistics Review, 1975-2002. Bethesda, Md: 
National Cancer Institute, 2005.  
6. Herbst RS, Heymach JV, Lippman SM. Molecular origins of cancer: Lung cancer. N Engl J 
Med 2008; 359:1367-80. 
7. Mok TS, Wu YL, Thongprasert S, et al. Getfitinib or carboplatin-paclitaxel in pulmonary 
adenocarcinoma. N Engl J Med 2009; 361:947-57. 
8. Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell 
lung cancer with mutated EGFR. N Engl J Med 2010; 362:2380-8. 
9. Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients 
with non-small-cell lung cancer harbouring mutations of the epidermal growth factor 
receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 
2010;11:121-8. 
10. Rosell R, Carcereny E, Gervais R, et al. Spanish Lung Cancer Group in collaboration with 
Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia Toracica. 
Erlotinib versus standard chemotherapy as first-line treatment for European patients with 
advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, 
open-label, randomised phase 3 trial. Lancet Oncol 2012; 13:239-46. 
11. Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for 
patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, 
CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 
2011;12:735-42. 
12. Herbst R, LoRusso P, Purdom M, Ward D. Dermatologic side effects associated with 
gefitinib therapy: clinical experience and management. Clin Lung Cancer 2003; 4:366-9. 
13. Perez-Soler R, Saltz L. Cutaneous adverse effects with HER1/EGFR targeted agents: is 
there a silver lining? J Clin Oncol 2005; 23:5235-46. 

Clovis Oncology, Inc. 
Clinical Protocol 
Rociletinib (CO-1686) 
CO-1686-032 
FINAL Version 1.0 
 26 May 2015 
 
 
Page 111 of 131 
Confidential 
 
14. Sridhar SS, Seymour L, Shepherd FA. Inhibitors of epidermal-growth-factor receptors: a 
review of clinical research with a focus on non-small-cell lung cancer. Lancet Oncol 2003; 
4:397-406. 
15. Wu JY, Shih JY, Yang CH, et al. Second-line treatments after first-line gefitinib therapy in 
advanced nonsmall cell lung cancer. Int J Cancer 2010; 126:247-55. 
16. Goldberg SB, Oxnard GR, Digumarthy S, et al. Chemotherapy with Erlotinib or 
chemotherapy alone in advanced non-small cell lung cancer with acquired resistance to 
EGFR tyrosine kinase inhibitors. Oncologist 2013; 18:1214-20. 
17. Sequist LV, Waltman BA, Dias-Santagata D, et al. Genotypic and histological evolution of 
lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 2011; 3:75ra26. 
18. Rosell R, Moran T, Queralt C, et al. Screening for epidermal growth factor receptor 
mutations in lung cancer. N Engl J Med 2009; 361:958-67. 
19. Pao W, Miller VA, Politi KA, et al. Acquired resistance of lung adenocarcinomas to 
gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS 
Med 2005; 2:e73. 
20. Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal Growth Factor Receptor 
Mutations in Lung Cancer. Nat Rev Cancer 2007; 7:169-81. 
21. Sequist LV, Besse B, Lynch TJ, et al. Neratinib, an irreversible pan-ErbB receptor tyrosine 
kinase inhibitor: Results of a Phase II trial in patients with advanced non-small-cell lung 
cancer. J Clin Oncol 2010; 28:3076-83. 
22. Yu HA, Arcila ME, Rekhtman N, et al. Analysis of tumor specimens at the time of acquired 
resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin 
Cancer Res 2013; 19:2240-7. 
23. Walter AO, Sjin RT, Haringsma HJ, et al. Discovery of a mutant-selective covalent inhibitor 
of EGFR that overcomes T790M-mediated resistance in NSCLC. Cancer Discov. 2013; 
3:1404-15. 
24. National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.03. 
Available at < http://www.eortc.be/services/doc/ctc/CTCAE_4.03_2010-06-
14_QuickReference_5x7.pdf>. Accessed 04 May 2015. 
25. Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in 
patients with advanced cancer. N Engl J Med 2012; 366:2455-65.  
26. Topalian SL, Hodi FS, Brahmer, JR, et al. Safety, Activity, and Immune Correlates of Anti–
PD-1 Antibody in Cancer. N Engl J Med 2012; 366:2443-54. 
27. Stagg J, Loi S, Divisekera U, et al. Anti-ErbB-2 mAb therapy requires type I and II 
interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy. Proc Natl Acad Sci 
USA 2011; 108:7142-7. 

Clovis Oncology, Inc. 
Clinical Protocol 
Rociletinib (CO-1686) 
CO-1686-032 
FINAL Version 1.0 
 26 May 2015 
 
 
Page 112 of 131 
Confidential 
 
14 
APPENDICES 

Clovis Oncology, Inc. 
Clinical Protocol 
Rociletinib (CO-1686) 
CO-1686-032 
FINAL Version 1.0 
 26 May 2015 
 
 
Page 113 of 131 
Confidential 
 
Appendix A: Response Evaluation Criteria in Solid Tumor (RECIST) Version 1.1 
The RECIST guidelines (Version 1.1) are described in Eisenhauer (2009) and at 
http://www.eortc.be/Recist/Default.htm. A short summary is given below. 
Measurable Disease: 
Tumor lesions: measurable lesions are defined as those that can be accurately measured in at 
least one dimension (longestameter to be recorded) with the following: 
1. A minimum size of 10 mm by CT scan (CT scan thickness no greater than 5 mm); 
2. A minimum size of 10 mm caliper measurement by clinical exam (lesions that cannot be 
accurately measured with calipers should be recorded as nonmeasurable); 
3. A minimum size of 20 mm by chest X-ray. 
All tumor measurements must be recorded in millimeters (or decimal fractions of 
centimeters). 
Malignant lymph nodes: to be considered pathologically enlarged and measurable, a lymph node 
must be ≥ 15 mm in short axis when assessed by CT scan (CT scan slice thickness recommended 
to be not greater than 5 mm). At baseline and in follow up, only the short axis will be measured 
and followed. 
Nonmeasurable Disease: 
All other lesions (or sites of disease), including small lesions (longest diameter < 10 mm or 
pathological lymph nodes with ≥ 10 to < 15 mm short axis), as well as truly nonmeasurable 
lesions, are considered nonmeasurable disease. Lesions considered truly nonmeasurable include 
leptomeningeal disease, ascites, pleural/pericardial effusions, inflammatory breast disease, 
lymphangitic involvement of skin and lung, and abdominal masses/abdominal organomegaly 
identified by physical exam that is not measurable by reproducible imaging techniques. 
Bone Lesions 
Bone lesions, cystic lesion, and lesions previously treated with local therapy require particular 
comment. Bone scan, positron emission tomography (PET) scan, or plain films are not 
considered adequate imaging techniques to measure bone lesions. However, these techniques can 
be used to confirm the presence or disappearance of bone lesions. 
Lytic bone lesions or mixed lytic-blastic lesions with identifiable soft tissue components that can 
be evaluated by cross-sectional imaging techniques such as CT or MRI can be considered as 
measurable lesions if the soft tissue component meets the definition of measurability described 
above. 
Blastic bone lesions are nonmeasurable. 

Clovis Oncology, Inc. 
Clinical Protocol 
Rociletinib (CO-1686) 
CO-1686-032 
FINAL Version 1.0 
 26 May 2015 
 
 
Page 114 of 131 
Confidential 
 
Cystic Lesions 
Lesions that meet the criteria for radiographically defined simple cysts should not be considered 
as malignant lesions (neither measurable nor nonmeasurable) because they are, by definition, 
simple cysts. 
Cystic lesions thought to represent cystic metastases can be considered as measurable lesions if 
they meet the definition of measurability described above. However, if noncystic lesions are 
present in the same patient, these are preferred as target lesions. 
Lesions with Prior Local Treatment 
Tumor lesions situated in a previous irradiated area or in an area subjected to other locoregional 
therapy are usually not considered measurable unless there has been demonstrated progression in 
the lesion. 
Target Lesions 
All measurable lesions up to a maximum of two lesions per organ and five lesions in total, 
representative of all involved organs, should be identified as target lesions and recorded and 
measured at baseline. Target lesions should be selected on the basis of their size (lesions with the 
longest diameter) and their suitability for accurate repeated measurements (either by imaging 
techniques or clinically). A sum of the longest diameter (LD) for all target lesions will be 
calculated and reported as the baseline sum LD. The baseline sum LD will be used as reference 
by which to characterize the overall tumor response. 
Non-target Lesions 
RECIST criteria require unequivocal quantification of the changes in tumor size for adequate 
interpretation of the sum of target lesions. Consequently, when the boundaries of the primary are 
difficult to delineate, this tumor should not be considered a target lesion. 
Guidelines for Evaluation of Measurable Disease 
The same method of assessment and the same technique should be used to characterize each 
identified and reported lesion at baseline and during follow up. Imaging-based evaluation is 
preferred to evaluation by clinical examination when both methods have been used to assess the 
antitumor effect of a treatment. 

Clovis Oncology, Inc. 
Clinical Protocol 
Rociletinib (CO-1686) 
CO-1686-032 
FINAL Version 1.0 
 26 May 2015 
 
 
Page 115 of 131 
Confidential 
 
Evaluation of Target Lesions 
Complete Response 
Disappearance of all target lesions. Any pathological lymph nodes 
(whether target or non-target) must have reduction in short axis to < 10 
mm. 
Partial Response 
At least a 30% decrease in the sum of the LD of target lesions, taking as 
reference the baseline sum LD. 
Stable Disease 
Neither sufficient shrinkage to qualify for partial response nor sufficient 
increase to qualify for PD, taking as reference the smallest sum LD 
since the treatment started. 
Progressive Disease 
At least a 20% increase in the sum of the LD of target lesions, taking as 
reference the smallest sum on study (this includes the baseline sum if 
that is the smallest on study). In addition to the relative increase of 20%, 
the sum must also demonstrate an absolute increase of at least 5 mm. 
The appearance of one or more new lesions is also considered 
progression. 
 
 
Evaluation of Non-Target Lesions 
Complete Response 
Disappearance of all non-target lesions and normalization of tumor 
marker level. 
Stable Disease/Incomplete 
Response 
Persistence of one or more non-target lesion(s) or/and maintenance of 
tumor marker level above the normal limits. 
Progressive Disease 
Appearance of one or more new lesions and/or unequivocal progression 
of existing non-target lesions. 
 
 
If tumor markers are initially above the institutional ULN, they must normalize for a patient to 
be considered a complete responder. 
Evaluation of Best Overall Response 
The best overall response is the best response recorded from the start of the treatment until 
disease progression/recurrence (taking as reference for PD the smallest measurements recorded 
since the treatment started). The patient’s best response assignment will depend on the 
achievement of both measurement and confirmation criteria. 
Time Point Response 
A response assessment will occur at the protocol-specified time points. The tables below provide 
a summary of the overall response status calculation at each time point for patients who have 
measureable and non-measureable disease (non-target disease only). 

Clovis Oncology, Inc. 
Clinical Protocol 
Rociletinib (CO-1686) 
CO-1686-032 
FINAL Version 1.0 
 26 May 2015 
 
 
Page 116 of 131 
Confidential 
 
Time point Response: Patients with Target (± non-target) Disease 
Target Lesions 
Non-target Lesions 
New Lesions 
Overall Response 
CR 
CR 
No 
CR 
CR 
Non-CR/non-PD 
No 
PR 
CR 
Not evaluated 
No 
PR 
PR 
Non-PD or not evaluated 
No 
PR 
SD 
Non-PD or not evaluated 
No 
SD 
Not Evaluated 
Non-PD 
No 
NE 
PD 
Any 
Yes or No 
PD 
Any 
PD 
Yes or No 
PD 
Any 
Any 
Yes 
PD 
CR, complete response; PD, progressive disease; PR, partial response; SD, stable disease; NE, Not evaluable. 
 
Evaluation of Best Overall Response When Confirmation of CR and PR Required 
Overall Response : 
First Time Point 
Overall Response: 
Subsequent Time Point 
Best Overall Response 
CR 
CR 
CR 
CR 
PR 
SD, PD or PRa 
CR 
SD 
SD provided minimum criteria for SD duration met, 
otherwise, PD 
CR 
PD 
SD provided minimum criteria for SD duration met, 
otherwise, PD 
CR 
NE 
SD provided minimum criteria for SD duration met, 
otherwise, NE 
PR 
CR 
PR 
PR 
PR 
PR 
PR 
SD 
SD 
PR 
PD 
SD provided minimum criteria for SD duration met, 
otherwise, PD 
PR 
NE 
SD provided minimum criteria for SD duration met, 
otherwise, NE 
NE 
NE 
NE 
CR, complete response; PD, progressive disease; PR, partial response; SD, stable disease; NE, Not evaluable. 
 
a 
If a CR is truly met at first time point, then any disease seen at a subsequent time point, even disease meeting PR criteria 
relative to baseline, makes this disease PD at that point (since disease must have reappeared after CR). Best response 
would depend on whether minimum duration for SD was met. However sometimes ‘CR’ may be claimed when 
subsequent scans suggest small lesions were likely still present and in fact the patient had PR, not CR at the first time 
point. Under these circumstances, the original CR should be changed to PR and the best response is PR. 
 

Clovis Oncology, Inc. 
Clinical Protocol 
Rociletinib (CO-1686) 
CO-1686-032 
FINAL Version 1.0 
 26 May 2015 
 
 
Page 117 of 131 
Confidential 
 
Missing Assessments and Not Evaluable Designation 
When no imaging/measurement is done at all at a particular time point, the patient is not 
evaluable (NE) at that time point. If only a subset of lesion measurements are made at an 
assessment, usually the case is also considered NE at that time point, unless a convincing 
argument can be made that the contribution of the individual missing lesion(s) would not change 
the assigned time point response, which is most likely to occur in the case of PD; eg, if only 2 of 
3 baseline target lesions are assessed and result in a > 20% increase in the sum, then the patient 
would be assessed as a PD regardless of the missing lesion. 
Patients with a global deterioration of health status requiring discontinuation of treatment 
without objective evidence of disease progression at that time should be classified as having 
symptomatic deterioration. Every effort should be made to document the objective progression, 
even after discontinuation of treatment. 
In some circumstances, it may be difficult to distinguish residual disease from normal tissue. 
When the evaluation of CR depends on this determination, it is recommended that the residual 
lesion be investigated (fine needle aspiration/biopsy) before confirming the CR status. 
Confirmatory Measurement/Duration of Response 
Confirmation 
Radiographic tumor assessments are required every 6-9 weeks (see Table 1). If an initial CR or 
PR is noted, confirmatory scans must be performed 4-6 weeks later. In the case of SD, follow-up 
measurements must have met the SD criteria at least once after study entry at a minimum interval 
of no less than 4 weeks. 
Duration of Overall Response 
The duration of overall response is measured from the time measurement criteria are met for CR 
or PR (whichever is first recorded) until the first date that recurrent or PD is objectively 
documented (taking as reference for PD the smallest measurements recorded since the treatment 
started). 
The duration of overall CR is measured from the time measurement criteria are first met for CR 
until the first date that recurrent disease is objectively documented. 
Duration of Stable Disease 
SD is measured from the start of the treatment until the criteria for progression are met, taking as 
reference the smallest measurements recorded since the treatment started. 
Reference: 
Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: 
revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45:228-247. 
 

Clovis Oncology, Inc. 
Clinical Protocol 
Rociletinib (CO-1686) 
CO-1686-032 
FINAL Version 1.0 
 26 May 2015 
 
 
Page 118 of 131 
Confidential 
 
Appendix B: Modified RECIST Incorporating Immune-Related Response Criteria  
Conventional response criteria may not be adequate to characterize the antitumor activity of 
immunotherapeutic agents like MPDL3280A, which can produce delayed responses that may be 
preceded by initial apparent radiological progression, including the appearance of new lesions. 
Therefore, modified response criteria have been developed that account for the possible 
appearance of new lesions and allow radiological progression to be confirmed at a subsequent 
assessment. In this protocol, patients will be permitted to continue study treatment even after 
modified Response Evaluation Criteria in Solid Tumors (RECIST) criteria for progressive 
disease are met if the benefit-risk ratio is judged to be favorable. 
These modified criteria are derived from RECIST version 1.1 (v1.1) conventions and 
immune-related response criteria (irRC).  
Modified RECIST and RECIST, Version 1.1: Summary of Changes 
 
RECIST v1.1 
Modified RECIST 
New lesions after baseline 
Define progression. 
New measurable lesions are 
added into the total tumor 
burden and followed. 
Non-target lesions 
May contribute to the 
designation of overall 
progression 
Contribute only in the 
assessment of a complete 
response 
Radiographic progression 
First instance of  20% 
increase in the sum of 
diameters or unequivocal 
progression in non-target 
disease 
Determined only on the basis 
of measurable disease; may be 
confirmed by a consecutive 
assessment  4 weeks from the 
date first documented  
RECIST  Response Evaluation Criteria in Solid Tumors. 
Definitions of Measurable/Nonmeasurable Lesions 
All measurable and nonmeasurable lesions should be assessed at screening and at the protocol-
specified tumor assessment time points. Additional assessments may be performed, as clinically 
indicated for suspicion of progression.  
Measurable Lesions 
Tumor Lesions. Tumor lesions must be accurately measured in at least one dimension (longest 
diameter in the plane of measurement is to be recorded) with a minimum size as follows: 
10 mm by CT or MRI scan (CT/MRI scan slice thickness/interval no greater than 5 mm); 
10-mm caliper measurement by clinical examination (lesions that cannot be accurately 
measured with calipers should be recorded as nonmeasurable). 
Malignant Lymph Nodes. To be considered pathologically enlarged and measurable, a lymph 
node must be  15 mm in the short axis when assessed by CT scan (CT scan slice thickness 
recommended to be no greater than 5 mm). At baseline and follow up, only the short axis will be 
measured and followed. 

Clovis Oncology, Inc. 
Clinical Protocol 
Rociletinib (CO-1686) 
CO-1686-032 
FINAL Version 1.0 
 26 May 2015 
 
 
Page 119 of 131 
Confidential 
 
Nonmeasurable Lesions 
Nonmeasurable tumor lesions encompass small lesions (longest diameter  10 mm or 
pathological lymph nodes with short axis  10 but  15 mm), as well as truly nonmeasurable 
lesions. Lesions considered truly nonmeasurable include leptomeningeal disease, ascites, pleural 
or pericardial effusion, inflammatory breast disease, lymphangitic involvement of skin or lung, 
peritoneal spread, and abdominal mass/abdominal organomegaly identified by physical 
examination that is not measurable by reproducible imaging techniques. 
Special Considerations Regarding Lesion Measurability 
Bone lesions, cystic lesions, and lesions previously treated with local therapy require particular 
comment, as outlined below. 
Bone Lesions 
Bone scan, positron emission tomography (PET) scan, or plain films are not considered adequate 
imaging techniques for measuring bone lesions. However, these techniques can be used to 
confirm the presence or disappearance of bone lesions. 
Lytic bone lesions or mixed lytic-blastic lesions, with identifiable soft tissue components, that 
can be evaluated by cross-sectional imaging techniques such as CT or MRI can be considered as 
measurable lesions if the soft tissue component meets the definition of measurability described 
above. 
Blastic bone lesions are nonmeasurable. 
Cystic Lesions 
Lesions that meet the criteria for radiographically defined simple cysts should not be considered 
as malignant lesions (neither measurable nor non-measurable) since they are, by definition, 
simple cysts. 
Cystic lesions thought to represent cystic metastases can be considered as measurable lesions, if 
they meet the definition of measurability described above. However, if noncystic lesions are 
present in the same patient, these are preferred for selection as target lesions. 
Lesions with Prior Local Treatment 
Tumor lesions situated in a previously irradiated area or in an area subjected to other loco-
regional therapy are usually not considered measurable unless there has been demonstrated 
progression in the lesion. Study protocols should detail the conditions under which such lesions 
would be considered measurable. 

Clovis Oncology, Inc. 
Clinical Protocol 
Rociletinib (CO-1686) 
CO-1686-032 
FINAL Version 1.0 
 26 May 2015 
 
 
Page 120 of 131 
Confidential 
 
Tumor Response Evaluation 
Definitions of Target/Non-target Lesions 
Target Lesions 
When more than one measurable lesion is present at baseline, all lesions up to a maximum of 
five lesions total (and a maximum of two lesions per organ) representative of all involved organs 
should be identified as target lesions and will be recorded and measured at baseline. This means 
that, for instances in which patients have only one or two organ sites involved, a maximum of 
two lesions (one site) and four lesions (two sites), respectively, will be recorded. Other lesions 
(albeit measurable) in those organs will be recorded as non-measurable lesions (even if the size 
is  10 mm by CT scan). 
Target lesions should be selected on the basis of their size (lesions with the longest diameter) and 
be representative of all involved organs, but in addition, should lend themselves to reproducible 
repeated measurements. It may be the case that, on occasion, the largest lesion does not lend 
itself to reproducible measurement, in which circumstance, the next largest lesion that can be 
measured reproducibly should be selected. 
Lymph nodes merit special mention since they are normal anatomical structures that may be 
visible by imaging even if not involved by tumor. As noted above, pathological nodes that are 
defined as measurable and may be identified as target lesions must meet the criterion of a short 
axis of  15 mm by CT scan. Only the short axis of these nodes will contribute to the baseline 
sum. The short axis of the node is the diameter normally used by radiologists to judge if a node is 
involved by solid tumor. Nodal size is normally reported as two dimensions in the plane in which 
the image is obtained (for CT, this is almost always the axial plane; for MRI, the plane of 
acquisition may be axial, sagittal, or coronal). The smaller of these measures is the short axis. 
For example, an abdominal node that is reported as being 20 mm  30 mm has a short axis of 
20 mm and qualifies as a malignant, measurable node. In this example, 20 mm should be 
recorded as the node measurement. All other pathological nodes (those with short axis  10 mm 
but  15 mm) should be considered non-target lesions. Nodes that have a short axis of  10 mm 
are considered nonpathological and should not be recorded or followed. 
Lesions irradiated within 3 weeks prior to Cycle 1, Day 1 may not be counted as target lesions. 
Non-target Lesions 
All other lesions (or sites of disease), including pathological lymph nodes, should be identified as 
non-target lesions and should also be recorded at baseline. Measurements are not required. 
It is possible to record multiple non-target lesions involving the same organ as a single item on 
the Case Report Form (CRF) (eg, “multiple enlarged pelvic lymph nodes” or “multiple liver 
metastases”). 

Clovis Oncology, Inc. 
Clinical Protocol 
Rociletinib (CO-1686) 
CO-1686-032 
FINAL Version 1.0 
 26 May 2015 
 
 
Page 121 of 131 
Confidential 
 
After baseline, changes in non-target lesions will contribute only in the assessment of complete 
response (ie, a complete response is attained only with the complete disappearance of all tumor 
lesions, including non-target lesions) and will not be used to assess progressive disease.  
Calculation of Sum of the Diameters  
A sum of the diameters (longest for non-nodal lesions, short axis for nodal lesions) for all target 
lesions will be calculated as a measure of tumor burden. 
The sum of the diameters is calculated at baseline and at each tumor assessment for the purpose 
of classification of tumor responses. 
Sum of the Diameters at Baseline: The sum of the diameters for all target lesions identified at 
baseline prior to treatment on Day 1. 
Sum of the Diameters at Tumor Assessment: For every on-study tumor assessment collected 
per protocol or as clinically indicated, the sum of the diameters at tumor assessment will be 
calculated using tumor imaging scans. All target lesions and all new measurable lesions that have 
emerged after baseline will contribute to the sum of the diameters at tumor assessment. Hence, 
each net percentage change in tumor burden per assessment with use of modified RECIST 
accounts for the size and growth kinetics of both old and new lesions as they appear. 
Response Criteria 
Evaluation of Target Lesions 
Complete Response (CR): Disappearance of all target lesions. Lymph nodes that shrink to  10 
mm short axis are considered normal. 
Partial Response (PR): At least a 30% decrease in the sum of the diameters of all target and all 
new measurable lesions, taking as reference the baseline sum of diameters, in the absence of CR. 
Note: The appearance of new measurable lesions is factored into the overall tumor burden but 
does not automatically qualify as progressive disease until the sum of the diameters increases by 
 20% when compared with the sum of the diameters at nadir. 
Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to 
qualify for PD, taking as reference the smallest sum of the diameters while on study. 
Progressive Disease (PD): At least a 20% increase in the sum of diameters of all target and all 
new measurable lesions, taking as reference the smallest sum on study (this includes the baseline 
sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must 
also demonstrate an absolute increase of at least 5 mm. 

Clovis Oncology, Inc. 
Clinical Protocol 
Rociletinib (CO-1686) 
CO-1686-032 
FINAL Version 1.0 
 26 May 2015 
 
 
Page 122 of 131 
Confidential 
 
Impact of New Lesions on Modified RECIST 
New lesions alone do not qualify as progressive disease. However, their contribution to total 
tumor burden is included in the sum of the diameters, which is used to determine the overall 
modified RECIST tumor response. 
Evaluation of Best Overall Response Using modified RECIST 
Timepoint Response 
It is assumed that at each protocol-specified time point, a response assessment occurs. The 
following table provides a summary of the overall response status calculation at each time point 
for patients who have measurable disease at baseline. 
Modified RECIST Time point Response Definition 
% Change in Sum of the 
Diameters (Including 
Measurable New Lesions 
When Present) 
Target 
Lesion 
Definition 
Non-target 
Lesion 
Definition 
New 
Measurable 
Lesions 
New 
Unmeasurable 
Lesions 
Overall 
Modified 
RECIST 
Timepoint 
Response 
- 100% a 
CR 
CR 
No 
No 
CR 
- 100% a 
CR 
Non-CR or not 
all evaluated 
No 
No 
PR 
 - 30% 
PR 
Any 
Yes or no 
Yes or no 
PR 
 - 30% to   20% 
SD 
Any 
Yes or no 
Yes or no 
SD 
Not all evaluated 
Not evaluated 
Any 
Yes or no 
Yes or no 
NE 
  20% 
PD 
Any 
Yes or no 
Yes or no 
PD 
CR, complete response; NE, not evaluable; PD, progressive disease; PR, partial response; RECIST, Response Evaluation Criteria in Solid 
Tumors; SD, stable disease. 
 
a When lymph nodes are included as target lesions, the % change in the sum of the diameters may not be 100% even if complete response 
 criteria are met since a normal lymph node is defined as having a short axis of  10 mm. Any pathological lymph nodes (whether target or 
 non-target) must have reduction in short axis to  10 mm in order to meet the definition of CR. 
 
Missing Assessments and Inevaluable Designation 
When no imaging/measurement is done at all at a particular time point, the patient is 
not evaluable (NE) at that time point. If only a subset of lesion measurements are made at an 
assessment, usually the case is also considered NE at that time point, unless a convincing 
argument can be made that the contribution of the individual missing lesion(s) would not change 
the assigned time point response. This would be most likely to happen in the case of PD. For 
example, if a patient had a baseline sum of 50 mm with three measured lesions and at follow up 
only two lesions were assessed but those gave a sum of 80 mm, the patient will have achieved 
PD status, regardless of the contribution of the missing lesion 

Clovis Oncology, Inc. 
Clinical Protocol 
Rociletinib (CO-1686) 
CO-1686-032 
FINAL Version 1.0 
 26 May 2015 
 
 
Page 123 of 131 
Confidential 
 
Best Overall Response: All Time Points 
The best overall response is determined once all the data for the patient are known. The best 
overall response according to modified RECIST is interpreted as below: 
• CR: Complete disappearance of all tumor lesions (target and non-target) and no new 
measurable or unmeasurable lesions, confirmed by a consecutive assessment  4 weeks from 
the date first documented. All lymph nodes short axes must be  10 mm. 
• PR: Decrease in the sum of the diameters of all target and all new measurable lesions  30% 
relative to baseline, in the absence of CR, confirmed by a consecutive assessment  4 weeks 
from the date first documented. 
• SD: Criteria for CR, PR, and PD are not met. 
• PD: Increase in the sum of the diameters of all target and all new measurable lesions  20% 
relative to the nadir, which may be confirmed by a consecutive assessment  4 weeks from 
the date first documented as follows: 
The confirmatory assessment shows an additional measurable increase in tumor burden as 
measured by the sum of the diameters of all target and all new measurable lesions. 
This protocol allows patients to continue to receive study treatment even after confirmed 
radiographic PD per modified RECIST, and patients may achieve a best overall response of PR 
or CR based on tumor regression achieved at any time prior to study treatment discontinuation. 
 
 
 

Clovis Oncology, Inc. 
Clinical Protocol 
Rociletinib (CO-1686) 
CO-1686-032 
FINAL Version 1.0 
 26 May 2015 
 
 
Page 124 of 131 
Confidential 
 
Appendix C: Eastern Cooperative Oncology Group Performance Status Scale 
 
ECOG Performance Status 
0 
Fully active, able to carry on all pre-disease performance without restriction. 
1 
Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or 
sedentary nature (eg, light house work or office work). 
2 
Ambulatory and capable of all self-care but unable to carry out any work activities. Up and about 
more than 50% of waking hours. 
3 
Capable of only limited self-care; confined to bed or chair more than 50% of waking hours. 
4 
Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair. 
5 
Dead. 
 
 

Clovis Oncology, Inc. 
Clinical Protocol 
Rociletinib (CO-1686) 
CO-1686-032 
FINAL Version 1.0 
 26 May 2015 
 
 
Page 125 of 131 
Confidential 
 
Appendix D: QT Interval on Electrocardiogram Corrected Using the Fridericia’s 
 
Formula (QTcF) 
Fridericia’s formula used to correct QT interval for heart rate is: 
 
where QTCF is the QT interval corrected for heart rate, RR is the interval from the onset of one 
QRS complex to the onset of the next QRS complex, measured in seconds, often derived from 
the heart rate (HR) as 60/HR, and QT is the QT interval measured in milliseconds. 
Reference: 
Fridericia LS. Die Systolendauer im Elektrokardiogramm bei normalen Menschen und bei 
Herzkranken. Acta Med Scand 1920; 53: 3469-486. 
 
 
 

Clovis Oncology, Inc. 
Clinical Protocol 
Rociletinib (CO-1686) 
CO-1686-032 
FINAL Version 1.0 
 26 May 2015 
 
 
Page 126 of 131 
Confidential 
 
Appendix E: Pre-Existing Autoimmune Diseases 
Patients should be carefully questioned regarding their history of acquired or congenital immune 
deficiencies or autoimmune disease. Patients with any history of immune deficiencies or 
autoimmune disease listed in the table below will be excluded from participating in the study. 
Possible exceptions to this exclusion could be patients with a medical history of such entities as 
atopic disease or childhood arthralgias where the clinical suspicion of autoimmune disease is 
low. Patients with a history of autoimmune-related hypothyroidism on a stable dose of thyroid 
replacement hormone may be eligible for this study. In addition, transient autoimmune 
manifestations of an acute infectious disease that resolved upon treatment of the infectious agent 
are not excluded (eg, acute Lyme arthritis). Please contact the Medical Monitor regarding any 
uncertainty over autoimmune exclusions.  
Acute disseminated 
encephalomyelitis 
Addison’s disease 
Ankylosing spondylitis 
Antiphospholipid antibody 
Syndrome 
Aplastic anemia 
Autoimmune hemolytic anemia 
Autoimmune hepatitis 
Autoimmune 
hypoparathyroidism 
Autoimmune hypophysitis 
Autoimmune hypothyroidism a 
Autoimmune myocarditis 
Autoimmune oophoritis 
Autoimmune orchitis 
Autoimmune thrombocytopenic 
purpura 
Behcet’s disease 
Bullous pemphigold 
Chronic inflammatory 
demyelinating 
polyneuropathy 
Chung-Strauss syndrome 
Crohn’s disease  
Dermatomyositis 
Diabetes mellitus Type 1a 
Dysautonomia 
Epidermolysis bullosa acquista 
Gestational pemphigoid 
Giant cell arteritis 
Glomerulonephritis 
Goodpasture’s syndrome 
Graves’ disease 
Guillain-Barré syndrome 
Hashimoto’s disease 
IgA nephropathy 
Immune-mediated ocular disease 
(eg, uveitis, episcleritis, iritis) 
Inflammatory bowel disease 
Interstitial cystitis 
Kawasaki’s disease  
Lambert-Eaton myasthenia 
syndrome 
Lupus erythematosus 
Lyme disease - chronic 
Meniere’s syndrome 
Mooren’s ulcer 
Morphea 
Multiple sclerosis 
Myasthenia gravis 
Myasthenia gravis 
Myositis  
Neuromyotonia 
Opsoclonus myoclonus 
syndrome 
Optic neuritis 
Ord’s thyroiditis 
Pemphigus 
Pernicious anemia 
Polyarteritis nodusa 
Polyarthritis 
Polyglandular autoimmune 
syndrome 
Primary biliary cirrhosis 
Psoriasis 
Reiter’s syndrome 
Rheumatoid arthritis 
Sarcoidosis 
Scleroderma 
Sjögren’s syndrome 
Stiff-Person syndrome 
Takayasu’s arteritis 
Ulcerative colitis 
Vasculitis 
Vogt-Kovanagi-Harada disease 
Wegener’s granulomatosis 
a Patients with a history of Type 1 diabetes on a stable anti-hyperglycemic regimen or autoimmune-related 
hypothyroidism on a stable dose of thyroid replacement hormone are eligible for this study. 
 
 

Clovis Oncology, Inc. 
Clinical Protocol 
Rociletinib (CO-1686) 
CO-1686-032 
FINAL Version 1.0 
 26 May 2015 
 
 
Page 127 of 131 
Confidential 
 
Appendix F: Anaphylaxis Precautions 
EQUIPMENT NEEDED 
• Tourniquet; 
• Oxygen; 
• Epinephrine for subcutaneous, IV, and/or endotracheal use in accordance with standard 
practice; 
• Antihistamines; 
• Corticosteroids; 
• Intravenous infusion solutions, tubing, catheters, and tape. 
 
PROCEDURES 
In the event of a suspected severe or life-threatening anaphylactic reaction during study drug 
infusion, the following procedures should be performed: 
1. Stop the study drug infusion. 
2. Apply a tourniquet proximal to the injection site to slow systemic absorption of study drug. 
Do not obstruct arterial flow in the limb. 
3. Maintain an adequate airway. 
4. Administer antihistamines, epinephrine, or other medications as required by patient status 
and directed by the physician in charge. 
5. Continue to observe the patient and document observations. 
 
 
 

Clovis Oncology, Inc. 
Clinical Protocol 
Rociletinib (CO-1686) 
CO-1686-032 
FINAL Version 1.0 
 26 May 2015 
 
 
Page 128 of 131 
Confidential 
 
Appendix G: New York Heart Association Classification of Functional Cardiac Capacity 
Class 
Description 
I 
No limitation: Ordinary physical activity does not cause undue fatigue, dyspnea, 
or palpitation. 
II 
Slight limitation of physical activity: Such patients are comfortable at rest. 
Ordinary physical activity results in fatigue, palpitations, dyspnea, or angina. 
III 
Marked limitation of physical activity: Although patients are comfortable at rest, 
less than ordinary physical activity will lead to symptoms. 
IV 
Inability to carry on physical activity without discomfort: Symptoms of congestive 
heart failure are present even at rest. With any physical activity, increased 
discomfort is experienced. 
From: Criteria Committee, New York Heart Association, Inc. Diseases of the heart and blood vessels. 
Nomenclature and criteria for diagnosis. 6th ed. Boston, Little, Brown and Co, 1964:114. 
 
 
 

Clovis Oncology, Inc. 
Clinical Protocol 
Rociletinib (CO-1686) 
CO-1686-032 
FINAL Version 1.0 
 26 May 2015 
 
 
Page 129 of 131 
Confidential 
 
Appendix H: The Modified Toxicity Probability Interval (mTPI) Method 
 
The modified toxicity probability interval methodology is described in detail in Ji et al, 2010, 
and Ji et al, 2013. A short summary is given below. 
Dose-finding method: 
The mTPI design employs a simple beta-binomial hierarchical model. Decision rules are based 
on calculating the probability of three outcomes corresponding to underdosing, proper dosing, 
and overdosing in terms of toxicity. 
Consider d dose levels of a certain cytotoxic drug in a phase 1 trial. Let pi be the unknown 
probability of toxicity associated with the i-th dose, I = 1, . . . , d. The toxicity probability usually 
increases with the dose level, so we assume p1 < p2 <. . .< pd. Suppose that dose i is currently 
used for treating patients and ni (ni ≥ 1) patients have been treated at this dose. Suppose xi 
(xi ≤ ni) patients experienced toxicity. Based on the observed values of xi and ni, we assume that 
physicians choose one of the following three decisions:  
1. de-escalate (D) to the next lower dose (i-1);  
2. stay (S) at the same dose i; or  
3. escalate (E) to the next higher dose (i+1). 
Depending on the decision, the next cohort is treated at dose j which can be one of the 3 doses 
{i-1, i, i+1}; the values of xj and nj are then observed for the new cohort, and an appropriate 
decision is chosen once again. The trial thus proceeds with the next cohort. 
These additional rules are important for practical concerns: 
• Safety rule 1 (early termination): Suppose that dose 1 has been used to treat patients. If there 
is greater than a 95% probability that toxicity with dose 1 is greater than the target toxicity 
level (33%), then terminate the trial due to excessive toxicity. 
• Safety rule 2 (dose exclusion): Suppose that the decision is E, to escalate from dose i to (i+1). 
If there is greater than 95% probability that toxicity with dose i+1 is greater than the target 
toxicity level (33%), then treat the next cohort of patients at dose i and exclude doses (i+1) 
and higher from the trial, that is, these doses will never be used again in the trial.  
• At the end of the trial, select as the MTD, the dose with the estimated probability of toxicity 
closest to 33%. 

Clovis Oncology, Inc. 
Clinical Protocol 
Rociletinib (CO-1686) 
CO-1686-032 
FINAL Version 1.0 
 26 May 2015 
 
 
Page 130 of 131 
Confidential 
 
Implementation of the mTPI in Study CO-1686-018: 
The decision table for escalating, reducing or maintaining the same dose is based on algorithm 
provided by Ji et al, 2010, with the following 3 inputs: 
1. Maximum of 14 patients treated at any dose 
2.  Target toxicity probability of 33% 
3. Equivalence interval of 5% so that any dose with an estimated probability of toxicity in 
the interval [28%, 38%] can be selected as the MTD 
 
References:  
Ji Y, Liu P, Li Y, Bekele BN. A modified toxicity probability interval method for dose-finding 
trials. Clin Trials. 2010;7:653-63. 
Ji Y and Wang S-J. Modified Toxicity Probability Interval Design: A Safer and More Reliable 
Method Than the 3+3 Design for Practical Phase 1 Trials. J Clin Oncol 2013;31:1785-91. 
 
 
 
 

Clovis Oncology, Inc. 
Clinical Protocol 
Rociletinib (CO-1686) 
CO-1686-032 
FINAL Version 1.0 
 26 May 2015 
 
 
Page 131 of 131 
Confidential 
 
 
Cohort Decision Table 
 
Number of patients treated at current dose 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
Number of dose limiting toxicities (DLT's) 
0 
E E 
E 
E 
E 
E 
E 
E 
E 
E 
E 
E 
E 
E 
1 
D S 
S 
S 
S 
E 
E 
E 
E 
E 
E 
E 
E 
E 
2 
DU D 
S 
S 
S 
S 
S 
S 
E 
E 
E 
E 
E 
3 
DU DU D 
S 
S 
S 
S 
S 
S 
S 
S 
S 
4 
DU DU DU D 
S 
S 
S 
S 
S 
S 
S 
5 
DU DU DU DU D 
S 
S 
S 
S 
S 
6 
DU DU DU DU DU D 
S 
S 
S 
7 
DU DU DU DU DU DU D 
S 
8 
DU DU DU DU DU DU DU 
9 
DU DU DU DU DU DU 
10 
DU DU DU DU DU 
11 
DU DU DU DU 
12 
DU DU DU 
13 
DU DU 
14 
DU 
 
 
 
E = Escalate to the next higher dose 
S = Stay at the current dose 
D = De-escalate to the next lower dose 
U = The current dose is unacceptably toxic 
MTD=33% 
Sample size = 14